
==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067
MDPI

10.3390/ijms22158325
ijms-22-08325
Review
Tackling Dysfunction of Mitochondrial Bioenergetics in the Brain
Zanfardino Paola 1
https://orcid.org/0000-0002-5534-8253
Doccini Stefano 2
Santorelli Filippo M. 2*
https://orcid.org/0000-0001-8771-6033
Petruzzella Vittoria 1*
Atlante Anna Academic Editor
Valenti Daniela Academic Editor
1 Department of Medical Basic Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, 70124 Bari, Italy; paola.zanfardino@uniba.it
2 IRCCS Fondazione Stella Maris, Calambrone, 56128 Pisa, Italy; stefano.doccini@fsm.unipi.it
* Correspondence: filippo.santorelli@fsm.unipi.it (F.M.S.); vittoria.petruzzella@uniba.it (V.P.)
03 8 2021
8 2021
22 15 832516 6 2021
30 7 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Oxidative phosphorylation (OxPhos) is the basic function of mitochondria, although the landscape of mitochondrial functions is continuously growing to include more aspects of cellular homeostasis. Thanks to the application of -omics technologies to the study of the OxPhos system, novel features emerge from the cataloging of novel proteins as mitochondrial thus adding details to the mitochondrial proteome and defining novel metabolic cellular interrelations, especially in the human brain. We focussed on the diversity of bioenergetics demand and different aspects of mitochondrial structure, functions, and dysfunction in the brain. Definition such as ‘mitoexome’, ‘mitoproteome’ and ‘mitointeractome’ have entered the field of ‘mitochondrial medicine’. In this context, we reviewed several genetic defects that hamper the last step of aerobic metabolism, mostly involving the nervous tissue as one of the most prominent energy-dependent tissues and, as consequence, as a primary target of mitochondrial dysfunction. The dual genetic origin of the OxPhos complexes is one of the reasons for the complexity of the genotype-phenotype correlation when facing human diseases associated with mitochondrial defects. Such complexity clinically manifests with extremely heterogeneous symptoms, ranging from organ-specific to multisystemic dysfunction with different clinical courses. Finally, we briefly discuss the future directions of the multi-omics study of human brain disorders.

mitochondria
mitochondrial DNA
nervous tissue
OxPhos complexes
bioenergetics
genomics
proteomics
mitochondrial diseases
==== Body
1. Introduction

The panoply of mitochondrial functions reflects on highly heterogeneous clinical presentations when an error in a mitochondrial protein or function occurs. Mitochondria are dynamic and mobile organelles representing a hub where exchange of information among the nucleus and other cellular compartments takes place to modulate energy production and metabolites provision to the cell’s specific needs and nutrient availability [1]. The basic function of mitochondria is the generation of more than 90% of cellular energy via the oxidative phosphorylation (OxPhos) system [2] but, in addition, they play many roles in the different types of cells: compartmentalize metabolites for the maintenance of redox homeostasis; function as centers for metabolic waste management [3]; surveil calcium homeostasis [4]; initiate caspase-dependent apoptosis and other intermediate cellular stress response [5]; provide sulfur metabolism and iron-sulfur cluster biogenesis [6,7]; house the synthesis of cardiolipin, steroids, quinone, and heme [8,9]; breakdown fatty acids through β-oxidation; and serve as a metabolic platform for the tricarboxylic acid (TCA), and urea cycles [10]. All these functions include homeostatic regulation of organelle morphology and dynamics [11], quality control [12], and participation in the immune response [13,14]. Alteration of each of the above functions and activities can have different effects according to the specificity of the organ and cell type, but alteration of mitochondrial energy production can impact tissues with the highest energy requirements such as the nervous system, both central (CNS) and peripheral (PNS) [15,16].

The term ‘mitochondrial medicine’ categorizes the ample array of clinical presentations associated with all types of mitochondrial defects having directly or secondarily defect of one or several mitochondrial functions although ‘mitochondrial diseases’ traditionally indicate dysfunction of the OxPhos system [6,17]. The direct link between human disease and the genetic alteration of a mitochondrial function has found a breakthrough with the application of -omics technologies (i.e., genomics, transcriptomics, proteomics, metabolomics, and epigenomics, etc.). Rapidly, high-throughput omics techniques—that is detection of biologically significant differences, even if not high magnitude changes, in a multitude of molecular constituents in organisms supported by sophisticated bioinformatics tools—have allowed progress in cataloging the predicted human mitochondrial proteins thus revealing new details and providing clues to elucidating still unknown basic aspects of mitochondrial structure and function. These novel high-throughput techniques have enhanced the final diagnosis of several mitochondrial disorders. This is a very relevant aspect, especially considering that mitochondrial diseases individually are rare but are probably the most frequent genetic disorder in adults (incidence of 1 in 5000 live births) [18]. More recently, genome editing technology applied to neural cultures and cerebral organoids generated from patients-derived iPSCs is revolutionizing the landscape and offering new opportunities for understanding the pathogenetic effects of mutations in nervous tissue.

This review aims to focus on the dysfunction of OxPhos defects mostly in the nervous system to highlighting the contributions of powerful omics technologies to mitochondrial medicine to land from the laboratory to the clinic.

2. Mitoexome, Mitochondrial Proteome, and Mitointeractome

Before Next-Generation Sequencing (NGS) improved our understanding of how mutations cause diseases, first attempts to identify the mitochondrial proteome were based on ‘cyberscreening’ of available genome databases. This allowed the discovery of few human mitochondrial genes presenting orthologs in lower eukaryotes. An example of the cyberscreening strategy used Saccharomyces cerevisiae proteins as ‘probes’ to identify BCS1, PET112, SCO1, COX15, and COX11, five yeast genes that present orthologs (respectively, BCS1L, GATB, SCO1, COX15, and COX11) in humans [19]. Except for COX11, a COX-assembly, all genes have been implicated in mitochondrial diseases [OMIM 603647.0001-603647.0013; OMIM 603645.0001-603645.0002; OMIM 603644.0001-603644.0002; OMIM 603646.0001-603646.0004], see paragraphs 4.3 and 4.4. To date, whole-exome (WES) and whole-genome (WGS) resequencing have dramatically enhanced the ability to identify the underlying gene mutations in patients with isolated or multiple mitochondrial respiratory chain complex defects [20,21]. The collection of mt genes and coding exons of the 1034 nuclear genes encoding the human mitochondrial proteome is defined as ‘MitoExome’ [22,23]. This multigene panel is useful in performing targeted resequencing of the OxPhos nuclear genes because it includes not only the 77 nuclear structural OxPhos subunits and the 37 mitochondrial (mt) DNA genes including the 13 structural genes for OxPhos subunits [24] but also genes for mitochondrial proteins either already known or not to be associated with a specific mitochondrial disease, including assembly factors and electron carriers’ genes which represent a large fraction of the overall mitochondrial genes that can cause mitochondrial dysfunction [21]. Application of MitoExome resequencing provides novel mutation candidates, enables the discovery of unusual clinical variants [25,26] and new clinical phenotypes [26] (Figure 1). Furthermore, the integration of MitoExome sequencing with the study of mitochondrial proteome potentiates the detection of variants causing protein destabilization and/or aberrantly low expression [27].

Biochemical and ultrastructural characterizations have uncovered the heterogeneity of mitochondria in their function, trafficking patterns, lifespan, and morphology across cell types and different cellular compartments. Different tissues, cell types, and cellular states have unique signatures of protein localization to mitochondria. In the proteomic comparison of the mitochondrial proteins, almost half are found as core components in virtually all tissues, whereas the remaining are tissue-specific [28,29]. The study of mitochondrial proteome starts with the isolation of mt compartment from cells and tissues and stands behind the availability of methodologies to isolate pure mitochondria from different sources to define exactly the function of each protein in each cell type of the human body [30]. The performance of proteomics analysis is driven by the reduction of sample complexity, enhancement of mass spectrometry (MS) power of resolution, and the possibility to reduce the contamination of the sample with non-mitochondrial proteins owed to chemical and physical similarities between mitochondria and other cellular components (e.g., lysosomes). Since the initial rough estimates, it has been suggested that the mammalian mitochondrial proteome encompassed about 1000–1500 distinct proteins—including the 13 mtDNA-encoded proteins [24]—that represent an important subset of the ~20,000 distinct mammalian proteins [31,32] (Figure 2).

Quantitative two-dimensional (2D) gels of highly purified mitochondria estimated ~1500 distinct spots [33], a number higher than the ~1000 distinct protein products encoded by the genomes of alpha-proteobacteria, which are the closest living relatives of modern-day mitochondria [34]. Several databases have been used to integrate the experimental data with bioinformatic predictions based on mitochondrial localization or interaction. For example, the MitoProteome is an object-related database developed at the UCSD Supercomputer Center, which contains information on mitochondria-localized proteins [35,36]. Each entry in the MitoProteome corresponds to a gene encoding a protein that is localized within mitochondria and its basic information, along with annotations of isoforms, splice variants, and functions of the corresponding protein. To date, the most comprehensive study elucidating the mitochondrial proteome of different mammalian tissues is represented by the MitoCarta inventory [29,37]. This catalog combines multiple experimental and computational approaches, i.e., mass spectrometry (MS) analysis of mitochondria isolated from 14 mouse tissues, large-scale GFP-fusion microscopy analysis, and bioinformatics using data mining, prediction, evolutionary conservation, and a Bayesian integration of seven additional data sources. The first release was represented by MitoCarta1.0 (http://www.broadinstitute.org/pubs/MitoCarta/; accessed 25 July 2021) which contained about 1000 distinct gene loci [29]. Updated in 2016, MitoCarta 2.0 listed about 1200 genes [37]. Another dedicated database that collected, curated, and annotated information on mitochondrial proteins is the MitoMiner database (http://mitominer.mrc-mbu.cam.ac.uk/; accessed 25 July 2021) [38] (version 4.0, 2018). It is based on the literature and proteomics data based on both LC-MS and 2D gel studies, antibody staining, and other subcellular localization data, and provides a collective score for each protein’s probability to have the mitochondrial association. MitoMiner records mitochondrial proteins from 12 organisms [38]. Using the data contained within MitoMiner, the Integrated Mitochondrial Protein Index (IMPI) was also developed (http://www.mrc-mbu.cam.ac.uk/impi; accessed 25 July 2021). IMPI version Q2 (2018) contains 1626 human genes that encode mitochondrially localized proteins, 1184 known to be mitochondrial and 442 predicted to be mitochondrial. The large amount of information provided by mito-databases as MitoMiner 4.0 v2018 JUN (http://mitominer.mrc-mbu.cam.ac.uk; accessed 25 July 2021), makes it possible to define different score systems for mitochondrial confidence combining data from various mitochondrial and functional annotation databases. These strategies allow increasing the stringency of protein accepted as inherently mitochondrial [39]. An exhaustive list of the major data sources loaded with the latest version and links to the relevant resources is reported in the Data Sources section of the Mitominer (https://mitominer.mrc-mbu.cam.ac.uk/release-4.0/dataCategories.do; accessed 25 July 2021).

More recent advances in the experimental proteomic approaches, specifically in labeling and MS methods, have further expanded and defined the known mitochondrial proteome and have simultaneously revealed the sub-mitochondrial localization of many of them [40,41]. A novel spatial proteomics pipeline demonstrated that many proteins cannot be classified to a single localization as they either transit between compartments or carry out their functional role(s) in multiple locations [41]. The redundant functions, or functions affecting multiple cellular processes, rendered difficult the study and it was estimated that about ~20% of mitochondrial proteins remained uncharacterized [42].

Along with technological progress that has enabled the discovery of approximately 78,120 human proteins [based on The UniProt Knowledgebase (UniProtKB), as of 23 February 2021], derives the challenge of identifying a large amount of potential protein-protein interactions (PPIs). An example of the network-based approaches analyzing protein-protein interaction is represented by MitoInteractome, a web-based portal containing 6549 protein sequences extracted from SwissProt (http://www.expasy.ch/sprot/; accessed 25 July 2021), MitoP (http://www.mitop.de:8080/mitop2/; accessed 25 July 2021), MitoProteome (http://www.mitoproteome.org/; accessed 25 July 2021), HPRD (http://www.hprd.org; accessed 25 July 2021) and Gene Ontology database (http://www.geneontology.org; accessed 25 July 2021). This enables the elucidation of integrative mitochondrial functions and can expedite the discovery of novel interactions which otherwise may have been missed using traditional experimental techniques. MEGADOCK [43,44], a structure-based PPI prediction method, was first developed and then followed the MEGADOCK-Web-Mito database which is a PPI prediction data archive, that includes prediction results for protein pairs of 654 mitochondria-related human proteins [45]. All these approaches have been key in the study of PPI as a means to infer functions for uncharacterized proteins and to enable the discovery of novel proteins, e.g., several complex I assembly factors [46,47] (Figure 1).

For expert reviews on the details about the technical approaches, the required bioinformatics pipelines, and how (multi)omics technologies can help in studying the dysfunction of mitochondrial bioenergetics, see [48,49].

3. Diversity of Bioenergetics Demand in the Brain

The brain relies on glucose metabolism for ATP generation and many other activities and an inappropriate supply of either glucose or oxygen degrades brain function. The principal energy request of the brain is due to activities of the neuronal signaling that include resting and action potentials, glutamate cycling, post-synaptic Ca2, postsynaptic receptors, while the activities of the non-signaling, e.g., turnover of proteins, phospholipids, and nucleic acids, remodeling of the actin in the cytoskeleton, axonal transport, mitochondrial proton leak, etc., are less demanding. Specifically, gray matter and white matter have different energetic requests for non-signaling (30% versus 80%, respectively) and signaling (70% versus 20%, respectively) activities [50,51]. These findings would suggest that the energy demands of signaling activities in gray matter are mainly due to synaptic activity while the energetic demands in white matter satisfy the request of billions of unmyelinated axons and glial cells [50]. Beyond ATP generation, glucose is important for the synthesis of several molecules within the brain, including neurotransmitters and neuromodulators. For these reasons, mitochondria are quite heterogeneous as anatomical localization, activity, and metabolism at regional, cellular, subcellular levels and during differentiation, when the upregulation of mitochondrial metabolism is the basis of cell proliferation in neuronal stem cells and progenitor cells. Although different regions of the brain contain about half as many mitochondria as the heart, the mitochondria of the brain are qualitatively different to support the high metabolic demand that requires, for example, close cooperation between neurons and astrocytes [52]. Astrocytes are metabolically and structurally supportive [52,53,54] and are crucial in neurotransmission [55,56] and behavior [57,58]. The ATP utilized by neurons is produced by the OxPhos process, while most of the energy needs of astrocytes are met by glycolysis [59,60]. The mitochondrial ATP production per molecule of glucose oxidized is ~16 times more than glycolysis. The survival of neurons requires OxPhos [52] and in mature neurons, the local ATP supply provided by mitochondria is used to regulate axonal and dendritic development, axonal regeneration, as well as contributing to synaptic transmission and plasticity. The different energy metabolisms of the two cell types are closely coupled, with astrocytes releasing the glycolytic end-product, lactate, which is used by neighboring neurons to drive OxPhos [61,62].

An example of heterogeneity of mitochondria in metabolic enzyme diversity has been provided by a study comparing the mitochondrial proteome of the three major cerebellar cell types: Granule cells (GC), the most abundant excitatory neuron; Purkinje cells (PC), the major inhibitory neuron of the cerebellum and astrocytes [63]. In the adult cerebellum, ~15% of the annotated mitochondrial proteome was shown to be differentially regulated among the three cell types. Fatty acids were more efficiently metabolized by astrocytic than neuronal mitochondria due to the enrichment of two beta-oxidation enzymes, i.e., short-chain-specific acyl-coenzyme A dehydrogenase and carnitine palmitoyl-transferase 1a, an enzyme that limits the rate of oxidative reactions of long-chain fatty acids [63]. In particular, the mitochondrial proteome of astrocytes showed a remarkable enrichment of peroxisomal proteins, some of which are known to have a double localization (i.e., catalase) [64] or binding to mitochondria (i.e., Eci2 and Pex11b).

In the same work, the mitochondrial calcium uniporter (MCU) [4,63,65] and its regulators were detected mostly in GC [63]. Recent studies suggest that the markedly different modes of ATP production in the neurons and astrocytes reside also in the supra-organization of the mitochondrial respiratory chain in supercomplexes (see Section 4.6 paragraph) able to regulate different rates of respiration and mitochondrial ROS production [66].

The brain mitochondrial proteome is not a unicum also when considering synaptic and non-synaptic mitochondria (sMito and nsMito). Proteomic profiling of sMito vs. nsMito revealed mitochondrial complex I as an upstream regulator of degenerative processes associated with a high range of age-related neuropathologies characterized by synaptic dysfunction [67]. In a separate study, an accurate analysis of quantitative proteomics was performed to differentiate sMito and nsMito using Stable Isotope Labeling with Aminoacids in Cell culture (SILAC) labeled mitochondria from cultured cells as an internal standard. In SILAC, cells are differentially labeled by growing them in a ‘light’ medium, containing normal amino acids, or a ‘heavy’ medium, containing a stable isotope [68]. Significant differential expression was shown for 522 proteins involved in several pathways including the OxPhos system, mitochondrial fission/fusion, calcium transport, and mtDNA replication and maintenance. Lower levels of Pyruvate dehydrogenase (PDH) subunits in the synapse to other parts of the cell and reduced expression of complex I, II, and IV (expect for COX4I2) suggested decreased bioenergetic function of sMito compared to nsMito [68]. Consistent with this finding, sMito exhibited increased age-associated mtDNA deletions and reduced levels of TFAM and mtSod2, suggesting a reduced ability of sMito to withstand ROS, thus providing insights into synaptic mitochondrial susceptibility to damage [68] (Figure 3).

The extreme heterogeneity of mitochondria activities and functioning has been recently shown by a novel and fine imaging approach that specifically allows to label and monitor mitochondrial translation products for microscopic fluorescent imaging. In neuronal cultures, mitochondrial translation was monitored in axonal and dendritic mitochondria as well as in pre-and post-synaptic regions of neurites by specifically labeling the peptides newly synthesized by mitochondrial ribosomes, revealing that not all mitochondria translate to the same extent in different cell types [69]. Finally, the fundamental role of mitochondria during neurogenesis has been recapitulated in the cellular and organoid model of Leigh syndrome (LS), a severe manifestation of mitochondrial disease in children [70]. Mutations in SURF1, a complex IV assembly gene, cause neuronal impairment because of defective metabolic programming of neural progenitor cells (NPCs) that prevents the establishment of neuronal morphogenesis. Using CRISPR/Cas9 engineered SURF1 patient-derived iPSCs, a human model of LS was developed. Single-cell RNA-sequencing and multi-omics analysis revealed compromised neuronal morphogenesis in mutant 2D neural cultures and 3D brain organoids (Figure 1d). The defects already emerged at the level of NPCs, which were unable to shift toward OxPhos and retained a proliferative glycolytic state that fails to instruct neuronal morphogenesis. Interestingly, gene augmentation and PGC1A induction via Bezafibrate treatment inducing mitochondria biogenesis supported the metabolic programming of LS NPCs, leading to restored neuronal morphogenesis [70]. It is interesting to point out that the current understanding of LS is that the disease is caused by neuronal degeneration. This interpretation had led to experimental treatment schemes focused on antioxidants to prevent the build-up of damaging free radicals. The multi-omics analysis in 2D and 3D models adopted by Prigione [70] provided a novel perspective to LS pathology by showing that the disease mechanisms may not necessarily involve a redox imbalance but rather an impairment of neuronal morphogenesis following the loss of NPC commitment. Evidence that Surf1 impairment may affect the neurogenesis was described also in the SURF1-knock out swine model that shows a disorganized cortical structure with several immature neurons and developing of a severe early-onset neurological phenotype [71]. These findings overall suggest that mutations associated with mitochondrial diseases could impair neurogenesis and shift the view of therapeutic approaches that might lead to novel interventions aiming at promoting the reestablishment of physiological neurogenesis [72] rather than merely preventing the degeneration of mature neurons.

4. Structure, Assembly, and Disorders of Bioenergetics Complexes

The development of mito-omics-based approaches has been crucial in understanding the functional and bioenergetic consequences of mutations responsible for the onset of primary mitochondrial diseases. The OxPhos is the enzymatic machinery by which mitochondria produce the ATP needed by the cells. The reactions are performed by five multimeric enzyme complexes (EC): Complex I (EC 1.6.5.3) or NADH-Ubiquinone Reductase, CI, 45 subunits; Complex II (EC 1.3.5.1) or Succinate-Ubiquinone Oxidoreductase, CII, 4 subunits; Complex III (EC 1.10.2.2) or Ubiquinol: cytochrome c (cyt c) oxidoreductase, CIII, 10 subunits; Complex IV (EC 1.9.31) or Cyt c oxidase (COX), CIV, 13 subunits; Complex V (EC 3.6.14) or ATP synthase, CV, 16 subunits; and two-electron transport carriers, namely, ubiquinone (coenzyme Q, CoQ) and cyt c [73]. Reactions catalyzed by CI, CIII, and CIV result in the release of protons in the inner membrane space, thereby creating the proton gradient needed for ATP synthase activity. The correct function of the OxPhos system depends on the concerted action of several chaperones and other assembly factors that play essential roles in the formation, regulation, and stability of the five complexes and the mobile electron carriers, and nucleotide transporters [74]. Assembly factors of CI, CII, CIII, and CV have been classified as early-stage factors, acting in the structural assembly of individual subunits and sub-complexes, and late-stage accessory factors, called LYRM (leucine-tyrosine-arginine motif) proteins, controlling the incorporation and/or activation of last subunits and/or cofactors (i.e., Fe-S clusters). The human mitoproteome contains at least 12 LYRM proteins [75].

The OxPhos system is under a dual genetic control: 13 subunits are of mtDNA origin [24] and the remaining are encoded by the nuclear DNA (nDNA) [76]. MtDNA is a small circular genome [24] that encodes only 13 mitochondrial proteins, 22 mt-tRNAs, and 2 mt-rRNAs. Hence, the nuclear-encoded mitochondrial proteome requires sophisticated machinery for the transport into mitochondria [77,78,79]. Over the last years, a growing number of human proteins involved in mtDNA replication, and expression have been identified owing to the study of primary mitochondrial diseases. The coordination between the two genomes is crucial for mtDNA integrity, copy number regulation, and mitochondrial protein synthesis because mutations in nuclear genes encoding proteins for mtDNA replication and maintenance may affect its integrity and properties [80]. Dedicated reviews on these topics, including also the specific mechanisms regulating mtDNA replication [81], transcription [82], and translation [83,84] are available elsewhere.

Genetically, the mitochondrial diseases associated with the OxPhos system are split into two broad genetic categories: disorders due to mutations in the mtDNA, observing the rules of mitochondrial genetics; disorders due to mutations in the nDNA, transmitted as a Mendelian trait [6,85]. To date, mutations in both mitochondrial and nuclear genomes have been reported to cause mitochondrial disease manifesting with characteristic leukoencephalopathy and other clinical phenotypes either multisystemic or with single tissue involvement [86,87,88].

Since the first descriptions of mtDNA mutations [89,90,91], the number of mutations has been growing more and more until it counts over 1000 heteroplasmic rearrangements (large deletions/duplications) (http://mitobreak.portugene.com; accessed 25 July 2021), and over 500-point mutations possibly pathogenic among the 700 variants reported, which affect all mtDNA genes (https://www.mitomap.org; accessed 25 July 2021). A few major clinical phenotypes in adults have been recently reviewed [92]: LHON [91,93]; Neuropathy, ataxia, retinitis pigmentosa (NARP)/maternally inherited Leigh syndrome (MIILS) [94,95]; Maternally inherited nonsyndromic deafness, associated or not with aminoglycosides use [96]; Myoclonus, epilepsy, ragged-red-fibers syndrome (MERRF) [97,98]; Mitochondrial encephalopathy, lactic acidosis stroke-like syndrome (MELAS) [99,100]; Chronic progressive external ophthalmoplegia (CPEO) spectrum [89]; Kearns–Sayre syndrome (KSS) [101,102] and Pearson’s syndrome [103,104]. LHON and NARP/MILS are disorders that affect single OxPhos complex, complex I in LHON [105], and complex V in NARP/MILS [106], respectively. All these phenotypes are maternally inherited, displaying the hallmarks of mitochondrial diseases including variability of the phenotype, incomplete penetrance, and overlapping clinical features. The exception is represented by CPEO/KSS/Pearson associated with single mtDNA deletions, which are mostly sporadic [107,108].

Herein, we will provide some rapid information on structure, assembly, and disorders related to each of the OxPhos complexes. All the details of complexes assembly, including the factors, the interacting module/function, the associated clinical phenotypes, and the references have been adapted from [47,74,109,110].

4.1. NADH–Ubiquinone Oxidoreductase–Complex I

NADH–Ubiquinone Oxidoreductase (Complex I, CI) couples the electron transfer of the two electrons derived from NADH oxidation to the ubiquinone with the translocation of four protons into the intermembrane space (IMS) [111,112,113]. Most of the molecular studies of mitochondrial diseases have focused on Complex I, which is the largest and most complicated among the respiratory complexes. Of 45 subunits, seven are encoded by the mtDNA (MT-ND1-6 and MT-ND4L), and the remaining, including the dual copy of the acyl-carrier protein NDUFAB1 [114], are encoded by nDNA [114,115]. Structurally, CI is an L-shaped complex that is composed of two domains: the hydrophilic head protruding into the matrix and the hydrophobic part within the inner mitochondrial membrane (IMM) [116]. Fourteen core subunits, conserved from bacteria to humans, perform catalytic activities [114,117,118]. Seven core subunits in the hydrophilic arm contain the redox-active centers: a non-covalently bound FMN and seven Fe–S clusters [119]. All the seven mtDNA-encoded CI subunits are in the hydrophobic arm and form the proton channels [115]. The remaining 30 subunits are ‘supernumerary’ but important for assembly and stability [120]. Most accessory subunits are only found in eukaryotic complex I. A notable exception is represented by subunits NDUFS4, NDUFS6, and NDUFA12 that are already present in complex I from α proteobacteria [121].

The complete mammalian CI structure has been elucidated [111,122] and determined by X-ray crystallography [117,123] and cryo-EM [118,124,125,126,127,128,129]. It is organized in six independent modules, N, Q, ND1/PP-a, ND2/PP-b, ND4/PD, and ND5/PD-b, that, assisted by specific assembly factors, are incorporated in a specific order [130]. The overall L-shaped CI structure derives from the assembly of the N- and Q modules in the peripheral arm, and ND1, ND2, ND4, and ND5 modules in the P part of the membrane arm forming, at the hinge between the two arms, the channel of the CoQ binding site (Q-module) [119,120]. The N module, situated at the head of the hydrophilic part, contains the NADH-binding site and a flavomononucleotide (FMN) cofactor which oxidizes NADH to release two electrons [130]; the Q module for Q reduction, situated in the hydrophilic arm, contains eight Fe–S clusters where electrons flow to reach ubiquinone [130]. The N and Q modules form the peripheral arm containing the seven “core” subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7, and NDUFS8) whereas the 30 accessory subunits are necessary to stabilize the enzyme [131]. The P-module constitutes the membrane arm and is composed of the seven mtDNA-encoded proteins: ND1- ND4, ND4L, ND5, and ND6, involved in proton translocation [132]. Specific factors assisting the preassembly of the modules and the role of protein import machinery are summarized in Table 1.

A wide range of pathological phenotypes of the nervous system has been found to affect CI stability/activity both involving mitochondrial- and nuclear-encoded subunits [6]. Many pathological variants in the seven mtDNA encoded subunits, MT-ND1-6 and ND4L have been associated with a wide spectrum of syndromes with the age of onset occurring mostly during late childhood or early adulthood [178,179,180,181]. Mutations in three MT-ND genes are the main cause of Leber’s hereditary optic neuropathy (LHON) [OMIM 535 000], the most common mtDNA inherited disease [182]. LHON is one cause of bilateral acute or subacute, painless loss of central vision in young men (more than 80% of LHON patients are male, because of degeneration of retinal ganglion cell layers [183,184]. Important clues to understanding the pathogenesis of LHON, which is characterized by yet poorly understood genetic and environmental factors affecting the incomplete penetrance, have been obtained by analysis of mtDNA copy number and by proteomics approaches [185,186,187,188]. Mitochondrial DNA copy number is a key factor in differentiating LHON affected individuals from the unaffected mutation carriers [185,186,187,188]. A mitochondrial proteomic profile of 11778G>A mutant fibroblasts using 2-Dimensional Polyacrylamide Gel Electrophoresis (2-DE) and MS [189] disclosed that most of the mitochondrial proteins–including those involved in intermediary metabolic processes, nucleoid-related proteins, chaperones, cristae remodeling ones, and an antioxidant enzyme–were down-regulated, and some OxPhos subunits were altered [189]. The major bioenergetics consequences, particularly of MT-ND4 and MT-ND1 mutations, resulted in CI-dependent reduction of ATP synthesis and redox balance leading to increased ROS levels and decreased antioxidant enzyme activities [190,191,192].

The main pathological mutations found in structural CI subunits are summarized in Table 2.

Quantitative proteomics has revealed the importance of the 30 non-catalytically active supernumerary subunits of CI. Pathological variants causing CI deficiency have been described in NDUFAF1 [CIA30], ACAD9, and TMEM126B that together with ECSIT, COA1 and TMEM186, form the Mitochondrial Complex I Intermediate Assembly (MCIA) [172] important for the biogenesis of the ND2-module. NDUFAF3 (C3ORF60) and NDUFAF4 (C6ORF66) working together in the assembly of the Q-module, have been found mutated in different cases of infantile mitochondrial disease [150,151,228,229,230,231].

The gene NDUFS4 (NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, NM_002495.2), is a hotspot for pathogenic mutations. Inactivation of the NDUFS4 gene is known to cause mostly, Leigh or Leigh-like syndrome [232,233,234,235,236,237,238,239,240], a rare disease with a prevalence of roughly 1:40.000 live births [241,242]. Unfortunately, the prognosis of NDUFS4-linked LS is poor. Loss of NDUFS4 affects complex I assembly and causes detrimental structural changes in assembled complex I [232,243]. Several pieces of evidence have suggested that NDUFS4 plays a role in the late stage of complex I assembly [233,235,244]. NDUFS4 knock out mouse models [245,246], human and murine cell lines, and more recently induced pluripotent stem cells (iPSCs) from LS patients carrying mtDNA mutations in the NDUFS4 [70] have been set up to explore strategies to counteract pathophysiological consequences of complex I deficiency. LS patient-derived neural cells have shown defective bioenergetics [247,248], decreased protein synthesis [249], impaired mitochondrial calcium homeostasis [248,250], and abnormal corticogenesis [251]. The presence of defective neurite outgrowth has been confirmed also in neural progenitor cells (NPCs) carrying mutations in the NDUFS4 as well as in the SURF1 (Surfeit locus protein 1, NM_003172.2) genes, another well-known cause of LS [252,253,254].

Structural subunits and specific factors assisting the assembly associated with human diseases are summarized in Table 1 and Table 2.

4.2. Succinate–Ubiquinone Oxidoreductase–Complex II

Succinate dehydrogenase (SDH, complex II, CII), a ~120 kDa integral membrane complex, participates in both the TCA cycle and the respiratory chain. CII transfers the electrons to CoQ and does not contribute to proton pumping across the mitochondrial membrane. All four subunits are encoded by the nuclear genome. The largest hydrophilic domain is a heterodimer composed of SDHA and SDHB that protrude toward the matrix and contain the redox-active groups’ flavin adenine dinucleotide (FAD(H2)) and three Fe–S clusters, respectively. The smaller hydrophobic domain is composed of SDHC and SDHD and contains two CoQ binding sites [255] providing reduction of ubiquinone to ubiquinol, the mobile electron carrier that links to CIII. Four specific chaperones [SDH assembly factor 1–4 (SDHAF1–4)] participate in the stabilization and incorporation of the prosthetic groups into each of the structural subunits SDHA, SDHB, and SDHC + SDHD [130,256]. In the late stage of assembly of CII, ACN9, similarly to LYRM-8 (also known as SDHAF1), is important for the formation and stabilization of CII throughout the insertion or retention of the Fe-S centers within the protein backbones and FMC1 (Formation of mitochondrial complex V assembly factor 1) [257].

CII defects are quite rare and represent less than 10% of OxPhos deficiency cases [258]. Different forms of encephalopathy and rare neuroendocrine tumors are the two main pathological manifestations that can originate from mutations in CII subunits or assembly factors. Mutations in SDHA, encoding the 70 kDa Flavoprotein subunit, have also been found in rare cases of Leigh syndrome [259,260,261,262,263,264]. Ultrarare association of bi-genomic variants in the SDHB and mitochondrial MT-CYB genes has been described in a patient with clinical and metabolic features of a ME-LAS-like syndrome [265].

The main pathological mutations found in CII subunits or assembly factors are summarized in Table 3.

4.3. Ubiquinol: Cytochrome C Oxidoreductase–Complex III

The ubiquinol: cytochrome c oxidoreductase (cytochrome bc1, complex III, CIII) constitutes the central part of the respiratory chain. CIII receives two electrons through reduced CoQ (CoQH2) and transfers them, one at a time, to cytochrome c, by cytochrome b (MT-CYB-human nomenclature), which contains two binding sites with CoQ and two heme b groups; UQCRFS1, the Rieske Fe-S protein; and CYC1, containing heme c. Each of the two ‘monomers’ is composed of 10 different subunits and associate as a symmetric dimer [279]. The complex assembly starts with the synthesis, membrane insertion, and hemylation of cytochrome b, mediated by UQCC1–3 in humans [280,281,282], followed by the sequential incorporation of the remaining subunits into a dimeric pre-CIII2 [282]. MZM1L (LYRM7), BCS1L, and tetratricopeptide repeat domain-containing protein 19 (TTC19) are the three assembly factors, known to be involved in the stabilization, incorporation, and metabolism of UQCRFS1 [283,284,285,286,287,288,289,290]. LYRM7 chaperone binds the Rieske protein before its incorporation as the last step of the biogenesis of the nascent CIII dimer (CIII2), acted by BCS1L [284,286,291].

The first mutations found in CIII were identified in MT-CYB, the only subunit encoded by mtDNA [292,293,294,295]. Most of these pathological variants were found in heteroplasmy and mainly associated with late-onset sporadic myopathy and exercise intolerance [292,293,294,295,296,297,298]. Other MT-CYB mutations were associated with histiocytoid cardiomyopathy [299], parkinsonism and MELAS overlap syndrome [293], or multisystem disorders [300,301,302,303].

Among the cases of CIII deficiency of nuclear origin are mutations in assembly factors [304] and the most common are nonsense and missense mutations in TTC19 [305], LYRM7 [306], and BCS1L [307], which cause defective CIII assembly/stability and decreased ubiquinol:cyt c oxidoreductase activity. Interestingly, a shuttle of electrons from NADH and/or ubiquinol to CIII, pyocyanin, has been used to efficiently recover mitochondrial function thus ameliorating bioenergetic efficiency in fibroblasts derived from patients’ dysfunction due to TTC19, BCS1L, and LYRM7 [291].

The main pathological mutations found in CIII subunits or assembly factors are summarized in Table 4.

4.4. Cytochrome C Oxidase–Complex IV

Cytochrome c oxidase (COX, complex IV, CIV) is the terminal complex of the ETC. The enzyme transfers electrons from cytochrome c to molecular oxygen. In humans, it is composed of 14 subunits, with the NDUFA4, the most recently discovered subunit initially attributed to CI [331,332], found to be incorporated in the structure of monomeric human CIV [333]. Only two, MT-CO1 and MT-CO2, are catalytical subunits. MTCO1 contains three prosthetic groups: cytochrome a3 and CuB, which form the bi-nuclear center that binds oxygen, and cytochrome a. MT-CO2 incorporates the CuA center [334]. MT-CO3 is necessary to provide additional stability to the enzyme while it undergoes turnover [335]. Subunits such as COX4, 5A, 5B, 6A, 6B, 6C, 7A, 7B, 7C, 8A are believed to play a role in stabilizing the structure of the complex. The cytochrome c oxidase complex is unique among the ETC complexes to have tissue, developmental and species-specific isoforms for COX subunits 4, 6A, 6B, 7A, 7B, and 8A [336,337].

CIV assembly grows with a modular process through the incorporation of modules formed by different subunits and defined by each of the mtDNA-encoded core subunits [130,338,339]. Any subunit of complex IV could carry mutations and rise a mitochondriopathy [337,340,341,342]. Mutations in the MT-CO1, MT-CO2, and MT-CO3 are causative of COX deficiency and mitochondrial disease with an extreme clinical heterogeneity (Table 5).

Pathological variants in ‘supernumerary’ COX subunits have been reported in tissue and development-specific isoforms [336]. Among the assembly factors, the most representative is SURF1, the functional absence of which causes LS [252,253,276] or even Charcot–Marie–Tooth disease [367]. The elucidation of the pathogenetic mechanism has received an impulse recently [70]. Mutations in COX10, which catalyzes the farnesylation of a vinyl group of heme b, cause LS and other forms of the fatal early-onset neurological syndrome [368,369,370]. Mutations in COX15, which catalyzes the subsequent step of heme synthesis, cause variable clinical presentations [371,372,373]. Copper delivery to the active sites of MT-CO1 and MT-CO2 involves factors essential for COX activity [130,374]. SCO1, SCO2, and COA6 have been found mutated in patients showing CIV deficiency and fatal outcomes [338,368,375,376,377,378,379,380,381,382,383,384,385,386]. Among complex IV proteins, COX6B1 assists CIV assembly, working as a linking subunit at the dimeric interface of CIV [387].

The specific functions of the remaining proteins (all associated with human diseases, see Table 6) are known only in part and require additional studies.

4.5. ATP Synthase–Complex V

ATP synthase (Complex V, CV) is the enzyme that catalyzes the synthesis of ATP required as an energy source for various cellular processes from ADP and phosphate utilizing the proton-motive force generated through electron transfer. ATP synthase F1FO consists of two functional domains: the hydrophilic domain F1 facing the matrix which serves for the production of ATP and the FO domain facing the membrane which serves to translocate protons [433,434]. The proton translocation leads to the rotational movement of the c ring in the FO domain which is connected to the catalytic subunit F1 by the peripheral stalk (PS). The human CV is composed of 29 proteins of 18 kinds, including the Inhibitory factor 1, IF1, in which only FO-ATP6 and ATP8 are mtDNA encoded [435]. The complete structure of the dimeric and monomeric mammalian mitochondrial F1Fo-ATP synthase has been just recently resolved by Cryo-EM [436,437].

The assembly pathway of human CV is also modular [433,435,438,439] since three subcomplexes, F1 module, c-ring, and PS are formed individually and then associate together. The assembly starts from the three alpha and three beta subunits that make up the F1 domain to which the other subunits subsequently bind. The eight units of the c-ring assemble inside the IMM. When these two sub-complexes join, the PS subunits also bind, followed by the membrane domain’s remaining subunits, which include MT-ATP6 and MT-ATP8 [130]. To date, only three assembly factors are known, including ATPAF1 and ATPAF2, that binds and stabilizes subunit beta [440] and subunit alpha [441], respectively.

Pathogenic mutations have been reported both in mtDNA and nDNA encoded ATP synthase subunits. The coding sequences of two Fo subunits are overlapping in the human mtDNA and pathological variants in both are the cause of sporadic and maternally inherited mitochondrial disease (Table 7).

Mutations in MT-ATP6 have been identified in neuropathy, ataxia, and retinitis pigmentosa syndrome (NARP) [94] and maternally inherited Leigh syndrome (MILS) [442,466]. NARP is a slowly progressive form that manifests in adulthood, while MILS is an early onset, highly disabling, often fatal disease. In many cases, NARP and MILS are associated with the 8993 T > C or T > G mutation [443,467,468]. The T > G transversion usually presents with a more severe form that correlates with the degree of heteroplasmy of the mutation in post-mitotic tissues [95,468]. Until now, only three of the sixteen nucleus-encoded CV subunits and three assembly factors (e.g., ATPAF2; ATP12 and TMEM70) have been associated with mitochondrial disease (see Table 7).

4.6. Respiratory Supercomplexes

OxPhos complexes associate with each other resulting in the formation of higher-order structures which have been called supercomplexes (SC). Complexes IV and V can form dimers and oligomers [469,470,471] and based on the size and composition of the subunits, the main SCs that have been recognized have the following stoichiometries: III2IV1, I1III2, I1III2IV1, and I2III2IV1-2. In particular, the association of complexes I, III2 and IV, SC I1III2IV1, considered as a functional unit capable of transferring electrons from NADH to O2, is defined as the ‘respirasome’ [472] whereas the supercomplex I2III2IV2 has been named as ‘respiratory megacomplex’ [129]. High-resolution Cryo-EM structures of the respirasome of several mammalian species, including humans, have been recently resolved [129,473,474,475,476]. The respirasome organization was supposed to be functionally advantageous making electron transfer from CI to CIV through CIII2 more efficient and decreasing the formation of deleterious ROS [477,478,479,480]. It has been suggested that the functional unit of OxPhos is composed of the dimer of ATP synthase flanked by the adenine nucleotide and the phosphate transporters, located at the apices of cristae and the CI-CIII2-CIV supercomplexes organized along the cristae membrane to perform the electron transfer and proton translocation [481].

The fact that the biogenesis of CIII2 and CIV occurs independently but the CI assembly does not can be an explanation for the reason why defects in CIII2 and CIV may result in secondary effects on CI assembly. When the defect is originated from mutations in CI components, the manifestation is almost always an isolated CI deficiency [209,482]. High-throughput proteomics techniques have recently been applied in human cybrids holo-CIII2-deficient, demonstrating the loss of SCs containing CIII2 and CI when the CIII2 is not fully assembled. In this model, the combination of null CIII and markedly reduced CI enzymatic activity, confirmed the well-established connection between CIII2 deficiency and hampered assembly process in CI [483].

In astrocytes, most of CI is free, resulting in poor mitochondrial respiration but high ROS production; while, in neurons, CI is mostly embedded into supercomplexes, thus resulting in high mitochondrial respiration and low ROS production [66]. Notably, crest-shaping proteins, as well as the proteins of mitochondrial contact sites and the cristae organization system complex (MICOS) are essential for the assembly and functionality of the OxPhos system [484]. Understanding the structure and assembly of SCs is very crucial to explain those cases of combined respiratory chain deficiency.

For expert reviews on the issue of the relationship between crest dynamics and bioenergetics, refer to [485,486]. For a detailed review of the formation and function of SCs, see [487].

5. Conclusions

An integrative approach that combines multi-omics data could represent a strategic way to solve, at least in part, the complexity of mitochondrial diseases and mitochondrial medicine highlighting the interrelationships of the involved OxPhos complexes and their functions, and the knowledge about genotype-phenotype correlation. However, the science behind combined omic approaches, will need the integration of data from genomics, transcriptomics, proteomics, and metabolomics, to include also the novel approaches looking to the epiproteome, the set of all post-translational modifications made to proteins comprising an organelle, a cell, or an organism, that provide the link between metabolism, mitochondrial proteome, and the two cellular genomes. The recent application of CRISPR/Cas9 technology to patient-specific iPSCs, to generate neural cultures and cerebral organoids is providing patient-specific cellular and tissue models that allow the investigation of the defects of neuronal morphogenesis caused by specific mutations (Figure 1). Thus, in the multi-omic era, the opportunity to understand the cause of each mitochondrial disease becomes ever more tangible.

Acknowledgments

We thank the patients’ association MITOCON and UILDM (Unione Italiana Lotta alla Distrofia Muscolare) and CollaGe-associazione-Genitori-Manzoni-Poli-Molfetta.

Author Contributions

Conceptualization, P.Z. and V.P.; writing—original draft preparation, P.Z.; S.D. and V.P.; writing, review, supervision and editing, P.Z. and V.P.; supervision, V.P. and F.M.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from REGIONE PUGLIA-MALATTIE RARE-Petruzzella Del. N.246 10.09.2019_UPB-SMBNOS and by donations of Parents’ Associations (to VP). This study received partial financial support from the Italian Ministry of Health-Ricerca Corrente, MITO-NEXT, Mit-OMICS (to FMS), Fondazione Telethon (Grant numbers GUP09004). The authors alone are responsible for the content and writing.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Figure 1 Omics strategies advance in understanding mitochondrial function and dysfunction in brain disorders related to OxPhos gene mutations. Mitochondrial bioenergetics involves activities whose function and structure have been deeply elucidated by omics technologies; (a) The introduction of high-resolution technologies has been resolutive to deepen the structure of the respiratory chain complexes and supercomplexes; (b) Quantitative proteomics, e.g., LC-MS/MS enable the identification and quantification of mitoproteins and provide large amounts of data. Through Network-based approaches analyzing protein-protein interactions, the huge amount of information allows the discovery of novel accessory subunits and assembly factors of the five multi-subunit enzyme complexes; (c) The re-sequencing carried out with MitoExome increases the possibility of identifying new or previously reported mutations in both mitochondrial and nuclear genes in patients; (d) Novel multi-omics analysis, based on single-cell omics, is applied to two-dimensional (2D) neural cultures and three-dimensional (3D) cerebral organoids generated from patients-derived iPSCs that can be engineered by CRISPR/Cas9. Abbreviations: LC-MS/MS: Liquid Chromatography with tandem mass spectrometry; PPIs: Protein-protein Interactions; nDNA: nuclear DNA; mtDNA: mitochondrial DNA; iPS cells: Induced Pluripotent Stem cells.

Figure 2 Functional diversity of mitochondrial proteins and bioenergetics consequences of OxPhos system dysfunction. The mammalian mitochondrial proteome includes both mitochondrial and nuclear DNA- encoded proteins. Most of the proteins required for the various activities in which mitochondria are involved are encoded by the nuclear genome, whereas the mitochondrial energy-producing system, i.e., the OxPhos complexes, has either mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) encoded components. The enlarged mitochondrion shows most of the bioenergetics consequences (indicated by the red bolt lightning) of genetic defects involving the OxPhos complexes. Abbreviations: IP3: Inositol Trisphosphate; IP3R: Inositol Trisphosphate Receptor; VDAC: Voltage-dependent anion channel; ETC: Electron Transport Chain; TCA: Tricarboxylic Acid Cycle; ATP: Adenosine triphosphate.

Figure 3 Diversity of mitochondrial proteome in synaptic and non-synaptic mitochondria. Synaptic mitochondria show defects in energy metabolism due to low levels of Pyruvate dehydrogenase (PDH) subunits [68] (A), reduced expression of complex I [67,68], II, and IV [68] (B), and increased susceptibility to damage (increased mtDNA deletions) [68] (C), compared to non-synaptic mitochondria. ADP: Adenosine diphosphate; ATP: Adenosine triphosphate.

ijms-22-08325-t001_Table 1 Table 1 Complex I assembly factors with interacting module/function, associated clinical phenotypes, and references. Adapted from [47,74,110,133].

Assembly Factors	CI Interacting
Module/Function	Associated Clinical Phenotypes	References	
ACAD9	ND2/PP-b module
Component of MCIA complex, necessary for insertion of ND2	Cardiorespiratory depression, hypertrophic cardiomyopathy, encephalopathy, and severe lactic acidosis	[134,135]	
ECSIT	ND2/PP-b module
Component of MCIA complex, necessary for insertion of ND2	-	[136]	
FOXRED1	ND4/PD module	Leigh syndrome, congenital lactic acidosis, athetoid movements of the limbs in early
childhood, hypotonia and cerebellar atrophy, mitochondrial respiratory CI deficiency associated with Leigh syndrome, encephalocardiomyopathy, or ataxia	[137,138,139]	
ATP5SL/DMAC2	ND4/PD module	-	[140]	
TMEM70	ND4/PD module	Neonatal mitochondrial encephalocardiomyopathy, mitochondrial CV deficiency, nuclear type 2, occasionally facial dysmorphisms and CI deficiency	[141,142,143,144,145,146]	
NDUFAF1	N module, ND1
Component of MCIA complex, necessary for insertion of ND2	Hypertrophic cardiomyopathy, developmental delay, lactic acidosis, hypotonia, and Wolff–Parkinson–White syndrome	[147,148]	
NDUFAF2	N module.
Stabilization of pre-CI or 830 kDa subcomplex	Ataxia, lethargy, nystagmus, hypotonia, optic atrophy, and episodic respiratory, insufficiency, generic encephalopathic syndromes, or Leigh syndrome	[149]	
NDUFAF3/C3ORF60	Q module	Macrocephaly, weak cry, no eye contact,
wide anterior fontanel and axial hypotonia	[150]	
NDUFAF4/C6ORF66	Q module	Severe encephalopathy and antenatal
Cardiomyopathy	[151]	
NDUFAF5/C20ORF7	Not known.
Catalyze hydroxylation of NDUFS7 and dimethylation of NDUFS2 of the Q module	Facial dysmorphism, progressive lactic acidosis and neurological defects, severe early-onset encephalopathy	[152,153]	
NDUFAF6	Not known.
Maintain a normal level of mt-ND1 subunit	Focal seizures, decreased movement and strength, ataxia, lactic acidosis, and Leigh syndrome	[29,154,155,156,157,158]	
NDUFAF7	Not known.
Catalyze dimethylation of NDUFS2 of the Q module	-	[159,160]	
NDUFAF8/C17ORF89	Not known.
Stabilization of NDUFAF5	Leigh syndrome	[161]	
NUBPL	Supposed to interact with the developing
N module and possibly Q module.
Insertion of iron-sulfur clusters in N and Q module subunits	Infantile onset hepatopathy, renal tubular acidosis, developmental delay, short stature, leukoencephalopathy, myopathy, nystagmus, and ataxia	[162,163,164]	
TIMMDC1/C3ORF1	ND1/PP-a
Insertion of ND1	Infantile onset hypotonia, failure to thrive, delayed or minimal psychomotor
development, sensorineural deafness, dysmetria, dyskinetic movements, peripheral
neuropathy, nystagmus, and Leigh syndrome	[140,165,166]	
TMEM126A	ND4 module
Component of MCIA complex, necessary for building the intermediate ND2 module	Autosomal recessive optic atrophy	[167,168,169,170,171]	
TMEM126B	ND2/PP-b module
Component of MCIA complex, necessary for building the intermediate ND2 module	Exercise intolerance, muscle weakness, myalgia, early-onset renal tubular acidosis, and hypertrophic cardiomyopathy	[172,173,174]	
TMEM186	ND2/PP-b module-
Interact strongly with newly synthesized ND3	-	[175]	
DMAC1/TMEM261	ND5/PD-b	-	[120]	
COA1/MITRAC15	ND2/PP-b module	-	[175]	
COA7	-	Autosomal recessive spinocerebellar ataxia with axonal neuropathy type 3	[176]	
LYRM-2	NADH-Dehydrogenase module
Maturation of N-module	-	[177]	

ijms-22-08325-t002_Table 2 Table 2 Complex II subunits with location, associated clinical phenotypes, and references. Adapted from [47,74,110,133].

Subunits	Location	Associated Clinical Phenotypes	References	
MTND1	ND1-module	Leber optic atrophy, MELAS syndrome, dystonia, spasticity, and myopathy	[193,194,195]	
MTND2	ND2-module	Leber optic atrophy	[196]	
MTND3	ND2-module	Infantile encephalopathy and Leigh syndrome	[197]	
MTND4	ND4-module	Leber optic atrophy and MELAS syndrome	[198,199]	
MTND4L	ND2-module	Leber optic atrophy	[200]	
MTND5	ND5-module	Leber optic atrophy and MELAS syndrome	[201,202]	
MTND6	ND2-module	Leber optic atrophy and MELAS syndrome	[201,203]	
NDUFV1	N-module	Severe encephalopathy and neurologic abnormalities	[204,205]	
NDUFV2	N-module	Hypertrophic cardiomyopathy, truncal hypotonia, and encephalopathy	[206]	
NDUFV3	N-module	Complex I deficiency	-	
NDUFS1	N-module	Growth retardation, axial hypotonia, hepatomegaly, dystonia, and persistent hyperlactatemia	[205]	
NDUFS2	Q-module	Neonatal lactic acidosis and hypertrophic cardiomyopathy	[207]	
NDUFS3	Q-module	Leigh syndrome, severe axial dystonia with oral and pharyngeal motor dysfunction,
dysphagia and a tetraparetic syndrome	[208]	
NDUFS4	Q-module	Muscular hypotonia, absence of visual and auditive attention, and cardiac defects	[209]	
NDUFS6	Q-module	Fatal infantile lactic acidosis, neonatal myopathy, encephalopathy, and lactic acidosis	[210,211]	
NDUFS7	Q-module	Leigh syndrome, feeding problems, dysarthria, and ataxia	[212]	
NDUFS8	Q-module	Leigh syndrome, poor feeding, and episodes of apnea and cyanosis	[213]	
NDUFA11	ND2-module	Fatal infantile metabolic acidosis, brain atrophy, no motor development and
hypertrophic cardiomyopathy	[214]	
NDUFA1	ND1-module	Leigh syndrome, hypotonia, nystagmus, generalized choreoathetosis, and decreased
reflexes	[215]	
NDUFA2	N-module	Leigh syndrome, hypertrophic cardiomyopathy, and developmental delay	[216]	
NDUFA3	ND1-module	-	-	
NDUFA5	Q-module	-	-	
NDUFA6/LYRM-6	LYR protein	Auditory and optic neuropathy, mitochondrial-related infantile death, brain disorder, leukoencephalopathy	[217]	
NDUFA7	N-module	-	-	
NDUFA8	IMS protein
(ND1-module)	Intrauterine growth retardation, respiratory insufficiency, lactic acidosis and
hypoglycemia	[178]	
NDUFA9	Q-module	Severe neonatal hypotonia, dysmorphic features, epilepsy, and signs of brainstem
involvement	[218]	
NDUFA10	ND2-module	Leigh syndrome	-	
NDUFA11	ND2-module	Encephalocardiomyopathy and fatal infantile lactic acidemia, neuromuscular disorder	-	
NDUFA12	N-module	Respiratory and metabolic acidosis, hearing loss, apneas, and retinitis pigmentosa	[219]	
NDUFA13	ND1-module	Leigh syndrome, progressive loss of motor abilities, scoliosis, and dystonia	[220]	
NDUFB1	ND4-module	-	-	
NDUFB2	ND5-module	-	-	
NDUFB3	ND5-module	Delayed development, hypotonia, poor eye contact, abnormal eye movements, poor
feeding, encephalopathy, and hearing loss	[221]	
NDUFB4	ND4-module	-	-	
NDUFB5	ND4-module	-	-	
NDUFB6	ND5-module	-	-	
NDUFB7	ND5-module	-	-	
NDUFB8	ND5-module	Encephalopathy, myopathy, hypotonia, developmental delay, and lactic acidosis, mitochondrial Complex I Deficiency in Individuals with Leigh-like Encephalomyopathy	[222]	
NDUFB9/LYRM-3	LYR protein	Leigh syndrome, respiratory failure,
seizures, hypotonia, cardiac hypertrophy, failureto thrive and severely delayed psychomotor development	[221]	
NDUFB10	IMS protein(ND4 module)	Progressive hypotonia associated with increased serum lactate	[223]	
NDUFB11	ND4-module	Lethal complex I deficiency, X-linked microphthalmia with linear skin defects (MLS) syndrome	[224,225,226]	
NDUFC1	ND2-module	-	-	
NDUFC2	ND2-module	X-linked microphthalmia with linear skin defects (MLS) syndrome, cardiomyopathy
and other congenital anomalies	[227]	
NDUFS5	IMS protein
(ND2 module)	-	-	

ijms-22-08325-t003_Table 3 Table 3 Complex II subunits and assembly factors with function, associated clinical phenotypes, and references. Adapted from [74,133].

Subunits	Function	Associated Clinical Phenotypes	References	
SDHA	CII subunit	Leigh syndrome, neonatal dilated cardiomyopathy,
catecholamine-secreting extra-adrenal paraganglioma	[259,260,261,262,263,264,265,266,267]	
SDHB	CII subunit	Paraganglioma, pheochromocytoma, gastrointestinal stromal tumors	[268,269]	
SDHC	CII subunit	Paraganglioma, gastric stromal sarcoma	[270,271]	
SDHD	CII subunit	Paraganglioma, pheochromocytoma, gastric stromal sarcoma	[271,272]	
Assembly Factors				
SDHAF1/LYRM-8	Insert Fe/S clusters into mature SDHB	Leukoencephalopathy, spastic quadriplegia, psychomotor regression	[257]	
SDHAF2	Insert FAD cofactor into apo-protein SDHA	Paraganglioma and pheochromocytomas	[270,272,273,274,275,276]	
SDHAF3/NDUFV1/LYRM-10	Maintain SHDB stability	Familial and sporadic pheochromocytomas
and paraganglioma	[277]	
SDHAF4	Protect the subunit from auto-oxidation and facilitates the assembly with SDHB	Vagal paragangliomas	[278]	

ijms-22-08325-t004_Table 4 Table 4 Complex III subunits and assembly factors with function, associated clinical phenotypes, and references. Adapted from [74,133].

Subunits	Function	Associated Clinical Phenotypes	References	
UQCRC1	CIII subunit	Parkinsonism with polyneuropathy	[308]	
UQCRC2	CIII subunit	Hypoglycemia, lactic acidosis, ketosis, and hyperammonemia	[309]	
MT-CYB	CIII subunit	Leber optic atrophy, exercise intolerance, encephalomyopathy, cardiomyopathy, and multisystemic disorder, histiocytosis cardiomyopathy, parkinsonism, and MELAS overlap syndrome	[293,294,299,300,310,311]	
CYC1	CIII subunit	Neurologic deterioration, insulin-responsive hyperglycemia, ketoacidosis with increased serum
lactate, liver failure, and hyperammonemia	[312]	
UQCRFS1	CIII subunit	Cardiomyopathy and alopecia totalis	[313]	
UQCRH	CIII subunit	-	-	
UQCRB	CIII subunit	Gastroenteritis, liver enlargement, hypoglycemia, and metabolic acidosis but normal
psychomotor development at age 4, hepatopathy	[314]	
UQCRQ	CIII subunit	Severe neurologic phenotype, early-onset severe encephalopathy	[315]	
UQCR10	CIII subunit	-	-	
UQCR11	CIII subunit	-	-	
Assembly Factors				
UQCC1	Cytochrome b assembly factor	-	-	
UQCC2	Cytochrome b assembly factor	Intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction	[281,316]	
UQCC3	Cytochrome b assembly factor	Lactic acidosis, hypoglycemia, hypotonia, and delayed development	[282]	
VPS53	Heme lyase (Cytochrome c1)	Complicated hereditary spastic paraparesis	[317]	
BCS1L	AAA-ATPase involved in Rieske protein incorporation.
Stabilization, incorporation, and metabolism of UQCRFS1	GRACILE Syndrome, Bjornstad Syndrome, myopathy, encephalopathy, proximal tubulopathy, and liver failure	[26,288,304,318,319,320,321,322,323]	
MZM1L/LYRM-7	Matrix protein involved in Rieske protein incorporation. Stabilization, incorporation, and metabolism of UQCRFS1	Neurological decompensation and regression, leukoencephalopathy and liver failure, infantile CIII deficiency associated with cavitating leukoencephalopathy metabolic decompensation	[306,324,325,326]	
TTC19	Rieske protein metabolism Stabilization, incorporation, and metabolism of UQCRFS1	Progressive encephalopathy, ataxia, spastic paraparesis, and psychiatric phenotype	[305,327,328,329,330]	

ijms-22-08325-t005_Table 5 Table 5 Complex IV subunits with associated clinical phenotypes and references. Adapted from [74,133].

Subunits	Associated Clinical Phenotypes	References	
MTCO1	MELAS syndrome, myopathy, myoglobinuria, motor neuron disease, exercise intolerance, epilepsy,
multisystem disorders, deafness, LHON, or mitochondrial sensorineural hearing loss	[343,344,345,346,347]	
MTCO2	Encephalomyopathy, LHON, myopathy, hypertrophic cardiomyopathy	[348,349,350,351]	
MTCO3	MIDD, LHON, myopathy, Leigh disease, myoglobinuria, sporadic bilateral optic neuropathy,
rhabdomyolysis, encephalopathy	[352,353,354,355,356,357]	
COX4I1	Short stature, poor weight gain, mild dysmorphic features, Fanconi anemia, Leigh-like syndrome	[358,359]	
COX4I2	Exocrine pancreatic insufficiency, dyserythropoietic anemia, calvarial hyperostosis	[360]	
COX5A	Early-onset pulmonary arterial hypertension, lactic acidemia, failure to thrive	[361]	
COX6A1	Charcot–Marie–Tooth disease	[362]	
COX6A2	Muscle weakness and hypotonia, cardiomyopathy	[363]	
COX6B1	Severe infantile encephalomyopathy	[341,342]	
COX7A1	Failure to thrive, encephalopathy, hypotonia	[364]	
COX7B	Microphthalmia with linear skin lesions	[365]	
COX8A	Leigh-like syndrome presenting with leukodystrophy and severe epilepsy	[366]	
NDUFA4	Leigh syndrome	[331]	

ijms-22-08325-t006_Table 6 Table 6 Complex IV assembly factors with function, associated clinical phenotypes, and references. Adapted from [74,133].

Assembly Factors	Function	Associated Clinical Phenotypes	References	
	RNA Stability and Translation			
TACO1	Translational activator of mitochondria encoded MTCO1	Leigh syndrome	[388,389]	
LRPPRC	Mitochondrial mRNA stability	French Canadian type of Leigh syndrome	[390]	
FASTKD2	Involved in post-transcriptional RNA maturation, ribosome biogenesis and
translation	Brain atrophy, epilepsy, delayed psychomotor development, bilateral optic atrophy, spastic hemiparesis,
cardiomyopathy	[391,392,393]	
	Heme a Biosynthesis and Insertion			
COX10	Heme a synthesis (conversion of heme b into heme o)	Leigh syndrome, encephalopathy, cardiomyopathy, sensorineural deafness, and metabolic acidosis	[369,370,394,395]	
COX15	Heme a synthesis (conversion of heme o into heme a)	Leigh syndrome, encephalopathy, cardiomyopathy, sensorineural deafness, and metabolic acidosis	[369,371,373,396,397]	
SURF1	Involved in the insertion or stabilization of heme a3	Leigh syndrome, Charcot–Marie–Tooth disease	[252,253,276,367,398]	
	Copper Metabolism and Insertion			
COA5/C2ORF64	Involved in the unknown step of CIV biogenesis
	Fatal infantile cardioencephalomyopathy	[399]	
COA6/C1ORF31	Copper homeostasis and transport to CIV	Fatal infantile cardioencephalopathy	[385,386,400]	
SCO1	Incorporation of copper atoms (biogenesis of CuA center)	Cardioencephalomyopathy, Leigh syndrome-like symptoms, spinal muscular atrophy-like presentations, Charcot–Marie–Tooth disease type 4, CIV deficiency, neonatal hepatopathy, encephalopathy with hepatopathy and cardiomyopathy, pure encephalopathy, metabolic syndrome with exclusively fatal lactic acidosis	[375,381,383,395,401,402]	
SCO2	Incorporation of copper atoms (biogenesis of CuA center)	Cardioencephalomyopathy, Leigh syndrome-like symptoms, spinal muscular atrophy-like presentations, Charcot–Marie–Tooth disease type 4, CIV deficiency, cardiac hypertrophy	[377,378,379,380,381]	
COX11	Copper chaperone	Coloboma, Ocular, With or Without Hearing Impairment, Cleft Lip/Palate, And/Or Mental Retardation and Spinal Muscular Atrophy, Distal, X-Linked 3	[403]	
COX16	MTCO2 maturation	-	[404,405]	
COX17	Copper transfer	-	[406]	
COX19	Stabilization of COX11	-	[407,408]	
COX20	Stabilization of MT-CO2	Cerebellar ataxia	[409,410,411]	
	Assembly			
COA3/MITRAC12	Required for MTCO1 stability and assembly, involved in translational regulation of MTCO1 and prevention of MTCO1 aggregation before assembly	Mild phenotype, exercise intolerance, peripheral neuropathy, obesity, and short stature	[412,413,414,415]	
COA7	Unknown	Ataxia and peripheral neuropathy, cognitive impairments, leukodystrophy	[176,416]	
COX14/C12ORF62	MTCO1 stability and assembly; avoids MTCO1 aggregation	Severe lactic acidosis and dysmorphic features	[417]	
CMC1	Stabilizes the interaction between MTCO1, COX14, and COA3		[418]	
COX20/FAM36A	MTCO2 chaperone for copper metalation	Growth delay, hypotonia, cerebellar ataxia	[410,411,419]	
PET100	Stabilizes MT-CO2 module	Early-onset psychomotor delay, seizures, hypotonia, Leigh syndrome, CIV deficiency, and fatal infantile lactic acidosis	[420,421,422]	
PET117	Assembly factor: possible role in Cox15 oligomerization and function, stabilizes MT-CO2 module	Neurodevelopmental regression and bulbar lesions	[423,424,425]	
MR-1S	Interacts with PET117 and PET100,	-	[339]	
APOPT1/COA8	intermediates assembly steps Putative role in CIV protection from ROS damage, enhances CIV biogenesis	Leukodystrophy, neurological signs	[426,427,428]	
COX18	Promotes the translocation of MTCO2 globular domain through the IMM	Isolated COX deficiency in infancy	[429,430,431]	
COX19	Stabilization of COX11	Isolated COX deficiency in infancy	[407,408,431]	
COA-X	Putative assembly factor	-	[432]	
HIGD2A	Promotes incorporation of MT-CO3 module	-	-	

ijms-22-08325-t007_Table 7 Table 7 Complex V subunits and assembly factors with function, associated clinical phenotypes, and references. Adapted from [74,133].

Subunits	Location	Associated Clincial
Phenotypes	References	
MT-ATP6	Fo domain	Mitochondrial CV deficiency Neuropathy, Ataxia and Retinitis Pigmentosa (NARP) syndrome
Leigh syndrome
Adult-onset ataxia and polyneuropathy Bilateral striatal necrosis
Motor neuron syndrome
Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia	[94,95,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457]	
MT-ATP8	Fo domain	Mitochondrial CV deficiency
Valproate-induced reversible brain atrophy
Hypertrophic cardiomyopathy	[458,459]	
MT-ATP6/8
overlap region	Fo domain	Mitochondrial CV deficiency
Infantile hypertrophic cardiomyopathy	[457]	
ATP5F1A	F1 domain	Mitochondrial CV deficiency
Combined OXPHOS deficiency
Fatal infantile encephalopathy	[460,461]	
ATP5F1D	F1 domain	Mitochondrial CV deficiency
Metabolic decompensation with lactic acidosis, hypoglycemia, hyperammonemia, and 3-methylglutaconic aciduria, encephalopathy	[462]	
ATP5F1E	F1 domain	Mitochondrial CV deficiency
Neonatal-onset lactic acidosis, 3-methylglutaconic aciduria, mild mental retardation, hypertrophic cardiomyopathy, and peripheral neuropathy	[463]	
Assembly Factors				
ATPAF1	Binds and stabilIzes subunit beta of F1
Domain	Asthma in children	[464]	
ATPAF2	Binds and stabilizes subunit alpha of F1 domain	Degenerative encephalopathy, elevated lactate levels, developmental delay	[465]	
TMEM70	Unknown	Neonatal mitochondrial encephalocardiomyopathy
Mitochondrial CV deficiency, nuclear type 2
Occasionally facial dysmorphisms
CI deficiency	[141,142,143,144,145,146]	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Chandel N.S. Mitochondria as signaling organelles BMC Biol. 2014 12 34 10.1186/1741-7007-12-34 24884669
2. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism Nature 1961 191 144 148 10.1038/191144a0 13771349
3. Spinelli J.B. Haigis M.C. The multifaceted contributions of mitochondria to cellular metabolism Nat. Cell Biol. 2018 20 745 754 10.1038/s41556-018-0124-1 29950572
4. De Stefani D. Raffaello A. Teardo E. Szabò I. Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter Nature 2011 476 336 340 10.1038/nature10230 21685888
5. Green D.R. Galluzzi L. Kroemer G. Metabolic control of cell death Science 2014 345 1250256 10.1126/science.1250256 25237106
6. Gorman G.S. Chinnery P.F. DiMauro S. Hirano M. Koga Y. McFarland R. Suomalainen A. Thorburn D.R. Zeviani M. Turnbull D.M. Mitochondrial diseases Nat. Rev. Dis. Prim. 2016 2 16080 10.1038/nrdp.2016.80 27775730
7. Muraresku C.C. McCormick E.M. Falk M.J. Mitochondrial disease: Advances in Clinical diagnosis, management, therapeutic development, and preventative strategies Curr. Genet. Med. Rep. 2018 6 62 72 10.1007/s40142-018-0138-9 30393588
8. Piel R.B. Dailey H.A. Medlock A.E. The mitochondrial heme metabolon: Insights into the complex(Ity) of heme synthesis and distribution Mol. Genet. Metab. 2019 128 198 203 10.1016/j.ymgme.2019.01.006 30709775
9. Miller W.L. Steroid hormone synthesis in mitochondria Mol. Cell. Endocrinol. 2013 379 62 73 10.1016/j.mce.2013.04.014 23628605
10. Anderson A.J. Jackson T.D. Stroud D.A. Stojanovski D. Mitochondria—Hubs for regulating cellular biochemistry: Emerging concepts and networks Open Biol. 2019 9 190126 10.1098/rsob.190126 31387448
11. Chan D.C. Fusion and fission: Interlinked processes critical for mitochondrial health Annu. Rev. Genet. 2012 46 265 287 10.1146/annurev-genet-110410-132529 22934639
12. Pickles S. Vigié P. Youle R.J. Mitophagy and quality control mechanisms in mitochondrial maintenance Curr. Biol. 2018 28 R170 R185 10.1016/j.cub.2018.01.004 29462587
13. Mills E.L. Kelly B. O’Neill L.A.J. Mitochondria are the powerhouses of immunity Nat. Immunol. 2017 18 488 498 10.1038/ni.3704 28418387
14. Tiku V. Tan M.-W. Dikic I. Mitochondrial functions in infection and immunity Trends Cell Biol. 2020 30 263 275 10.1016/j.tcb.2020.01.006 32200805
15. Schapira A.H. Mitochondrial disease Lancet 2006 368 70 82 10.1016/S0140-6736(06)68970-8 16815381
16. DiMauro S. Schon E.A. Mitochondrial respiratory-chain diseases N. Engl. J. Med. 2003 348 2656 2668 10.1056/NEJMra022567 12826641
17. Luft R. The development of mitochondrial medicine Proc. Natl. Acad. Sci. USA 1994 91 8731 8738 10.1073/pnas.91.19.8731 8090715
18. La Morgia C. Maresca A. Caporali L. Valentino M.L. Carelli V. Mitochondrial diseases in adults J. Intern. Med. 2020 287 592 608 10.1111/joim.13064 32463135
19. Petruzzella V. Tiranti V. Fernandez P. Ianna P. Carrozzo R. Zeviani M. Identification and characterization of human CDNAs specific to BCS1, PET112, SCO1, COX15, and COX11—Five genes involved in the formation and function of the mitochondrial respiratory chain Genomics 1998 54 494 504 10.1006/geno.1998.5580 9878253
20. Stenton S.L. Prokisch H. Advancing genomic approaches to the molecular diagnosis of mitochondrial disease Essays Biochem. 2018 62 399 408 10.1042/EBC20170110 29950319
21. Stenton S.L. Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis EBioMedicine 2020 56 102784 10.1016/j.ebiom.2020.102784 32454403
22. Calvo S.E. Compton A.G. Hershman S.G. Lim S.C. Lieber D.S. Tucker E.J. Laskowski A. Garone C. Liu S. Jaffe D.B. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing Sci. Transl. Med. 2012 4 118ra10 10.1126/scitranslmed.3003310 22277967
23. Plutino M. Chaussenot A. Rouzier C. Ait-El-Mkadem S. Fragaki K. Paquis-Flucklinger V. Bannwarth S. Targeted next generation sequencing with an extended gene panel does not impact variant detection in mitochondrial diseases BMC Med. Genet. 2018 19 57 10.1186/s12881-018-0568-y 29625556
24. Anderson S. Bankier A.T. Barrell B.G. de Bruijn M.H.L. Coulson A.R. Drouin J. Eperon I.C. Nierlich D.P. Roe B.A. Sanger F. Sequence and organization of the human mitochondrial genome Nature 1981 290 457 465 10.1038/290457a0 7219534
25. Garone C. Donati M.A. Sacchini M. Garcia-Diaz B. Bruno C. Calvo S. Mootha V.K. DiMauro S. Mitochondrial encephalomyopathy due to a novel mutation in ACAD9 JAMA Neurol. 2013 70 1177 1179 10.1001/jamaneurol.2013.3197 23836383
26. Oláhová M. Berti C.C. Collier J.J. Alston C.L. Jameson E. Jones S.A. Edwards N. He L. Chinnery P.F. Horvath R. Molecular genetic investigations identify new clinical phenotypes associated with BCS1L-related mitochondrial disease Hum. Mol. Genet. 2019 28 3766 3776 10.1093/hmg/ddz202 31435670
27. Stenton S.L. Kremer L.S. Kopajtich R. Ludwig C. Prokisch H. The diagnosis of inborn errors of metabolism by an integrative “multi-omics’’ approach: A perspective encompassing genomics, transcriptomics, and proteomics J. Inherit. Metab. Dis. 2020 43 25 35 10.1002/jimd.12130 31119744
28. Mootha V.K. Bunkenborg J. Olsen J.V. Hjerrild M. Wisniewski J.R. Stahl E. Bolouri M.S. Ray H.N. Sihag S. Kamal M. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria Cell 2003 115 629 640 10.1016/S0092-8674(03)00926-7 14651853
29. Pagliarini D.J. Calvo S.E. Chang B. Sheth S.A. Vafai S.B. Ong S.-E. Walford G.A. Sugiana C. Boneh A. Chen W.K. A mitochondrial protein compendium elucidates complex I disease biology Cell 2008 134 112 123 10.1016/j.cell.2008.06.016 18614015
30. Gonczarowska-Jorge H. Zahedi R.P. Sickmann A. The proteome of baker’s yeast mitochondria Mitochondrion 2017 33 15 21 10.1016/j.mito.2016.08.007 27535110
31. Clamp M. Fry B. Kamal M. Xie X. Cuff J. Lin M.F. Kellis M. Lindblad-Toh K. Lander E.S. Distinguishing protein-coding and noncoding genes in the human genome Proc. Natl. Acad. Sci. USA 2007 104 19428 19433 10.1073/pnas.0709013104 18040051
32. Ponomarenko E.A. Poverennaya E.V. Ilgisonis E.V. Pyatnitskiy M.A. Kopylov A.T. Zgoda V.G. Lisitsa A.V. Archakov A.I. The size of the human proteome: The width and depth Int. J. Anal. Chem. 2016 2016 7436849 10.1155/2016/7436849 27298622
33. Lopez M.F. Kristal B.S. Chernokalskaya E. Lazarev A. Shestopalov A.I. Bogdanova A. Robinson M. High-throughput profiling of the mitochondrial proteome using affinity fractionation and automation Electrophoresis 2000 21 3427 3440 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L 11079563
34. Karlberg O. Canbäck B. Kurland C.G. Andersson S.G. The dual origin of the yeast mitochondrial proteome Yeast 2000 17 170 187 10.1155/2000/597406 11025528
35. Cotter D. MitoProteome: Mitochondrial protein sequence database and annotation system Nucleic Acids Res. 2004 32 D463 D467 10.1093/nar/gkh048 14681458
36. Guda P. Subramaniam S. Guda C. Mitoproteome: Human heart mitochondrial protein sequence database Methods Mol Biol. 2007 357 375 383 10.1385/1-59745-214-9:375 17172703
37. Calvo S.E. Clauser K.R. Mootha V.K. MitoCarta2.0: An updated inventory of mammalian mitochondrial proteins Nucleic Acids Res. 2016 44 D1251 D1257 10.1093/nar/gkv1003 26450961
38. Smith A.C. Robinson A.J. MitoMiner v3.1, an update on the mitochondrial proteomics database Nucleic Acids Res. 2016 44 D1258 D1261 10.1093/nar/gkv1001 26432830
39. Doccini S. Morani F. Nesti C. Pezzini F. Calza G. Soliymani R. Signore G. Rocchiccioli S. Kanninen K.M. Huuskonen M.T. Proteomic and functional analyses in disease models reveal CLN5 protein involvement in mitochondrial dysfunction Cell Death Discov. 2020 6 18 10.1038/s41420-020-0250-y 32257390
40. Hung V. Lam S.S. Udeshi N.D. Svinkina T. Guzman G. Mootha V.K. Carr S.A. Ting A.Y. Correction: Proteomic mapping of cytosol-facing outer mitochondrial and ER membranes in living human cells by proximity biotinylation eLife 2019 8 e50707 10.7554/eLife.50707 31378216
41. Geladaki A. Kočevar Britovšek N. Breckels L.M. Smith T.S. Vennard O.L. Mulvey C.M. Crook O.M. Gatto L. Lilley K.S. Combining LOPIT with differential ultracentrifugation for high-resolution spatial proteomics Nat. Commun. 2019 10 331 10.1038/s41467-018-08191-w 30659192
42. Sung A.Y. Floyd B.J. Pagliarini D.J. Systems biochemistry approaches to defining mitochondrial protein function Cell Metab. 2020 31 669 678 10.1016/j.cmet.2020.03.011 32268114
43. Ohue M. Matsuzaki Y. Uchikoga N. Ishida T. Akiyama Y. MEGADOCK: An all-to-all protein-protein interaction prediction system using tertiary structure data Protein Pept. Lett. 2013 21 766 778 10.2174/09298665113209990050
44. Ohue M. Shimoda T. Suzuki S. Matsuzaki Y. Ishida T. Akiyama Y. MEGADOCK 4.0: An ultra–high-performance protein–protein docking software for heterogeneous supercomputers Bioinformatics 2014 30 3281 3283 10.1093/bioinformatics/btu532 25100686
45. Hayashi T. Matsuzaki Y. Yanagisawa K. Ohue M. Akiyama Y. MEGADOCK-Web: An integrated database of high-throughput structure-based protein-protein interaction predictions BMC Bioinform. 2018 19 62 10.1186/s12859-018-2073-x
46. Floyd B.J. Wilkerson E.M. Veling M.T. Minogue C.E. Xia C. Beebe E.T. Wrobel R.L. Cho H. Kremer L.S. Alston C.L. Mitochondrial protein interaction mapping identifies regulators of respiratory chain function Mol. Cell 2016 63 621 632 10.1016/j.molcel.2016.06.033 27499296
47. Formosa L.E. Dibley M.G. Stroud D.A. Ryan M.T. Building a complex complex: Assembly of mitochondrial respiratory chain complex I Semin. Cell Dev. Biol. 2018 76 154 162 10.1016/j.semcdb.2017.08.011 28797839
48. Labory J. Fierville M. Ait-El-Mkadem S. Bannwarth S. Paquis-Flucklinger V. Bottini S. Multi-omics approaches to improve mitochondrial disease diagnosis: Challenges, advances, and perspectives Front. Mol. Biosci. 2020 7 590842 10.3389/fmolb.2020.590842 33240932
49. Khan S. Ince-Dunn G. Suomalainen A. Elo L.L. Integrative omics approaches provide biological and clinical insights: Examples from mitochondrial diseases J. Clin. Investig. 2020 130 20 28 10.1172/JCI129202 31895050
50. Yu Y. Herman P. Rothman D.L. Agarwal D. Hyder F. Evaluating the gray and white matter energy budgets of human brain function J. Cereb. Blood Flow Metab. 2018 38 1339 1353 10.1177/0271678X17708691 28589753
51. Sokoloff L. Reivich M. Kennedy C. Rosiers M.H.D. Patlak C.S. Pettigrew K.D. Sakurada O. Shinohara M. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat J. Neurochem. 1977 28 897 916 10.1111/j.1471-4159.1977.tb10649.x 864466
52. Bélanger M. Allaman I. Magistretti P.J. Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation Cell Metab. 2011 14 724 738 10.1016/j.cmet.2011.08.016 22152301
53. Barros L.F. Courjaret R. Jakoby P. Loaiza A. Lohr C. Deitmer J.W. Preferential transport and metabolism of glucose in bergmann glia over purkinje cells: A multiphoton study of cerebellar slices Glia 2009 57 962 970 10.1002/glia.20820 19062182
54. Jha M.K. Morrison B.M. Glia-neuron energy metabolism in health and diseases: New insights into the role of nervous system metabolic transporters Exp. Neurol. 2018 309 23 31 10.1016/j.expneurol.2018.07.009 30044944
55. Parpura V. Basarsky T.A. Liu F. Jeftinija K. Jeftinija S. Haydon P.G. Glutamate-mediated astrocyte–neuron signalling Nature 1994 369 744 747 10.1038/369744a0 7911978
56. Xin W. Bonci A. Functional astrocyte heterogeneity and implications for their role in shaping neurotransmission Front. Cell. Neurosci. 2018 12 141 10.3389/fncel.2018.00141 29896091
57. Oliveira J.F. Sardinha V.M. Guerra-Gomes S. Araque A. Sousa N. Do stars govern our actions? Astrocyte involvement in rodent behavior Trends Neurosci. 2015 38 535 549 10.1016/j.tins.2015.07.006 26316036
58. Allen N.J. Star power: Astrocytes regulate behavior Cell 2019 177 1091 1093 10.1016/j.cell.2019.04.042 31100265
59. Herrero-Mendez A. Almeida A. Fernández E. Maestre C. Moncada S. Bolaños J.P. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C–Cdh1 Nat. Cell Biol. 2009 11 747 752 10.1038/ncb1881 19448625
60. Bittner C.X. Valdebenito R. Ruminot I. Loaiza A. Larenas V. Sotelo-Hitschfeld T. Moldenhauer H. San Martin A. Gutierrez R. Zambrano M. Fast and reversible stimulation of astrocytic glycolysis by K+ and a delayed and persistent effect of glutamate J. Neurosci. 2011 31 4709 4713 10.1523/JNEUROSCI.5311-10.2011 21430169
61. Bouzier-Sore A.-K. Voisin P. Canioni P. Magistretti P.J. Pellerin L. Lactate is a preferential oxidative energy substrate over glucose for neurons in culture J. Cereb. Blood Flow Metab. 2003 23 1298 1306 10.1097/01.WCB.0000091761.61714.25 14600437
62. Allaman I. Bélanger M. Magistretti P.J. Astrocyte–neuron metabolic relationships: For better and for worse Trends Neurosci. 2011 34 76 87 10.1016/j.tins.2010.12.001 21236501
63. Fecher C. Trovò L. Müller S.A. Snaidero N. Wettmarshausen J. Heink S. Ortiz O. Wagner I. Kühn R. Hartmann J. Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity Nat. Neurosci. 2019 22 1731 1742 10.1038/s41593-019-0479-z 31501572
64. Petrova V.Y. Drescher D. Kujumdzieva A.V. Schmitt M.J. Dual Targeting of yeast catalase A to peroxisomes and mitochondria Biochem. J. 2004 380 393 400 10.1042/bj20040042 14998369
65. Baughman J.M. Perocchi F. Girgis H.S. Plovanich M. Belcher-Timme C.A. Sancak Y. Bao X.R. Strittmatter L. Goldberger O. Bogorad R.L. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter Nature 2011 476 341 345 10.1038/nature10234 21685886
66. Lopez-Fabuel I. Le Douce J. Logan A. James A.M. Bonvento G. Murphy M.P. Almeida A. Bolaños J.P. Complex I Assembly into supercomplexes determines differential mitochondrial ROS production in neurons and astrocytes Proc. Natl. Acad. Sci. USA 2016 113 13063 13068 10.1073/pnas.1613701113 27799543
67. Graham L.C. Eaton S.L. Brunton P.J. Atrih A. Smith C. Lamont D.J. Gillingwater T.H. Pennetta G. Skehel P. Wishart T.M. Proteomic profiling of neuronal mitochondria reveals modulators of synaptic architecture Mol. Neurodegener. 2017 12 77 10.1186/s13024-017-0221-9 29078798
68. Stauch K.L. Purnell P.R. Fox H.S. Quantitative proteomics of synaptic and nonsynaptic mitochondria: Insights for synaptic mitochondrial vulnerability J. Proteome Res. 2014 13 2620 2636 10.1021/pr500295n 24708184
69. Yousefi R. Fornasiero E.F. Cyganek L. Montoya J. Jakobs S. Rizzoli S.O. Rehling P. Pacheu-Grau D. Monitoring mitochondrial translation in living cells EMBO Rep. 2021 22 e51635 10.15252/embr.202051635 33586863
70. Inak G. Rybak-Wolf A. Lisowski P. Pentimalli T.M. Jüttner R. Glažar P. Uppal K. Bottani E. Brunetti D. Secker C. Defective metabolic programming impairs early neuronal morphogenesis in neural cultures and an organoid model of leigh syndrome Nat. Commun. 2021 12 1929 10.1038/s41467-021-22117-z 33771987
71. Quadalti C. Brunetti D. Lagutina I. Duchi R. Perota A. Lazzari G. Cerutti R. Di Meo I. Johnson M. Bottani E. SURF1 knockout cloned pigs: Early onset of a severe lethal phenotype Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 2018 1864 2131 2142 10.1016/j.bbadis.2018.03.021
72. Bottani E. Lamperti C. Prigione A. Tiranti V. Persico N. Brunetti D. Therapeutic approaches to treat mitochondrial diseases: ‘’One-size-fits-all’’ and ‘’precision medicine’’ strategies Pharmaceutics 2020 12 1083 10.3390/pharmaceutics12111083
73. Papa S. Martino P.L. Capitanio G. Gaballo A. De Rasmo D. Signorile A. Petruzzella V. The oxidative phosphorylation system in mammalian mitochondria Advances in Mitochondrial Medicine Scatena R. Bottoni P. Giardina B. Springer Dordrecht, The Netherlands 2012 Volume 942 3 37
74. Fernandez-Vizarra E. Zeviani M. Mitochondrial disorders of the OXPHOS system FEBS Lett. 2021 595 1062 1106 10.1002/1873-3468.13995 33159691
75. Tang J.X. Thompson K. Taylor R.W. Oláhová M. Mitochondrial OXPHOS biogenesis: Co-regulation of protein synthesis, Import, and assembly pathways Int. J. Mol. Sci. 2020 21 3820 10.3390/ijms21113820
76. Bergman O. Ben-Shachar D. Mitochondrial Oxidative Phosphorylation System (OXPHOS) deficits in schizophrenia: Possible interactions with cellular processes Can. J. Psychiatry 2016 61 457 469 10.1177/0706743716648290 27412728
77. Chacinska A. Koehler C.M. Milenkovic D. Lithgow T. Pfanner N. Importing mitochondrial proteins: Machineries and mechanisms Cell 2009 138 628 644 10.1016/j.cell.2009.08.005 19703392
78. Carapito C. Kuhn L. Karim L. Rompais M. Rabilloud T. Schwenzer H. Sissler M. Two proteomic methodologies for defining N-termini of mature human mitochondrial aminoacyl-TRNA synthetases Methods 2017 113 111 119 10.1016/j.ymeth.2016.10.012 27793688
79. Russell O.M. Gorman G.S. Lightowlers R.N. Turnbull D.M. Mitochondrial diseases: Hope for the future Cell 2020 181 168 188 10.1016/j.cell.2020.02.051 32220313
80. Rusecka J. Kaliszewska M. Bartnik E. Tońska K. Nuclear genes involved in mitochondrial diseases caused by instability of mitochondrial DNA J. Appl. Genet. 2018 59 43 57 10.1007/s13353-017-0424-3 29344903
81. Yasukawa T. Kang D. An overview of mammalian mitochondrial DNA replication mechanisms J. Biochem. 2018 164 183 193 10.1093/jb/mvy058 29931097
82. Barshad G. Marom S. Cohen T. Mishmar D. Mitochondrial DNA transcription and its regulation: An evolutionary perspective Trends Genet. 2018 34 682 692 10.1016/j.tig.2018.05.009 29945721
83. Boczonadi V. Ricci G. Horvath R. Mitochondrial DNA transcription and translation: Clinical syndromes Essays Biochem. 2018 62 321 340 10.1042/EBC20170103 29980628
84. Kummer E. Ban N. Mechanisms and regulation of protein synthesis in mitochondria Nat. Rev. Mol. Cell Biol. 2021 22 307 325 10.1038/s41580-021-00332-2 33594280
85. Wallace D.C. Bioenergetics in human evolution and disease: Implications for the origins of biological complexity and the missing genetic variation of common diseases Philos. Trans. R. Soc. B Biol. Sci. 2013 368 20120267 10.1098/rstb.2012.0267
86. DiMauro S. Schon E.A. Carelli V. Hirano M. The clinical maze of mitochondrial neurology Nat. Rev. Neurol. 2013 9 429 444 10.1038/nrneurol.2013.126 23835535
87. Wallace D.C. Mitochondrial Genetic medicine Nat. Genet. 2018 50 1642 1649 10.1038/s41588-018-0264-z 30374071
88. Ferreira C.R. Rahman S. Keller M. Zschocke J. ICIMD Advisory GroupAbdenur J. Ali H. Artuch R. Ballabio A. Barshop B. An international classification of inherited metabolic disorders (ICIMD) J. Inherit. Metab. Dis. 2021 44 164 177 10.1002/jimd.12348 33340416
89. Holt I.J. Harding A.E. Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies Nature 1988 331 717 719 10.1038/331717a0 2830540
90. Wallace D. Singh G. Lott M. Hodge J. Schurr T. Lezza A. Elsas L. Nikoskelainen E. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy Science 1988 242 1427 1430 10.1126/science.3201231 3201231
91. Wallace D.C. Zheng X. Lott M.T. Shoffner J.M. Hodge J.A. Kelley R.I. Epstein C.M. Hopkins L.C. Familial mitochondrial encephalomyopathy (MERRF): Genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease Cell 1988 55 601 610 10.1016/0092-8674(88)90218-8 3180221
92. Carelli V. La Morgia C. Clinical syndromes associated with MtDNA mutations: Where we stand after 30 years Essays Biochem. 2018 62 235 254 10.1042/EBC20170097 30030360
93. Leber T. Ueber hereditäre und congenital-angelegte sehnervenleiden Graefe’s Arch. Clin. Exp. Ophthalmol. 1871 17 249 291 10.1007/BF01694557
94. Holt I.J. Harding A.E. Petty R.K. Morgan-Hughes J.A. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy Am. J. Hum. Genet. 1990 46 428 433 2137962
95. Tatuch Y. Christodoulou J. Feigenbaum A. Clarke J.T. Wherret J. Smith C. Rudd N. Petrova-Benedict R. Robinson B.H. Heteroplasmic MtDNA mutation (T----G) at 8993 can cause leigh disease when the percentage of abnormal MtDNA is high Am. J. Hum. Genet. 1992 50 852 858 1550128
96. Prezant T.R. Agapian J.V. Bohlman M.C. Bu X. Öztas S. Qiu W.-Q. Arnos K.S. Cortopassi G.A. Jaber L. Rotter J.I. Mitochondrial ribosomal RNA mutation associated with both antibiotic–induced and non–syndromic deafness Nat. Genet. 1993 4 289 294 10.1038/ng0793-289 7689389
97. Fukuhara N. Tokiguchi S. Shirakawa K. Tsubaki T. Myoclonus epilepsy associated with ragged-red fibres (mitochondrial abnormalities): Disease entity or a syndrome? J. Neurol. Sci. 1980 47 117 133 10.1016/0022-510X(80)90031-3 6774061
98. Shoffner J.M. Lott M.T. Lezza A.M.S. Seibel P. Ballinger S.W. Wallace D.C. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA TRNALys mutation Cell 1990 61 931 937 10.1016/0092-8674(90)90059-N 2112427
99. Pavlakis S.G. Phillips P.C. DiMauro S. De Vivo D.C. Rowland L.P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome Ann. Neurol. 1984 16 481 488 10.1002/ana.410160409 6093682
100. Goto Y. Nonaka I. Horai S. A Mutation in the TRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies Nature 1990 348 651 653 10.1038/348651a0 2102678
101. Kearns T.P. Sayre G.P. Retinitis pigmentosa, external ophthalmophegia, and complete heart block: Unusual syndrome with histologic study in one of two cases AMA. Arch. Ophthalmol. 1958 60 280 289 10.1001/archopht.1958.00940080296016 13558799
102. Zeviani M. Moraes C.T. DiMauro S. Nakase H. Bonilla E. Schon E.A. Rowland L.P. Deletions of mitochondrial DNA in Kearns-Sayre syndrome Neurology 1988 38 1339 10.1212/WNL.38.9.1339 3412580
103. Pearson H.A. Lobel J.S. Kocoshis S.A. Naiman J.L. Windmiller J. Lammi A.T. Hoffman R. Marsh J.C. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction J. Pediatr. 1979 95 976 984 10.1016/S0022-3476(79)80286-3 501502
104. Rötig A. Cormier V. Blanche S. Bonnefont J.P. Ledeist F. Romero N. Schmitz J. Rustin P. Fischer A. Saudubray J.M. Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy J. Clin. Investig. 1990 86 1601 1608 10.1172/JCI114881 2243133
105. Carelli V. Ghelli A. Ratta M. Bacchilega E. Sangiorgi S. Mancini R. Leuzzi V. Cortelli P. Montagna P. Lugaresi E. Leber’s hereditary optic neuropathy: Biochemical effect of 11778/ND4 and 3460/ND1 mutations and correlation with the mitochondrial genotype Neurology 1997 48 1623 1632 10.1212/WNL.48.6.1623 9191778
106. Tatuch Y. Robinson B.H. The mitochondrial DNA mutation at 8993 associated with NARP slows the rate of ATP synthesis in isolated lymphoblast mitochondria Biochem. Biophys. Res. Commun. 1993 192 124 128 10.1006/bbrc.1993.1390 8476414
107. Bernes S.M. Bacino C. Prezant T.R. Pearson M.A. Wood T.S. Fournier P. Fischel-Ghodsian N. Identical mitochondrial DNA deletion in mother with progressive external ophthalmoplegia and son with Pearson marrow-pancreas syndrome J. Pediatr. 1993 123 598 602 10.1016/S0022-3476(05)80962-X 8410517
108. Shanske S. Tang Y. Hirano M. Nishigaki Y. Tanji K. Bonilla E. Sue C. Krishna S. Carlo J.R. Willner J. Identical mitochondrial DNA deletion in a woman with ocular myopathy and in her son with Pearson syndrome Am. J. Hum. Genet. 2002 71 679 683 10.1086/342482 12152148
109. Mukherjee S. Ghosh A. Molecular mechanism of mitochondrial respiratory chain assembly and its relation to mitochondrial diseases Mitochondrion 2020 53 1 20 10.1016/j.mito.2020.04.002 32304865
110. Dang Q.-C.L. Phan D.H. Johnson A.N. Pasapuleti M. Alkhaldi H.A. Zhang F. Vik S.B. Analysis of human mutations in the supernumerary subunits of complex I Life 2020 10 296 10.3390/life10110296
111. Hirst J. Mitochondrial complex I Ann. Rev. Biochem. 2013 82 551 575 10.1146/annurev-biochem-070511-103700 23527692
112. Ripple M.O. Kim N. Springett R. Mammalian complex I pumps 4 protons per 2 electrons at high and physiological proton motive force in living cells* J. Biol. Chem. 2013 288 5374 5380 10.1074/jbc.M112.438945 23306206
113. Efremov R.G. Baradaran R. Sazanov L.A. The architecture of respiratory complex I Nature 2010 465 441 445 10.1038/nature09066 20505720
114. Zhu J. Vinothkumar K.R. Hirst J. Structure of mammalian respiratory complex I Nature 2016 536 354 358 10.1038/nature19095 27509854
115. Vinothkumar K.R. Zhu J. Hirst J. Architecture of mammalian respiratory complex I Nature 2014 515 80 84 10.1038/nature13686 25209663
116. Clason T. Ruiz T. Schägger H. Peng G. Zickermann V. Brandt U. Michel H. Radermacher M. The structure of eukaryotic and prokaryotic complex I J. Struct. Biol. 2010 169 81 88 10.1016/j.jsb.2009.08.017 19732833
117. Baradaran R. Berrisford J.M. Minhas G.S. Sazanov L.A. Crystal structure of the entire respiratory complex I Nature 2013 494 443 448 10.1038/nature11871 23417064
118. Agip A.-N.A. Blaza J.N. Bridges H.R. Viscomi C. Rawson S. Muench S.P. Hirst J. Cryo-EM structures of complex I from mouse heart mitochondria in two biochemically defined states Nat. Struct. Mol. Biol. 2018 25 548 556 10.1038/s41594-018-0073-1 29915388
119. Hirst J. Roessler M.M. Energy conversion, redox catalysis and generation of reactive oxygen species by respiratory complex I Biochim. Biophys. Acta (BBA)-Bioenerg. 2016 1857 872 883 10.1016/j.bbabio.2015.12.009
120. Stroud D.A. Surgenor E.E. Formosa L.E. Reljic B. Frazier A.E. Dibley M.G. Osellame L.D. Stait T. Beilharz T.H. Thorburn D.R. Accessory subunits are integral for assembly and function of human mitochondrial complex I Nature 2016 538 123 126 10.1038/nature19754 27626371
121. Yip C. Harbour M.E. Jayawardena K. Fearnley I.M. Sazanov L.A. Evolution of respiratory complex I J. Biol. Chem. 2011 286 5023 5033 10.1074/jbc.M110.194993 21115482
122. Sazanov L.A. A giant molecular proton pump: Structure and mechanism of respiratory complex I Nat. Rev. Mol. Cell Biol. 2015 16 375 388 10.1038/nrm3997 25991374
123. Zickermann V. Wirth C. Nasiri H. Siegmund K. Schwalbe H. Hunte C. Brandt U. Mechanistic Insight from the crystal structure of mitochondrial complex I Science 2015 347 44 49 10.1126/science.1259859 25554780
124. Parey K. Wirth C. Vonck J. Zickermann V. Respiratory complex I—Structure, mechanism and evolution Curr. Opin. Struct. Biol. 2020 63 1 9 10.1016/j.sbi.2020.01.004 32058886
125. Kampjut D. Sazanov L.A. The coupling mechanism of mammalian respiratory complex I Science 2020 370 eabc4209 10.1126/science.abc4209 32972993
126. Grba D.N. Hirst J. Mitochondrial complex I structure reveals ordered water molecules for catalysis and proton translocation Nat. Struct. Mol. Biol. 2020 27 892 900 10.1038/s41594-020-0473-x 32747785
127. Klusch N. Senkler J. Yildiz Ö. Kühlbrandt W. Braun H.-P. A ferredoxin bridge connects the two arms of plant mitochondrial complex I Plant Cell 2021 33 2072 2091 10.1093/plcell/koab092 33768254
128. Soufari H. Parrot C. Kuhn L. Waltz F. Hashem Y. Specific features and assembly of the plant mitochondrial complex I revealed by Cryo-EM Nat. Commun. 2020 11 5195 10.1038/s41467-020-18814-w 33060577
129. Guo R. Zong S. Wu M. Gu J. Yang M. Architecture of human mitochondrial respiratory megacomplex I2III2IV2 Cell 2017 170 1247 1257 10.1016/j.cell.2017.07.050 28844695
130. Signes A. Fernandez-Vizarra E. Assembly of mammalian oxidative phosphorylation complexes I–V and supercomplexes Essays Biochem. 2018 62 255 270 10.1042/EBC20170098 30030361
131. Vartak R.S. Semwal M.K. Bai Y. An update on complex I assembly: The assembly of players J. Bioenerg. Biomembr. 2014 46 323 328 10.1007/s10863-014-9564-x 25030182
132. Carroll J. Ding S. Fearnley I.M. Walker J.E. Post-translational modifications near the quinone binding site of mammalian complex I* J. Biol. Chem. 2013 288 24799 24808 10.1074/jbc.M113.488106 23836892
133. Protasoni M. Zeviani M. Mitochondrial structure and bioenergetics in normal and disease conditions Int. J. Mol. Sci. 2021 22 586 10.3390/ijms22020586
134. Nouws J. Nijtmans L. Houten S.M. van den Brand M. Huynen M. Venselaar H. Hoefs S. Gloerich J. Kronick J. Hutchin T. Acyl-CoA dehydrogenase 9 is required for the biogenesis of oxidative phosphorylation complex I Cell Metab. 2010 12 283 294 10.1016/j.cmet.2010.08.002 20816094
135. Haack T.B. Danhauser K. Haberberger B. Hoser J. Strecker V. Boehm D. Uziel G. Lamantea E. Invernizzi F. Poulton J. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency Nat. Genet. 2010 42 1131 1134 10.1038/ng.706 21057504
136. Vogel R.O. Janssen R.J. van den Brand M.A.M. Dieteren C.E.J. Verkaart S. Koopman W.J.H. Willems P.H.G.M. Pluk W. van den Heuvel L.P.W.J. Smeitink J.A.M. Cytosolic signaling protein ecsit also localizes to mitochondria where it interacts with chaperone NDUFAF1 and functions in complex I assembly Genes Dev. 2007 21 615 624 10.1101/gad.408407 17344420
137. Rendón O.Z. Antonicka H. Horvath R. Shoubridge E.A. A mutation in the flavin adenine dinucleotide-dependent oxidoreductase FOXRED1 results in cell-type-specific assembly defects in oxidative phosphorylation complexes I and II Mol. Cell. Biol. 2016 36 2132 2140 10.1128/MCB.00066-16 27215383
138. Formosa L.E. Mimaki M. Frazier A.E. McKenzie M. Stait T.L. Thorburn D.R. Stroud D.A. Ryan M.T. Characterization of mitochondrial FOXRED1 in the assembly of respiratory chain complex I Hum. Mol. Genet. 2015 24 2952 2965 10.1093/hmg/ddv058 25678554
139. Calvo S.E. Tucker E.J. Compton A.G. Kirby D.M. Crawford G. Burtt N.P. Rivas M. Guiducci C. Bruno D.L. Goldberger O.A. High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency Nat. Genet. 2010 42 851 858 10.1038/ng.659 20818383
140. Andrews B. Carroll J. Ding S. Fearnley I.M. Walker J.E. Assembly factors for the membrane arm of human complex I Proc. Natl. Acad. Sci. USA 2013 110 18934 18939 10.1073/pnas.1319247110 24191001
141. Čížková A. Stránecký V. Mayr J.A. Tesařová M. Havlíčková V. Paul J. Ivánek R. Kuss A.W. Hansíková H. Kaplanová V. TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy Nat. Genet. 2008 40 1288 1290 10.1038/ng.246 18953340
142. Sánchez-Caballero L. Elurbe D.M. Baertling F. Guerrero-Castillo S. van den Brand M. van Strien J. van Dam T.J.P. Rodenburg R. Brandt U. Huynen M.A. TMEM70 functions in the assembly of complexes I and V Biochim. Biophys. Acta (BBA)-Bioenerg. 2020 1861 148202 10.1016/j.bbabio.2020.148202
143. Catteruccia M. Verrigni D. Martinelli D. Torraco A. Agovino T. Bonafé L. D’Amico A. Donati M.A. Adorisio R. Santorelli F.M. Persistent pulmonary arterial hypertension in the newborn (PPHN): A frequent manifestation of TMEM70 defective patients Mol. Genet. Metab. 2014 111 353 359 10.1016/j.ymgme.2014.01.001 24485043
144. Staretz-Chacham O. Wormser O. Manor E. Birk O.S. Ferreira C.R. TMEM70 deficiency: Novel mutation and hypercitrullinemia during metabolic decompensation Am. J. Med. Genet. 2019 179 1293 1298 10.1002/ajmg.a.61138 30950220
145. Hirono K. Ichida F. Nishio N. Ogawa-Tominaga M. Fushimi T. Feichtinger R.G. Mayr J.A. Kohda M. Kishita Y. Okazaki Y. Mitochondrial complex deficiency by novel compound heterozygous TMEM70 variants and correlation with developmental delay, undescended testicle, and left ventricular noncompaction in a Japanese patient: A case report Clin. Case Rep. 2019 7 553 557 10.1002/ccr3.2050 30899493
146. Spiegel R. Khayat M. Shalev S.A. Horovitz Y. Mandel H. Hershkovitz E. Barghuti F. Shaag A. Saada A. Korman S.H. TMEM70 mutations are a common cause of nuclear encoded ATP synthase assembly defect: Further delineation of a new syndrome J. Med. Genet. 2011 48 177 182 10.1136/jmg.2010.084608 21147908
147. Vogel R.O. Janssen R.J.R.J. Ugalde C. Grovenstein M. Huijbens R.J. Visch H.-J. van den Heuvel L.P. Willems P.H. Zeviani M. Smeitink J.A.M. Human mitochondrial complex I assembly is mediated by NDUFAF1 FEBS J. 2005 272 5317 5326 10.1111/j.1742-4658.2005.04928.x 16218961
148. Dunning C.J.R. McKenzie M. Sugiana C. Lazarou M. Silke J. Connelly A. Fletcher J.M. Kirby D.M. Thorburn D.R. Ryan M.T. Human CIA30 is involved in the early assembly of mitochondrial complex I and mutations in its gene cause disease EMBO J. 2007 26 3227 3237 10.1038/sj.emboj.7601748 17557076
149. Ogilvie I. Ogilvie I. Kennaway N.G. Shoubridge E.A. A molecular chaperone for mitochondrial complex I assembly is mutated in a progressive encephalopathy J. Clin. Investig. 2005 115 2784 2792 10.1172/JCI26020 16200211
150. Saada A. Edvardson S. Rapoport M. Shaag A. Amry K. Miller C. Lorberboum-Galski H. Elpeleg O. C6ORF66 is an assembly factor of mitochondrial complex I Am. J. Hum. Genet. 2008 82 32 38 10.1016/j.ajhg.2007.08.003 18179882
151. Saada A. Vogel R.O. Hoefs S.J. van den Brand M.A. Wessels H.J. Willems P.H. Venselaar H. Shaag A. Barghuti F. Reish O. Mutations in NDUFAF3 (C3ORF60), encoding an NDUFAF4 (C6ORF66)-interacting complex I assembly protein, cause fatal neonatal mitochondrial disease Am. J. Hum. Genet. 2009 84 718 727 10.1016/j.ajhg.2009.04.020 19463981
152. Sugiana C. Pagliarini D.J. McKenzie M. Kirby D.M. Salemi R. Abu-Amero K.K. Dahl H.-H.M. Hutchison W.M. Vascotto K.A. Smith S.M. Mutation of C20orf7 disrupts complex I assembly and causes lethal neonatal mitochondrial disease Am. J. Hum. Genet. 2008 83 468 478 10.1016/j.ajhg.2008.09.009 18940309
153. Rhein V.F. Carroll J. Ding S. Fearnley I.M. Walker J.E. NDUFAF5 Hydroxylates NDUFS7 at an early stage in the assembly of human complex I J. Biol. Chem. 2016 291 14851 14860 10.1074/jbc.M116.734970 27226634
154. McKenzie M. Tucker E.J. Compton A.G. Lazarou M. George C. Thorburn D.R. Ryan M.T. Mutations in the gene encoding C8orf38 block complex I assembly by inhibiting production of the mitochondria-encoded subunit ND1 J. Mol. Biol. 2011 414 413 426 10.1016/j.jmb.2011.10.012 22019594
155. Bianciardi L. Imperatore V. Fernandez-Vizarra E. Lopomo A. Falabella M. Furini S. Galluzzi P. Grosso S. Zeviani M. Renieri A. Exome sequencing coupled with MRNA analysis identifies NDUFAF6 as a leigh gene Mol. Genet. Metab. 2016 119 214 222 10.1016/j.ymgme.2016.09.001 27623250
156. Catania A. Ardissone A. Verrigni D. Legati A. Reyes A. Lamantea E. Diodato D. Tonduti D. Imperatore V. Pinto A.M. Compound heterozygous missense and deep intronic variants in NDUFAF6 unraveled by exome sequencing and MRNA analysis J. Hum. Genet. 2018 63 563 568 10.1038/s10038-018-0423-1 29531337
157. Baide-Mairena H. Gaudó P. Marti-Sánchez L. Emperador S. Sánchez-Montanez A. Alonso-Luengo O. Correa M. Grau A.M. Ortigoza-Escobar J.D. Artuch R. Mutations in the mitochondrial complex I assembly factor NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in childhood Mol. Genet. Metab. 2019 126 250 258 10.1016/j.ymgme.2019.01.001 30642748
158. Hartmannová H. Piherová L. Tauchmannová K. Kidd K. Acott P.D. Crocker J.F.S. Oussedik Y. Mallet M. Hodaňová K. Stránecký V. Acadian variant of fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a non-coding mutation in complex I assembly factor NDUFAF6 Hum. Mol. Genet. 2016 25 4062 4079 10.1093/hmg/ddw245 27466185
159. Carilla-Latorre S. Gallardo M.E. Annesley S.J. Calvo-Garrido J. Graña O. Accari S.L. Smith P.K. Valencia A. Garesse R. Fisher P.R. MidA is a putative methyltransferase that is required for mitochondrial complex I function J. Cell Sci. 2010 123 1674 1683 10.1242/jcs.066076 20406883
160. Rhein V.F. Carroll J. Ding S. Fearnley I.M. Walker J.E. NDUFAF7 methylates arginine 85 in the NDUFS2 subunit of human complex I J. Biol. Chem. 2013 288 33016 33026 10.1074/jbc.M113.518803 24089531
161. Alston C.L. Veling M.T. Heidler J. Taylor L.S. Alaimo J.T. Sung A.Y. He L. Hopton S. Broomfield A. Pavaine J. Pathogenic bi-allelic mutations in NDUFAF8 cause leigh syndrome with an isolated complex I deficiency Am. J. Hum. Genet. 2020 106 92 101 10.1016/j.ajhg.2019.12.001 31866046
162. Sheftel A.D. Stehling O. Pierik A.J. Netz D.J.A. Kerscher S. Elsässer H.-P. Wittig I. Balk J. Brandt U. Lill R. Human Ind1, an iron-sulfur cluster assembly factor for respiratory complex I Mol. Cell. Biol. 2009 29 6059 6073 10.1128/MCB.00817-09 19752196
163. Bych K. Kerscher S. Netz D.J.A. Pierik A.J. Zwicker K. Huynen M.A. Lill R. Brandt U. Balk J. The iron–sulphur protein Ind1 is required for effective complex I assembly EMBO J. 2008 27 1736 1746 10.1038/emboj.2008.98 18497740
164. Protasoni M. Bruno C. Donati M.A. Mohamoud K. Severino M. Allegri A. Robinson A.J. Reyes A. Zeviani M. Garone C. Novel compound heterozygous pathogenic variants in nucleotide-binding protein like protein (NUBPL) cause leukoencephalopathy with multi-systemic involvement Mol. Genet. Metab. 2020 129 26 34 10.1016/j.ymgme.2019.11.003 31787496
165. Guarani V. Paulo J. Zhai B. Huttlin E.L. Gygi S.P. Harper J.W. TIMMDC1/C3orf1 functions as a membrane-embedded mitochondrial complex I assembly factor through association with the MCIA complex Mol. Cell. Biol. 2014 34 847 861 10.1128/MCB.01551-13 24344204
166. Kremer L.S. Bader D.M. Mertes C. Kopajtich R. Pichler G. Iuso A. Haack T.B. Graf E. Schwarzmayr T. Terrile C. Genetic diagnosis of mendelian disorders via RNA sequencing Nat. Commun. 2017 8 15824 10.1038/ncomms15824 28604674
167. Désir J. Coppieters F. Van Regemorter N. De Baere E. Abramowicz M. Cordonnier M. TMEM126A mutation in a Moroccan family with autosomal recessive optic atrophy Mol. Vis. 2012 18 1849 1857 22815638
168. Hanein S. Perrault I. Roche O. Gerber S. Khadom N. Rio M. Boddaert N. Jean-Pierre M. Brahimi N. Serre V. TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy Am. J. Hum. Genet. 2009 84 493 498 10.1016/j.ajhg.2009.03.003 19327736
169. Kloth K. Synofzik M. Kernstock C. Schimpf-Linzenbold S. Schuettauf F. Neu A. Wissinger B. Weisschuh N. Novel Likely Pathogenic Variants in TMEM126A identified in non-syndromic autosomal recessive optic atrophy: Two case reports BMC Med. Genet. 2019 20 62 10.1186/s12881-019-0795-x 30961538
170. La Morgia C. Caporali L. Tagliavini F. Palombo F. Carbonelli M. Liguori R. Barboni P. Carelli V. First TMEM126A missense mutation in an italian proband with optic atrophy and deafness Neurol. Genet. 2019 5 e329 10.1212/NXG.0000000000000329 31119195
171. Meyer E. Michaelides M. Tee L.J. Robson A.G. Rahman F. Pasha S. Luxon L.M. Moore A.T. Maher E.R. Nonsense mutation in TMEM126A causing autosomal recessive optic atrophy and auditory neuropathy Mol. Vis. 2010 16 650 664 20405026
172. Heide H. Bleier L. Steger M. Ackermann J. Dröse S. Schwamb B. Zörnig M. Reichert A.S. Koch I. Wittig I. Complexome profiling identifies TMEM126B as a component of the mitochondrial complex I assembly complex Cell Metab. 2012 16 538 549 10.1016/j.cmet.2012.08.009 22982022
173. Sánchez-Caballero L. Ruzzenente B. Bianchi L. Assouline Z. Barcia G. Metodiev M.D. Rio M. Funalot B. van den Brand M.A.M. Guerrero-Castillo S. Mutations in complex I assembly factor TMEM126B result in muscle weakness and isolated complex I deficiency Am. J. Hum. Genet. 2016 99 208 216 10.1016/j.ajhg.2016.05.022 27374773
174. Alston C.L. Compton A.G. Formosa L.E. Strecker V. Oláhová M. Haack T.B. Smet J. Stouffs K. Diakumis P. Ciara E. Biallelic mutations in TMEM126B cause severe complex I deficiency with a variable clinical phenotype Am. J. Hum. Genet. 2016 99 217 227 10.1016/j.ajhg.2016.05.021 27374774
175. Guerrero-Castillo S. Baertling F. Kownatzki D. Wessels H.J. Arnold S. Brandt U. Nijtmans L. The assembly pathway of mitochondrial respiratory chain complex I Cell Metab. 2017 25 128 139 10.1016/j.cmet.2016.09.002 27720676
176. Martinez Lyons A. Ardissone A. Reyes A. Robinson A.J. Moroni I. Ghezzi D. Fernandez-Vizarra E. Zeviani M. COA7 (C1orf163/RESA1) mutations associated with mitochondrial leukoencephalopathy and cytochrome C oxidase deficiency J. Med. Genet. 2016 53 846 849 10.1136/jmedgenet-2016-104194 27683825
177. Dibley M.G. Formosa L.E. Lyu B. Reljic B. McGann D. Muellner-Wong L. Kraus F. Sharpe A.J. Stroud D.A. Ryan M.T. The mitochondrial acyl-carrier protein interaction network highlights important roles for LYRM family members in complex I and mitoribosome assembly Mol. Cell. Proteom. 2020 19 65 77 10.1074/mcp.RA119.001784
178. Bugiani M. Invernizzi F. Alberio S. Briem E. Lamantea E. Carrara F. Moroni I. Farina L. Spada M. Donati M.A. Clinical and molecular findings in children with complex I deficiency Biochim. Biophys. Acta (BBA)-Bioenerg. 2004 1659 136 147 10.1016/j.bbabio.2004.09.006
179. Malfatti E. Bugiani M. Invernizzi F. de Souza C.F.-M. Farina L. Carrara F. Lamantea E. Antozzi C. Confalonieri P. Sanseverino M.T. Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathy Brain 2007 130 1894 1904 10.1093/brain/awm114 17535832
180. Fassone E. Rahman S. Complex I deficiency: Clinical features, biochemistry and molecular genetics J. Med. Genet. 2012 49 578 590 10.1136/jmedgenet-2012-101159 22972949
181. Rodenburg R.J. Mitochondrial complex I-linked disease Biochim. Biophys. Acta (BBA)-Bioenerg. 2016 1857 938 945 10.1016/j.bbabio.2016.02.012
182. Man P.Y.-W. Griffiths P.G. Brown D.T. Howell N. Turnbull D.M. Chinnery P.F. The epidemiology of Leber hereditary optic neuropathy in the North East of England Am. J. Hum. Genet. 2003 72 333 339 10.1086/346066 12518276
183. Carelli V. Rugolo M. Sgarbi G. Ghelli A. Zanna C. Baracca A. Lenaz G. Napoli E. Martinuzzi A. Solaini G. Bioenergetics shapes cellular death pathways in Leber’s hereditary optic neuropathy: A model of mitochondrial neurodegeneration Biochim. Biophys. Acta (BBA)-Bioenerg. 2004 1658 172 179 10.1016/j.bbabio.2004.05.009
184. Yu-Wai-Man P. Griffiths P.G. Chinnery P.F. Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies Prog. Retin. Eye Res. 2011 30 81 114 10.1016/j.preteyeres.2010.11.002 21112411
185. Giordano C. Iommarini L. Giordano L. Maresca A. Pisano A. Valentino M.L. Caporali L. Liguori R. Deceglie S. Roberti M. Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy Brain 2014 137 335 353 10.1093/brain/awt343 24369379
186. Bianco A. Martínez-Romero I. Bisceglia L. D’Agruma L. Favia P. Ruiz-Pesini E. Guerriero S. Montoya J. Petruzzella V. Mitochondrial DNA copy number differentiates the Leber’s hereditary optic neuropathy affected individuals from the unaffected mutation carriers Brain 2016 139 e1 10.1093/brain/awv216 26209315
187. Bianco A. Bisceglia L. Russo L. Palese L.L. D’Agruma L. Emperador S. Montoya J. Guerriero S. Petruzzella V. High mitochondrial DNA copy number is a protective factor from vision loss in heteroplasmic Leber’s hereditary optic neuropathy (LHON) Investig. Opthalmol. Vis. Sci. 2017 58 2193 10.1167/iovs.16-20389
188. Bianco A. Valletti A. Longo G. Bisceglia L. Montoya J. Emperador S. Guerriero S. Petruzzella V. Mitochondrial DNA copy number in affected and unaffected LHON mutation carriers BMC Res. Notes 2018 11 911 10.1186/s13104-018-4025-y 30572950
189. Tun A.W. Chaiyarit S. Kaewsutthi S. Katanyoo W. Chuenkongkaew W. Kuwano M. Tomonaga T. Peerapittayamongkol C. Thongboonkerd V. Lertrit P. Profiling the mitochondrial proteome of Leber’s hereditary optic neuropathy (LHON) in Thailand: Down-regulation of bioenergetics and mitochondrial protein quality control pathways in fibroblasts with the 11778G>A mutation PLoS ONE 2014 9 e106779 10.1371/journal.pone.0106779 25215595
190. Lenaz G. Baracca A. Carelli V. D’Aurelio M. Sgarbi G. Solaini G. Bioenergetics of mitochondrial diseases associated with MtDNA mutations Biochim. Biophys. Acta (BBA)-Bioenerg. 2004 1658 89 94 10.1016/j.bbabio.2004.03.013
191. Brown M.D. Trounce I.A. Jun A.S. Allen J.C. Wallace D.C. Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber’s hereditary optic neuropathy mitochondrial DNA mutation J. Biol. Chem. 2000 275 39831 39836 10.1074/jbc.M006476200 10976107
192. Floreani M. Napoli E. Martinuzzi A. Pantano G. De Riva V. Trevisan R. Bisetto E. Valente L. Carelli V. Dabbeni-Sala F. Antioxidant defences in cybrids harboring MtDNA mutations associated with Leber’s hereditary optic neuropathy: Antioxidant defences in LHON cybrids FEBS J. 2005 272 1124 1135 10.1111/j.1742-4658.2004.04542.x 15720387
193. Simon D.K. Friedman J. Breakefield X.O. Jankovic J. Brin M.F. Provias J. Bressman S.B. Charness M.E. Tarsy D. Johns D.R. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia Neurogenetics 2003 4 199 205 10.1007/s10048-003-0150-3 12756609
194. Kirby D.M. Mutations of the mitochondrial ND1 gene as a cause of MELAS J. Med. Genet. 2004 41 784 789 10.1136/jmg.2004.020537 15466014
195. Howell N. Bindoff L.A. McCullough D.A. Kubacka I. Poulton J. Mackey D. Taylor L. Turnbull D.M. Leber hereditary optic neuropathy: Identification of the same mitochondrial ND1 mutation in six pedigrees Am. J. Hum. Genet. 1991 49 939 950 1928099
196. Johns D.R. Berman J. Alternative, simultaneous complex I mitochondrial DNA mutations in Leber’s hereditary optic neuropathy Biochem. Biophys. Res. Commun. 1991 174 1324 1330 10.1016/0006-291X(91)91567-V 1900003
197. McFarland R. Kirby D.M. Fowler K.J. Ohtake A. Ryan M.T. Amor D.J. Fletcher J.M. Dixon J.W. Collins F.A. Turnbull D.M. De novo mutations in the mitochondrial ND3 gene as a cause of infantile mitochondrial encephalopathy and complex I deficiency Ann. Neurol. 2004 55 58 64 10.1002/ana.10787 14705112
198. Torroni A. Petrozzi M. D’Urbano L. Sellitto D. Zeviani M. Carrara F. Carducci C. Leuzzi V. Carelli V. Barboni P. Haplotype and phylogenetic analyses suggest that one european-specific MtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484 Am. J. Hum. Genet. 1997 60 1107 1121 9150158
199. Lertrit P. Noer A.S. Jean-Francois M.J. Kapsa R. Dennett X. Thyagarajan D. Lethlean K. Byrne E. Marzuki S. A new disease-related mutation for mitochondrial encephalopathy lactic acidosis and strokelike episodes (MELAS) syndrome affects the ND4 subunit of the respiratory complex I Am. J. Hum. Genet. 1992 51 457 468 1323207
200. Brown M.D. Starikovskaya E. Derbeneva O. Hosseini S. Allen J.C. Mikhailovskaya I.E. Sukernik R.I. Wallace D.C. The role of MtDNA background in disease expression: A new primary LHON mutation associated with western eurasian haplogroup J. Hum. Genet. 2002 110 130 138 10.1007/s00439-001-0660-8 11935318
201. Brown M.D. Voljavec A.S. Lott M.T. Macdonald I. Wallace D.C. Leber’s hereditary optic neuropathy: A model for mitochondrial neurodegenerative diseases FASEB J. 1992 6 2791 2799 10.1096/fasebj.6.10.1634041 1634041
202. Liolitsa D. Rahman S. Benton S. Carr L.J. Hanna M.G. Is the mitochondrial complex I ND5 gene a hot-spot for MELAS causing mutations? Ann. Neurol. 2003 53 128 132 10.1002/ana.10435 12509858
203. Ravn K. Wibrand F. Hansen F.J. Horn N. Rosenberg T. Schwartz M. An MtDNA mutation, 14453G→A, in the NADH dehydrogenase subunit 6 associated with severe MELAS syndrome Eur. J. Hum. Genet. 2001 9 805 809 10.1038/sj.ejhg.5200712 11781695
204. Schuelke M. Smeitink J. Mariman E. Loeffen J. Plecko B. Trijbels F. Stöckler-Ipsiroglu S. van den Heuvel L. Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy Nat. Genet. 1999 21 260 261 10.1038/6772 10080174
205. Bénit P. Chretien D. Kadhom N. de Lonlay-Debeney P. Cormier-Daire V. Cabral A. Peudenier S. Rustin P. Munnich A. Rötig A. Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency Am. J. Hum. Genet. 2001 68 1344 1352 10.1086/320603 11349233
206. Bénit P. Beugnot R. Chretien D. Giurgea I. De Lonlay-Debeney P. Issartel J.-P. Corral-Debrinski M. Kerscher S. Rustin P. Rötig A. Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy: NDUFV2 and cardiomyopathy/encephalopathy Hum. Mutat. 2003 21 582 586 10.1002/humu.10225 12754703
207. Loeffen J. Elpeleg O. Smeitink J. Smeets R. Stöckler-Ipsiroglu S. Mandel H. Sengers R. Trijbels F. van den Heuvel L. Mutations in the complex I NDUFS2 gene of patients with cardiomyopathy and encephalomyopathy Ann. Neurol. 2001 49 195 201 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M 11220739
208. Benit P. Slama A. Cartault F. Giurgea I. Chretien D. Lebon S. Marsac C. Munnich A. Rotig A. Rustin P. Mutant NDUFS3 Subunit of mitochondrial complex I causes leigh syndrome J. Med. Genet. 2004 41 14 17 10.1136/jmg.2003.014316 14729820
209. Budde S.M.S. van den Heuvel L.P.W.J. Janssen A.J. Smeets R.J.P. Buskens C.A.F. DeMeirleir L. Van Coster R. Baethmann M. Voit T. Trijbels J.M.F. Combined enzymatic complex I and III deficiency associated with mutations in the nuclear encoded NDUFS4 gene Biochem. Biophys. Res. Commun. 2000 275 63 68 10.1006/bbrc.2000.3257 10944442
210. Spiegel R. Shaag A. Mandel H. Reich D. Penyakov M. Hujeirat Y. Saada A. Elpeleg O. Shalev S.A. Mutated NDUFS6 is the cause of fatal neonatal lactic acidemia in caucasus jews Eur. J. Hum. Genet. 2009 17 1200 1203 10.1038/ejhg.2009.24 19259137
211. Taylor R.W. Pyle A. Griffin H. Blakely E.L. Duff J. He L. Smertenko T. Alston C.L. Neeve V.C. Best A. Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies JAMA 2014 312 68 10.1001/jama.2014.7184 25058219
212. Smeitink J. van den Heuvel L. Human mitochondrial complex I in health and disease Am. J. Hum. Genet. 1999 64 1505 1510 10.1086/302432 10330338
213. Loeffen J. Smeitink J. Triepels R. Smeets R. Schuelke M. Sengers R. Trijbels F. Hamel B. Mullaart R. van den Heuvel L. The first nuclear-encoded complex I mutation in a patient with Leigh syndrome Am. J. Hum. Genet. 1998 63 1598 1608 10.1086/302154 9837812
214. Berger I. Hershkovitz E. Shaag A. Edvardson S. Saada A. Elpeleg O. Mitochondrial complex I deficiency caused by a deleterious NDUFA11 mutation Ann. Neurol. 2008 63 405 408 10.1002/ana.21332 18306244
215. Fernandez-Moreira D. Ugalde C. Smeets R. Rodenburg R.J.T. Lopez-Laso E. Ruiz-Falco M.L. Briones P. Martin M.A. Smeitink J.A.M. Arenas J. X-Linked NDUFA1 gene mutations associated with mitochondrial encephalomyopathy Ann. Neurol. 2007 61 73 83 10.1002/ana.21036 17262856
216. Hoefs S.J.G. Dieteren C.E.J. Distelmaier F. Janssen R.J.R.J. Epplen A. Swarts H.G.P. Forkink M. Rodenburg R.J. Nijtmans L.G. Willems P.H. NDUFA2 complex I mutation leads to Leigh disease Am. J. Hum. Genet. 2008 82 1306 1315 10.1016/j.ajhg.2008.05.007 18513682
217. Alston C.L. Heidler J. Dibley M.G. Kremer L.S. Taylor L.S. Fratter C. French C.E. Glasgow R.I.C. Feichtinger R.G. Delon I. Bi-Allelic mutations in NDUFA6 establish its role in early-onset isolated mitochondrial complex I deficiency Am. J. Hum. Genet. 2018 103 592 601 10.1016/j.ajhg.2018.08.013 30245030
218. van den Bosch B.J.C. Gerards M. Sluiter W. Stegmann A.P.A. Jongen E.L.C. Hellebrekers D.M.E.I. Oegema R. Lambrichs E.H. Prokisch H. Danhauser K. Defective NDUFA9 as a novel cause of neonatally fatal complex I disease J. Med. Genet. 2012 49 10 15 10.1136/jmedgenet-2011-100466 22114105
219. Ostergaard E. Rodenburg R.J. van den Brand M. Thomsen L.L. Duno M. Batbayli M. Wibrand F. Nijtmans L. Respiratory chain complex I deficiency due to NDUFA12 mutations as a new cause of Leigh syndrome J. Med. Genet. 2011 48 737 740 10.1136/jmg.2011.088856 21617257
220. Angebault C. Charif M. Guegen N. Piro-Megy C. de Camaret B.M. Procaccio V. Guichet P.-O. Hebrard M. Manes G. Leboucq N. Mutation in NDUFA13/GRIM19 leads to early onset hypotonia, dyskinesia and sensorial deficiencies, and mitochondrial complex I instability Hum. Mol. Genet. 2015 24 3948 3955 10.1093/hmg/ddv133 25901006
221. Haack T.B. Madignier F. Herzer M. Lamantea E. Danhauser K. Invernizzi F. Koch J. Freitag M. Drost R. Hillier I. Mutation screening of 75 candidate genes in 152 complex I deficiency cases identifies pathogenic variants in 16 genes including NDUFB9 J. Med. Genet. 2012 49 83 89 10.1136/jmedgenet-2011-100577 22200994
222. Piekutowska-Abramczuk D. Assouline Z. Mataković L. Feichtinger R.G. Koňařiková E. Jurkiewicz E. Stawiński P. Gusic M. Koller A. Pollak A. NDUFB8 mutations cause mitochondrial complex I deficiency in individuals with Leigh-like encephalomyopathy Am. J. Hum. Genet. 2018 102 460 467 10.1016/j.ajhg.2018.01.008 29429571
223. Friederich M.W. Erdogan A.J. Coughlin C.R. Elos M.T. Jiang H. O’Rourke C.P. Lovell M.A. Wartchow E. Gowan K. Chatfield K.C. Mutations in the accessory subunit NDUFB10 result in isolated complex I deficiency and illustrate the critical role of intermembrane space import for complex I holoenzyme assembly Hum. Mol. Genet. 2016 26 702 716 10.1093/hmg/ddw431
224. Van Rahden V.A. Fernandez-Vizarra E. Alawi M. Brand K. Fellmann F. Horn D. Zeviani M. Kutsche K. Mutations in NDUFB11, encoding a complex I component of the mitochondrial respiratory chain, cause microphthalmia with linear skin defects syndrome Am. J. Hum. Genet. 2015 96 640 650 10.1016/j.ajhg.2015.02.002 25772934
225. Reinson K. Kovacs-Nagy R. Õiglane-Shlik E. Pajusalu S. Nõukas M. Wintjes L.T. van den Brandt F.C.A. Brink M. Acker T. Ahting U. Diverse phenotype in patients with complex I deficiency due to mutations in NDUFB11 Eur. J. Med. Genet. 2019 62 103572 10.1016/j.ejmg.2018.11.006 30423443
226. Kohda M. Tokuzawa Y. Kishita Y. Nyuzuki H. Moriyama Y. Mizuno Y. Hirata T. Yatsuka Y. Yamashita-Sugahara Y. Nakachi Y. A comprehensive genomic analysis reveals the genetic landscape of mitochondrial respiratory chain complex deficiencies PLoS Genet. 2016 12 e1005679 10.1371/journal.pgen.1005679 26741492
227. Alahmad A. Nasca A. Heidler J. Thompson K. Oláhová M. Legati A. Lamantea E. Meisterknecht J. Spagnolo M. He L. Bi-allelic pathogenic variants in NDUFC2 cause early-onset Leigh syndrome and stalled biogenesis of complex I EMBO Mol. Med. 2020 12 e12619 10.15252/emmm.202012619 32969598
228. Baertling F. Sánchez-Caballero L. Timal S. van den Brand M.A. Ngu L.H. Distelmaier F. Rodenburg R.J. Nijtmans L.G. Mutations in mitochondrial complex I assembly factor NDUFAF3 cause Leigh syndrome Mol. Genet. Metab. 2017 120 243 246 10.1016/j.ymgme.2016.12.005 27986404
229. Baertling F. Sánchez-Caballero L. van den Brand M.A.M. Wintjes L.T. Brink M. van den Brandt F.A. Wilson C. Rodenburg R.J.T. Nijtmans L.G.J. NDUFAF4 variants are associated with Leigh syndrome and cause a specific mitochondrial complex I assembly defect Eur. J. Hum. Genet. 2017 25 1273 1277 10.1038/ejhg.2017.133 28853723
230. Ishiyama A. Muramatsu K. Uchino S. Sakai C. Matsushima Y. Makioka N. Ogata T. Suzuki E. Komaki H. Sasaki M. NDUFAF3 variants that disrupt mitochondrial complex I assembly may associate with cavitating leukoencephalopathy Clin. Genet. 2018 93 1103 1106 10.1111/cge.13215 29344937
231. Ugarteburu O. Teresa Garcia-Silva M. Aldamiz-Echevarria L. Gort L. Garcia-Villoria J. Tort F. Ribes A. Complex I deficiency, due to NDUFAF4 mutations, causes severe mitochondrial dysfunction and is associated to early death and dysmorphia Mitochondrion 2020 55 78 84 10.1016/j.mito.2020.09.003 32949790
232. Petruzzella V. Vergari R. Puzziferri I. Boffoli D. Lamantea E. Zeviani M. Papa S. A nonsense mutation in the NDUFS4 gene encoding the 18 KDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome Hum. Mol. Genet. 2001 10 529 535 10.1093/hmg/10.5.529 11181577
233. Petruzzella V. Papa S. Mutations in human nuclear genes encoding for subunits of mitochondrial respiratory complex I: The NDUFS4 gene Gene 2002 286 149 154 10.1016/S0378-1119(01)00810-1 11943471
234. Petruzzella V. Panelli D. Torraco A. Stella A. Papa S. Mutations in the NDUFS4 gene of mitochondrial complex I alter stability of the splice variants FEBS Lett. 2005 579 3770 3776 10.1016/j.febslet.2005.05.035 15975579
235. Scacco S. Petruzzella V. Budde S. Vergari R. Tamborra R. Panelli D. van den Heuvel L.P. Smeitink J.A. Papa S. Pathological mutations of the human NDUFS4 gene of the 18-KDa (AQDQ) subunit of complex I affect the expression of the protein and the assembly and function of the complex J. Biol. Chem. 2003 278 44161 44167 10.1074/jbc.M307615200 12944388
236. Lamont R.E. Beaulieu C.L. Bernier F.P. Sparkes R. Innes A.M. Jackel-Cram C. Ober C. Parboosingh J.S. Lemire E.G. A novel NDUFS4 frameshift mutation causes Leigh disease in the Hutterite population Am. J. Med. Genet. 2017 173 596 600 10.1002/ajmg.a.37983 27671926
237. Budde S.M.S. van den Heuvel L.P.W.J. Smeets R.J.P. Skladal D. Mayr J.A. Boelen C. Petruzzella V. Papa S. Smeitink J.A.M. Clinical heterogeneity in patients with mutations in the NDUFS4 gene of mitochondrial complex I J. Inherit. Metab. Dis. 2003 26 813 815 10.1023/B:BOLI.0000010003.14113.af 14765537
238. Leshinsky-Silver E. Lebre A.-S. Minai L. Saada A. Steffann J. Cohen S. Rötig A. Munnich A. Lev D. Lerman-Sagie T. NDUFS4 mutations cause Leigh syndrome with predominant brainstem involvement Mol. Genet. Metab. 2009 97 185 189 10.1016/j.ymgme.2009.03.002 19364667
239. Ortigoza-Escobar J.D. Oyarzabal A. Montero R. Artuch R. Jou C. Jiménez C. Gort L. Briones P. Muchart J. López-Gallardo E. Ndufs4 related Leigh syndrome: A case report and review of the literature Mitochondrion 2016 28 73 78 10.1016/j.mito.2016.04.001 27079373
240. Finsterer J. Zarrouk-Mahjoub S. NDUFS4-related Leigh syndrome in Hutterites Am. J. Med. Genet. 2017 173 1450 1451 10.1002/ajmg.a.38225 28371352
241. Rahman S. Blok R.B. Dahl H.-H.M. Danks D.M. Kirby D.M. Chow C.W. Christodoulou J. Thorburn D.R. Leigh Syndrome: Clinical features and biochemical and DNA abnormalities Ann. Neurol. 1996 39 343 351 10.1002/ana.410390311 8602753
242. Leigh D. Subacute necrotizing encephalomyelopathy in an infant J. Neurol. Neurosurg. Psychiatry 1951 14 216 221 10.1136/jnnp.14.3.216 14874135
243. Assouline Z. Jambou M. Rio M. Bole-Feysot C. de Lonlay P. Barnerias C. Desguerre I. Bonnemains C. Guillermet C. Steffann J. A constant and similar assembly defect of mitochondrial respiratory chain complex I allows rapid identification of NDUFS4 mutations in patients with Leigh syndrome Biochim. Biophys. Acta (BBA)-Mol. Basis Dis 2012 1822 1062 1069 10.1016/j.bbadis.2012.01.013 22326555
244. Lazarou M. McKenzie M. Ohtake A. Thorburn D.R. Ryan M.T. Analysis of the assembly profiles for mitochondrial—and nuclear-DNA-encoded subunits into complex I Mol. Cell. Biol. 2007 27 4228 4237 10.1128/MCB.00074-07 17438127
245. Breuer M.E. Willems P.H.G.M. Smeitink J.A.M. Koopman W.J.H. Nooteboom M. Cellular and animal models for mitochondrial complex I deficiency: A focus on the NDUFS4 subunit IUBMB Life 2013 65 202 208 10.1002/iub.1127 23378164
246. Ingraham C.A. Burwell L.S. Skalska J. Brookes P.S. Howell R.L. Sheu S.-S. Pinkert C.A. NDUFS4: Creation of a mouse model mimicking a complex I disorder Mitochondrion 2009 9 204 210 10.1016/j.mito.2009.02.001 19460290
247. Ma H. Folmes C.D.L. Wu J. Morey R. Mora-Castilla S. Ocampo A. Ma L. Poulton J. Wang X. Ahmed R. Metabolic rescue in pluripotent cells from patients with MtDNA disease Nature 2015 524 234 238 10.1038/nature14546 26176921
248. Galera-Monge T. Zurita-Díaz F. Canals I. Grønning Hansen M. Rufián-Vázquez L. Ehinger J.K. Elmér E. Martin M.A. Garesse R. Ahlenius H. Mitochondrial dysfunction and calcium dysregulation in Leigh syndrome induced pluripotent stem cell derived neurons Int. J. Mol. Sci. 2020 21 3191 10.3390/ijms21093191
249. Zheng X. Boyer L. Jin M. Kim Y. Fan W. Bardy C. Berggren T. Evans R.M. Gage F.H. Hunter T. Alleviation of neuronal energy deficiency by MTOR inhibition as a treatment for mitochondria-related neurodegeneration eLife 2016 5 e13378 10.7554/eLife.13378 27008180
250. Lorenz C. Lesimple P. Bukowiecki R. Zink A. Inak G. Mlody B. Singh M. Semtner M. Mah N. Auré K. Human IPSC-derived neural progenitors are an effective drug discovery model for neurological MtDNA disorders Cell Stem Cell 2017 20 659 674.e9 10.1016/j.stem.2016.12.013 28132834
251. Romero-Morales A. Rastogi A. Temuri H. Rasmussen M. McElroy G.S. Hsu L. Almonacid P.M. Milis B.A. Chandel N. Cartailler J.-P. Human iPSC-derived cerebral organoids model features of leigh syndrome and reveal abnormal corticogenesis Cell Biol. 2020 10.2139/ssrn.3611282
252. Zhu Z. Yao J. Johns T. Fu K. Bie I.D. Macmillan C. Cuthbert A.P. Newbold R.F. Wang J. Chevrette M. SURF1, Encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome Nat. Genet. 1998 20 337 343 10.1038/3804 9843204
253. Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency Am. J. Hum. Genet. 1998 63 1609 1621 10.1086/302150 9837813
254. Saneto R. Ruhoy I. The genetics of Leigh syndrome and its implications for clinical practice and risk management Appl. Clin. Genet. 2014 7 221 10.2147/TACG.S46176 25419155
255. Sun F. Huo X. Zhai Y. Wang A. Xu J. Su D. Bartlam M. Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II Cell 2005 121 1043 1057 10.1016/j.cell.2005.05.025 15989954
256. Van Vranken J.G. Na U. Winge D.R. Rutter J. Protein-mediated assembly of succinate dehydrogenase and its cofactors Crit. Rev. Biochem. Mol. Biol. 2015 50 168 180 10.3109/10409238.2014.990556 25488574
257. Ghezzi D. Goffrini P. Uziel G. Horvath R. Klopstock T. Lochmüller H. D’Adamo P. Gasparini P. Strom T.M. Prokisch H. SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy Nat. Genet. 2009 41 654 656 10.1038/ng.378 19465911
258. Munnich A. Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders Am. J. Med. Genet. 2001 106 4 17 10.1002/ajmg.1391 11579420
259. Bourgeron T. Rustin P. Chretien D. Birch-Machin M. Bourgeois M. Viegas-Péquignot E. Munnich A. Rötig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency Nat. Genet. 1995 11 144 149 10.1038/ng1095-144 7550341
260. Parfait B. Chretien D. Rötig A. Marsac C. Munnich A. Rustin P. Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome Hum. Genet. 2000 106 236 243 10.1007/s004399900218 10746566
261. Van Coster R. Seneca S. Smet J. Van Hecke R. Gerlo E. Devreese B. Van Beeumen J. Leroy J.G. De Meirleir L. Lissens W. Homozygous Gly555Glu mutation in the nuclear-encoded 70 KDa flavoprotein gene causes instability of the respiratory chain complex II Am. J. Med. Genet. 2003 120A 13 18 10.1002/ajmg.a.10202 12794685
262. Pagnamenta A.T. Hargreaves I.P. Duncan A.J. Taanman J.-W. Heales S.J. Land J.M. Bitner-Glindzicz M. Leonard J.V. Rahman S. Phenotypic variability of mitochondrial disease caused by a nuclear mutation in complex II Mol. Genet. Metab. 2006 89 214 221 10.1016/j.ymgme.2006.05.003 16798039
263. Horvath R. Abicht A. Holinski-Feder E. Laner A. Gempel K. Prokisch H. Lochmüller H. Klopstock T. Jaksch M. Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA) J. Neurol. Neurosurg. Psychiatry 2006 77 74 76 10.1136/jnnp.2005.067041 16361598
264. Jain-Ghai S. Cameron J.M. Al Maawali A. Blaser S. MacKay N. Robinson B. Raiman J. Complex II deficiency—A case report and review of the literature Am. J. Med. Genet. 2013 161 285 294 10.1002/ajmg.a.35714 23322652
265. Nesti C. Meschini M.C. Meunier B. Sacchini M. Doccini S. Romano A. Petrillo S. Pezzini I. Seddiki N. Rubegni A. Additive effect of nuclear and mitochondrial mutations in a patient with mitochondrial encephalomyopathy Hum. Mol. Genet. 2015 24 3248 3256 10.1093/hmg/ddv078 25736212
266. Levitas A. Muhammad E. Harel G. Saada A. Caspi V.C. Manor E. Beck J.C. Sheffield V. Parvari R. Familial neonatal isolated cardiomyopathy caused by a mutation in the flavoprotein subunit of succinate dehydrogenase Eur. J. Hum. Genet. 2010 18 1160 1165 10.1038/ejhg.2010.83 20551992
267. Burnichon N. Brière J.-J. Libé R. Vescovo L. Rivière J. Tissier F. Jouanno E. Jeunemaitre X. Bénit P. Tzagoloff A. SDHA is a tumor suppressor gene causing paraganglioma Hum. Mol. Genet. 2010 19 3011 3020 10.1093/hmg/ddq206 20484225
268. Astuti D. Latif F. Dallol A. Dahia P.L.M. Douglas F. George E. Sköldberg F. Husebye E.S. Eng C. Maher E.R. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma Am. J. Hum. Genet. 2001 69 49 54 10.1086/321282 11404820
269. Janeway K.A. Kim S.Y. Lodish M. Nosé V. Rustin P. Gaal J. Dahia P.L.M. Liegl B. Ball E.R. Raygada M. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations Proc. Natl. Acad. Sci. USA 2011 108 314 318 10.1073/pnas.1009199108 21173220
270. Baysal B.E. Willett-Brozick J. Filho P. Lawrence E.C. Myers E.N. Ferrell R. An alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma J. Med. Genet. 2004 41 703 709 10.1136/jmg.2004.019224 15342702
271. McWhinney S.R. Pasini B. Stratakis C.A. Familial gastrointestinal stromal tumors and germ-line mutations N. Engl. J. Med. 2007 357 1054 1056 10.1056/NEJMc071191 17804857
272. Baysal B.E. Ferrell R.E. Willett-Brozick J.E. Lawrence E.C. Myssiorek D. Bosch A. Van Der Mey A. Taschner P. Rubinstein W.S. Myers E.N. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 2000 287 848 851 10.1126/science.287.5454.848 10657297
273. Hao H.-X. Khalimonchuk O. Schraders M. Dephoure N. Bayley J.-P. Kunst H. Devilee P. Cremers C.W.R.J. Schiffman J.D. Bentz B.G. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma Science 2009 325 1139 1142 10.1126/science.1175689 19628817
274. Sköldberg F. Grimelius L. Woodward E.R. Rorsman F. Van Schothorst E.W. Winqvist O. Karlsson F.A. Åkerström G. Kämpe O. Husebye E.S. A family with hereditary extra-adrenal paragangliomas without evidence for mutations in the von Hippel-Lindau disease or Ret genes: Hereditary extra-adrenal paraganglioma Clin. Endocrinol. 1998 48 11 16 10.1046/j.1365-2265.1998.00320.x
275. Lussey-Lepoutre C. Buffet A. Gimenez-Roqueplo A.-P. Favier J. Mitochondrial deficiencies in the predisposition to paraganglioma Metabolites 2017 7 17 10.3390/metabo7020017
276. Ghezzi D. Zeviani M. Human diseases associated with defects in assembly of OXPHOS complexes Essays Biochem. 2018 62 271 286 10.1042/EBC20170099 30030362
277. Dwight T. Na U. Kim E. Zhu Y. Richardson A.L. Robinson B.G. Tucker K.M. Gill A.J. Benn D.E. Clifton-Bligh R.J. Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma BMC Cancer 2017 17 497 10.1186/s12885-017-3486-z 28738844
278. Kudryavtseva A.V. Kalinin D.V. Pavlov V.S. Savvateeva M.V. Fedorova M.S. Pudova E.A. Kobelyatskaya A.A. Golovyuk A.L. Guvatova Z.G. Razmakhaev G.S. Mutation profiling in eight cases of vagal paragangliomas BMC Med. Genom. 2020 13 115 10.1186/s12920-020-00763-4
279. Iwata S. Lee J.W. Okada K. Lee J.K. Iwata M. Rasmussen B. Link T.A. Ramaswamy S. Jap B.K. Complete structure of the 11-subunit bovine mitochondrial cytochrome Bc1 complex Science 1998 281 64 71 10.1126/science.281.5373.64 9651245
280. Hildenbeutel M. Hegg E.L. Stephan K. Gruschke S. Meunier B. Ott M. Assembly factors monitor sequential hemylation of cytochrome b to regulate mitochondrial translation J. Cell Biol. 2014 205 511 524 10.1083/jcb.201401009 24841564
281. Tucker E.J. Wanschers B.F.J. Szklarczyk R. Mountford H.S. Wijeyeratne X.W. van den Brand M.A.M. Leenders A.M. Rodenburg R.J. Reljić B. Compton A.G. Mutations in the UQCC1-interacting protein, UQCC2, cause human complex III deficiency associated with perturbed cytochrome b protein expression PLoS Genet. 2013 9 e1004034 10.1371/journal.pgen.1004034 24385928
282. Wanschers B.F.J. Szklarczyk R. van den Brand M.A.M. Jonckheere A. Suijskens J. Smeets R. Rodenburg R.J. Stephan K. Helland I.B. Elkamil A. A mutation in the human CBP4 ortholog UQCC3 impairs complex III assembly, activity and cytochrome b stability Hum. Mol. Genet. 2014 23 6356 6365 10.1093/hmg/ddu357 25008109
283. Bottani E. Cerutti R. Harbour M.E. Ravaglia S. Dogan S.A. Giordano C. Fearnley I.M. D’Amati G. Viscomi C. Fernandez-Vizarra E. TTC19 plays a husbandry role on UQCRFS1 turnover in the biogenesis of mitochondrial respiratory complex III Mol. Cell 2017 67 96 105 10.1016/j.molcel.2017.06.001 28673544
284. Atkinson A. Smith P. Fox J.L. Cui T.-Z. Khalimonchuk O. Winge D.R. The LYR protein Mzm1 functions in the insertion of the rieske Fe/S protein in yeast mitochondria Mol. Cell. Biol. 2011 31 3988 3996 10.1128/MCB.05673-11 21807901
285. Cui T.-Z. Smith P.M. Fox J.L. Khalimonchuk O. Winge D.R. Late-stage maturation of the Rieske Fe/S protein: Mzm1 stabilizes Rip1 but does not facilitate its translocation by the AAA ATPase Bcs1 Mol. Cell. Biol. 2012 32 4400 4409 10.1128/MCB.00441-12 22927643
286. Sánchez E. Lobo T. Fox J.L. Zeviani M. Winge D.R. Fernández-Vizarra E. LYRM7/MZM1L is a UQCRFS1 chaperone involved in the last steps of mitochondrial complex III assembly in human cells Biochim. Biophys. Acta (BBA)-Bioenerg. 2013 1827 285 293 10.1016/j.bbabio.2012.11.003
287. Cruciat C.-M. Hell K. Fölsch H. Neupert W. Stuart R.A. Bcs1p, an AAA-family member, is a chaperone for the assembly of the cytochrome Bc1 complex EMBO J. 1999 18 5226 5233 10.1093/emboj/18.19.5226 10508156
288. Fernandez-Vizarra E. Bugiani M. Goffrini P. Carrara F. Farina L. Procopio E. Donati A. Uziel G. Ferrero I. Zeviani M. Impaired complex III assembly associated with BCS1L gene mutations in isolated mitochondrial encephalopathy Hum. Mol. Genet. 2007 16 1241 1252 10.1093/hmg/ddm072 17403714
289. Tang W.K. Borgnia M.J. Hsu A.L. Esser L. Fox T. de Val N. Xia D. Structures of AAA protein translocase Bcs1 suggest translocation mechanism of a folded protein Nat. Struct. Mol. Biol. 2020 27 202 209 10.1038/s41594-020-0373-0 32042153
290. Wagener N. Ackermann M. Funes S. Neupert W. A pathway of protein translocation in mitochondria mediated by the AAA-ATPase Bcs1 Mol. Cell 2011 44 191 202 10.1016/j.molcel.2011.07.036 22017868
291. Peruzzo R. Corrà S. Costa R. Brischigliaro M. Varanita T. Biasutto L. Rampazzo C. Ghezzi D. Leanza L. Zoratti M. Exploiting pyocyanin to treat mitochondrial disease due to respiratory complex III dysfunction Nat. Commun. 2021 12 2103 10.1038/s41467-021-22062-x 33833234
292. Andreu A.L. Bruno C. Dunne T.C. Tanji K. Shanske S. Sue C.M. Krishna S. Hadjigeorgiou G.M. Shtilbans A. Bonilla E. A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria Ann. Neurol. 1999 45 127 130 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y 9894887
293. Andreu A.L. Hanna M.G. Reichmann H. Bruno C. Penn A.S. Tanji K. Pallotti F. Iwata S. Bonilla E. Lach B. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA N. Engl. J. Med. 1999 341 1037 1044 10.1056/NEJM199909303411404 10502593
294. De Coo I.F. Renier W.O. Ruitenbeek W. Ter Laak H.J. Bakker M. Schägger H. Van Oost B.A. Smeets H.J. A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome Ann. Neurol. 1999 45 130 133 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z 9894888
295. Keightley J.A. Anitori R. Burton M.D. Quan F. Buist N.R.M. Kennaway N.G. Mitochondrial encephalomyopathy and complex III deficiency associated with a stop-codon mutation in the cytochrome b gene Am. J. Hum. Genet. 2000 67 1400 1410 10.1086/316900 11047755
296. Andreu A.L. Bruno C. Shanske S. Shtilbans A. Hirano M. Krishna S. Hayward L. Systrom D.S. Brown R.H. DiMauro S. Missense mutation in the MtDNA cytochrome b gene in a patient with myopathy Neurology 1998 51 1444 1447 10.1212/WNL.51.5.1444 9818877
297. Lamantea E. Carrara F. Mariotti C. Morandi L. Tiranti V. Zeviani M. A novel nonsense mutation (Q352X) in the mitochondrial cytochrome b gene associated with a combined deficiency of complexes I and III Neuromuscul. Disord. 2002 12 49 52 10.1016/S0960-8966(01)00244-9 11731284
298. Mancuso M. Filosto M. Stevens J.C. Patterson M. Shanske S. Krishna S. DiMauro S. Mitochondrial myopathy and complex III deficiency in a patient with a new stop-codon mutation (G339X) in the cytochrome b gene J. Neurol. Sci. 2003 209 61 63 10.1016/S0022-510X(02)00462-8 12686403
299. Andreu A.L. Checcarelli N. Iwata S. Shanske S. Dimauro S. A missense mutation in the mitochondrial cytochrome b gene in a revisited case with histiocytoid cardiomyopathy Pediatr. Res. 2000 48 311 314 10.1203/00006450-200009000-00008 10960495
300. Wibrand F. Ravn K. Schwartz M. Rosenberg T. Horn N. Vissing J. Multisystem disorder associated with a missense mutation in the mitochondrial cytochromeb gene Ann. Neurol. 2001 50 540 543 10.1002/ana.1224 11601507
301. Schuelke M. Krude H. Finckh B. Mayatepek E. Janssen A. Schmelz M. Trefz F. Trijbels F. Smeitink J. Septo-optic dysplasia associated with a new mitochondrialcytochrome b mutation Ann. Neurol. 2002 51 388 392 10.1002/ana.10151 11891837
302. Ghelli A. Tropeano C.V. Calvaruso M.A. Marchesini A. Iommarini L. Porcelli A.M. Zanna C. De Nardo V. Martinuzzi A. Wibrand F. The cytochrome b p.278Y>C mutation causative of a multisystem disorder enhances superoxide production and alters supramolecular interactions of respiratory chain complexes Hum. Mol. Genet. 2013 22 2141 2151 10.1093/hmg/ddt067 23418307
303. Carossa V. Ghelli A. Tropeano C.V. Valentino M.L. Iommarini L. Maresca A. Caporali L. La Morgia C. Liguori R. Barboni P. A novel in-frame 18-Bp microdeletion in MT-CYB causes a multisystem disorder with prominent exercise intolerance Hum. Mutat. 2014 35 954 958 10.1002/humu.22596 24863938
304. Fernández-Vizarra E. Zeviani M. Nuclear gene mutations as the cause of mitochondrial complex III deficiency Front. Genet. 2015 6 134 10.3389/fgene.2015.00134 25914718
305. Ghezzi D. Arzuffi P. Zordan M. Da Re C. Lamperti C. Benna C. D’Adamo P. Diodato D. Costa R. Mariotti C. Mutations in TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans and flies Nat. Genet. 2011 43 259 263 10.1038/ng.761 21278747
306. Invernizzi F. Tigano M. Dallabona C. Donnini C. Ferrero I. Cremonte M. Ghezzi D. Lamperti C. Zeviani M. A homozygous mutation in LYRM 7/ MZM 1 L associated with early onset encephalopathy, lactic acidosis, and severe reduction of mitochondrial complex III activity Hum. Mutat. 2013 34 1619 1622 10.1002/humu.22441 24014394
307. de Lonlay P. Valnot I. Barrientos A. Gorbatyuk M. Tzagoloff A. Taanman J.-W. Benayoun E. Chrétien D. Kadhom N. Lombès A. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure Nat. Genet. 2001 29 57 60 10.1038/ng706 11528392
308. Lin C.-H. Tsai P.-I. Lin H.-Y. Hattori N. Funayama M. Jeon B. Sato K. Abe K. Mukai Y. Takahashi Y. Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy Brain 2020 143 3352 3373 10.1093/brain/awaa279 33141179
309. Miyake N. Yano S. Sakai C. Hatakeyama H. Matsushima Y. Shiina M. Watanabe Y. Bartley J. Abdenur J.E. Wang R.Y. Mitochondrial complex III deficiency caused by a homozygous UQCRC2 mutation presenting with neonatal-onset recurrent metabolic decompensation Hum. Mutat. 2013 34 446 452 10.1002/humu.22257 23281071
310. Brown M.D. Voljavec A.S. Lott M.T. Torroni A. Yang C.C. Wallace D.C. Mitochondrial DNA complex I and III mutations associated with Leber’s hereditary optic neuropathy Genetics 1992 130 163 173 10.1093/genetics/130.1.163 1732158
311. Bouzidi M.F. Schägger H. Collombet J.-M. Carrier H. Flocard F. Quard S. Mousson B. Godinot C. Decreased expression o ubiquinol-cytochrome c reductase subunits in patients exhibiting mitochondrial myopathy with progressive exercise intolerance Neuromuscul. Disord. 1993 3 599 604 10.1016/0960-8966(93)90123-2 8186719
312. Gaignard P. Menezes M. Schiff M. Bayot A. Rak M. de Baulny H.O. Su C.-H. Gilleron M. Lombes A. Abida H. Mutations in CYC1, encoding cytochrome C1 subunit of respiratory chain complex III, cause insulin-responsive hyperglycemia Am. J. Hum. Genet. 2013 93 384 389 10.1016/j.ajhg.2013.06.015 23910460
313. Gusic M. Schottmann G. Feichtinger R.G. Du C. Scholz C. Wagner M. Mayr J.A. Lee C.-Y. Yépez V.A. Lorenz N. Bi-allelic UQCRFS1 variants are associated with mitochondrial complex iii deficiency, cardiomyopathy, and alopecia totalis Am. J. Hum. Genet. 2020 106 102 111 10.1016/j.ajhg.2019.12.005 31883641
314. Haut S. Brivet M. Touati G. Rustin P. Lebon S. Garcia-Cazorla A. Saudubray J.M. Boutron A. Legrand A. Slama A. A deletion in the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic acidosis Hum. Genet. 2003 113 118 122 10.1007/s00439-003-0946-0 12709789
315. Barel O. Shorer Z. Flusser H. Ofir R. Narkis G. Finer G. Shalev H. Nasasra A. Saada A. Birk O.S. Mitochondrial complex III deficiency associated with a homozygous mutation in UQCRQ Am. J. Hum. Genet. 2008 82 1211 1216 10.1016/j.ajhg.2008.03.020 18439546
316. Feichtinger R.G. Brunner-Krainz M. Alhaddad B. Wortmann S.B. Kovacs-Nagy R. Stojakovic T. Erwa W. Resch B. Windischhofer W. Verheyen S. Combined respiratory chain deficiency and UQCC2 mutations in neonatal encephalomyopathy: Defective supercomplex assembly in complex III deficiencies Oxidative Med. Cell. Longev. 2017 2017 7202589 10.1155/2017/7202589
317. Hausman-Kedem M. Ben-Shachar S. Menascu S. Geva K. Sagie L. Fattal-Valevski A. VPS53 gene is associated with a new phenotype of complicated hereditary spastic paraparesis Neurogenetics 2019 20 187 195 10.1007/s10048-019-00586-1 31418091
318. Baker R.A. Priestley J.R.C. Wilstermann A.M. Reese K.J. Mark P.R. Clinical spectrum of BCS1L mitopathies and their underlying structural relationships Am. J. Med. Genet. 2019 179 373 380 10.1002/ajmg.a.61019 30582773
319. Visapää I. Fellman V. Varilo T. Palotie A. Raivio K.O. Peltonen L. Assignment of the locus for a new lethal neonatal metabolic syndrome to 2q33-37 Am. J. Hum. Genet. 1998 63 1396 1403 10.1086/302123 9792866
320. Siddiqi S. Siddiq S. Mansoor A. Oostrik J. Ahmad N. Kazmi S.A.R. Kremer H. Qamar R. Schraders M. Novel mutation in AAA domain of BCS1L causing Bjornstad syndrome J. Hum. Genet. 2013 58 819 821 10.1038/jhg.2013.101 24172246
321. Hinson J.T. Fantin V.R. Schönberger J. Breivik N. Siem G. McDonough B. Sharma P. Keogh I. Godinho R. Santos F. Missense mutations in the BCS1L gene as a cause of the Björnstad syndrome N. Engl. J. Med. 2007 356 809 819 10.1056/NEJMoa055262 17314340
322. Gil-Borlado M.C. González-Hoyuela M. Blázquez A. García-Silva M.T. Gabaldón T. Manzanares J. Vara J. Martín M.A. Seneca S. Arenas J. Pathogenic Mutations in the 5′ untranslated region of BCS1L MRNA in mitochondrial complex III deficiency Mitochondrion 2009 9 299 305 10.1016/j.mito.2009.04.001 19389488
323. Blázquez A. Gil-Borlado M.C. Morán M. Verdú A. Cazorla-Calleja M.R. Martín M.A. Arenas J. Ugalde C. Infantile mitochondrial encephalomyopathy with unusual phenotype caused by a novel BCS1L mutation in an isolated complex III-deficient patient Neuromuscul. Disord. 2009 19 143 146 10.1016/j.nmd.2008.11.016 19162478
324. Dallabona C. Abbink T.E.M. Carrozzo R. Torraco A. Legati A. van Berkel C.G.M. Niceta M. Langella T. Verrigni D. Rizza T. LYRM7 mutations cause a multifocal cavitating leukoencephalopathy with distinct MRI appearance Brain 2016 139 782 794 10.1093/brain/awv392 26912632
325. Hempel M. Kremer L.S. Tsiakas K. Alhaddad B. Haack T.B. Löbel U. Feichtinger R.G. Sperl W. Prokisch H. Mayr J.A. LYRM7—Associated complex III deficiency: A clinical, molecular genetic, MR tomographic, and biochemical study Mitochondrion 2017 37 55 61 10.1016/j.mito.2017.07.001 28694194
326. Kremer L.S. L’hermitte-Stead C. Lesimple P. Gilleron M. Filaut S. Jardel C. Haack T.B. Strom T.M. Meitinger T. Azzouz H. Severe respiratory complex III defect prevents liver adaptation to prolonged Fasting J. Hepatol. 2016 65 377 385 10.1016/j.jhep.2016.04.017 27151179
327. Morino H. Miyamoto R. Ohnishi S. Maruyama H. Kawakami H. Exome sequencing reveals a novel TTC19 mutation in an autosomal recessive spinocerebellar ataxia patient BMC Neurol. 2014 14 5 10.1186/1471-2377-14-5 24397319
328. Nogueira C. Barros J. Sá M.J. Azevedo L. Taipa R. Torraco A. Meschini M.C. Verrigni D. Nesti C. Rizza T. Novel TTC19 mutation in a family with severe psychiatric manifestations and complex III deficiency Neurogenetics 2013 14 153 160 10.1007/s10048-013-0361-1 23532514
329. Habibzadeh P. Inaloo S. Silawi M. Dastsooz H. Farazi Fard M.A. Sadeghipour F. Faghihi Z. Rezaeian M. Yavarian M. Böhm J. A novel TTC19 mutation in a patient with neurological, psychological, and gastrointestinal impairment Front. Neurol. 2019 10 944 10.3389/fneur.2019.00944 31551910
330. Mordaunt D.A. Jolley A. Balasubramaniam S. Thorburn D.R. Mountford H.S. Compton A.G. Nicholl J. Manton N. Clark D. Bratkovic D. Phenotypic variation of TTC19—deficient mitochondrial complex III deficiency: A case report and literature review Am. J. Med. Genet. 2015 167 1330 1336 10.1002/ajmg.a.36968 25899669
331. Balsa E. Marco R. Perales-Clemente E. Szklarczyk R. Calvo E. Landázuri M.O. Enríquez J.A. NDUFA4 is a subunit of complex IV of the mammalian electron transport chain Cell Metab. 2012 16 378 386 10.1016/j.cmet.2012.07.015 22902835
332. Pitceathly R.D.S. Rahman S. Wedatilake Y. Polke J.M. Cirak S. Foley A.R. Sailer A. Hurles M.E. Stalker J. Hargreaves I. NDUFA4 mutations underlie dysfunction of a cytochrome c oxidase subunit linked to human neurological disease Cell Rep. 2013 3 1795 1805 10.1016/j.celrep.2013.05.005 23746447
333. Zong S. Wu M. Gu J. Liu T. Guo R. Yang M. Structure of the intact 14-subunit human cytochrome c oxidase Cell Res. 2018 28 1026 1034 10.1038/s41422-018-0071-1 30030519
334. Hill B.C. The sequence of electron carriers in the reaction of cytochromec oxidase with oxygen J. Bioenerg. Biomembr. 1993 25 115 120 10.1007/BF00762853 8389744
335. Sharma V. Ala-Vannesluoma P. Vattulainen I. Wikström M. Róg T. Role of subunit III and its lipids in the molecular mechanism of cytochrome c oxidase Biochim. Biophys. Acta (BBA)-Bioenerg. 2015 1847 690 697 10.1016/j.bbabio.2015.04.007 25896562
336. Sinkler C.A. Kalpage H. Shay J. Lee I. Malek M.H. Grossman L.I. Hüttemann M. Tissue- and condition-specific isoforms of mammalian cytochrome c oxidase subunits: From function to human disease Oxidative Med. Cell. Longev. 2017 2017 1534056 10.1155/2017/1534056 28593021
337. Kadenbach B. Hüttemann M. The subunit composition and function of mammalian cytochrome c oxidase Mitochondrion 2015 24 64 76 10.1016/j.mito.2015.07.002 26190566
338. Nijtmans L.G.J. Taanman J.-W. Muijsers A.O. Speijer D. Van den Bogert C. Assembly of cytochrome-c oxidase in cultured human cells Eur. J. Biochem. 1998 254 389 394 10.1046/j.1432-1327.1998.2540389.x 9660196
339. Vidoni S. Harbour M.E. Guerrero-Castillo S. Signes A. Ding S. Fearnley I.M. Taylor R.W. Tiranti V. Arnold S. Fernandez-Vizarra E. MR-1S interacts with pet100 and pet117 in module-based assembly of human cytochrome c oxidase Cell Rep. 2017 18 1727 1738 10.1016/j.celrep.2017.01.044 28199844
340. Rak M. Bénit P. Chrétien D. Bouchereau J. Schiff M. El-Khoury R. Tzagoloff A. Rustin P. Mitochondrial cytochrome c oxidase deficiency Clin. Sci. 2016 130 393 407 10.1042/CS20150707
341. Massa V. Fernandez-Vizarra E. Alshahwan S. Bakhsh E. Goffrini P. Ferrero I. Mereghetti P. D’Adamo P. Gasparini P. Zeviani M. Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase Am. J. Hum. Genet. 2008 82 1281 1289 10.1016/j.ajhg.2008.05.002 18499082
342. Abdulhag U.N. Soiferman D. Schueler-Furman O. Miller C. Shaag A. Elpeleg O. Edvardson S. Saada A. Mitochondrial complex IV deficiency, caused by mutated COX6B1, is associated with encephalomyopathy, hydrocephalus and cardiomyopathy Eur. J. Hum. Genet. 2015 23 159 164 10.1038/ejhg.2014.85 24781756
343. Lamperti C. Diodato D. Lamantea E. Carrara F. Ghezzi D. Mereghetti P. Rizzi R. Zeviani M. MELAS-like encephalomyopathy caused by a new pathogenic mutation in the mitochondrial DNA encoded cytochrome c oxidase subunit I Neuromuscul. Disord. 2012 22 990 994 10.1016/j.nmd.2012.06.003 22832341
344. Valente L. Piga D. Lamantea E. Carrara F. Uziel G. Cudia P. Zani A. Farina L. Morandi L. Mora M. Identification of novel mutations in five patients with mitochondrial encephalomyopathy Biochim. Biophys. Acta (BBA)-Bioenerg. 2009 1787 491 501 10.1016/j.bbabio.2008.10.001
345. Comi G.P. Bordoni A. Salani S. Franceschina L. Sciacco M. Prelle A. Fortunato F. Zeviani M. Napoli L. Bresolin N. Cytochromec oxidase subunit I microdeletion in a patient with motor neuron disease Ann. Neurol. 1998 43 110 116 10.1002/ana.410430119 9450776
346. D’Aurelio M. Pallotti F. Barrientos A. Gajewski C.D. Kwong J.Q. Bruno C. Beal M.F. Manfredi G. In vivo regulation of oxidative phosphorylation in cells harboring a stop-codon mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I J. Biol. Chem. 2001 276 46925 46932 10.1074/jbc.M106429200 11595737
347. Nishigaki Y. Ueno H. Coku J. Koga Y. Fujii T. Sahashi K. Nakano K. Yoneda M. Nonaka M. Tang L. Extensive screening system using suspension array technology to detect mitochondrial DNA point mutations Mitochondrion 2010 10 300 308 10.1016/j.mito.2010.01.003 20064630
348. Clark K.M. Taylor R.W. Johnson M.A. Chinnery P.F. Chrzanowska-Lightowlers Z.M.A. Andrews R.M. Nelson I.P. Wood N.W. Lamont P.J. Hanna M.G. An MtDNA mutation in the initiation codon of the cytochrome c oxidase subunit II gene results in lower levels of the protein and a mitochondrial encephalomyopathy Am. J. Hum. Genet. 1999 64 1330 1339 10.1086/302361 10205264
349. Abu-Amero K.K. Bosley T.M. Mitochondrial abnormalities in patients with LHON-like optic neuropathies Investig. Opthalmol. Vis. Sci. 2006 47 4211 4220 10.1167/iovs.06-0295
350. Rahman S. Taanman J.-W. Cooper J.M. Nelson I. Hargreaves I. Meunier B. Hanna M.G. García J.J. Capaldi R.A. Lake B.D. A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy Am. J. Hum. Genet. 1999 65 1030 1039 10.1086/302590 10486321
351. Wei Y.-L. Yu C.-A. Yang P. Li A.-L. Wen J.-Y. Zhao S.-M. Liu H.-X. Ke Y.-N. Campbell W. Zhang Y.-G. Novel mitochondrial DNA mutations associated with chinese familial hypertrophic cardiomyopathy Clin. Exp. Pharmacol. Physiol. 2009 36 933 939 10.1111/j.1440-1681.2009.05183.x 19473338
352. Tabebi M. Mkaouar-Rebai E. Mnif M. Kallabi F. Ben Mahmoud A. Ben Saad W. Charfi N. Keskes-Ammar L. Kamoun H. Abid M. A novel mutation MT-COIII m.9267G>C and MT-COI m.5913G>A mutation in mitochondrial genes in a Tunisian family with maternally inherited diabetes and deafness (MIDD) associated with sever nephropathy Biochem. Biophys. Res. Commun. 2015 459 353 360 10.1016/j.bbrc.2015.01.151 25701779
353. Horvath R. Scharfe C. Hoeltzenbein M. Do B.H. Schröder C. Warzok R. Vogelgesang S. Lochmüller H. Müller-Höcker J. Gerbitz K.D. Childhood onset mitochondrial myopathy and lactic acidosis caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene J. Med. Genet. 2002 39 812 816 10.1136/jmg.39.11.812 12414820
354. Mkaouar-Rebai E. Ellouze E. Chamkha I. Kammoun F. Triki C. Fakhfakh F. Molecular-clinical correlation in a family with a novel heteroplasmic Leigh syndrome missense mutation in the mitochondrial cytochrome c oxidase III gene J. Child Neurol. 2011 26 12 20 10.1177/0883073810371227 20525945
355. Bosley T.M. Brodsky M.C. Glasier C.M. Abu-Amero K.K. Sporadic bilateral optic neuropathy in children: The role of mitochondrial abnormalities Investig. Opthalmol. Vis. Sci. 2008 49 5250 10.1167/iovs.08-2193
356. Marotta R. Chin J. Kirby D.M. Chiotis M. Cook M. Collins S.J. Novel single base pair COX III subunit deletion of mitochondrial DNA associated with rhabdomyolysis J. Clin. Neurosci. 2011 18 290 292 10.1016/j.jocn.2010.06.001 21163656
357. Hanna M.G. Nelson I.P. Rahman S. Lane R.J.M. Land J. Heales S. Cooper M.J. Schapira A.H.V. Morgan-Hughes J.A. Wood N.W. Cytochrome c oxidase deficiency associated with the first stop-codon point mutation in human MtDNA Am. J. Hum. Genet. 1998 63 29 36 10.1086/301910 9634511
358. Abu-Libdeh B. Douiev L. Amro S. Shahrour M. Ta-Shma A. Miller C. Elpeleg O. Saada A. Mutation in the COX4I1 gene is associated with short stature, poor weight gain and increased chromosomal breaks, simulating fanconi anemia Eur. J. Hum. Genet. 2017 25 1142 1146 10.1038/ejhg.2017.112 28766551
359. Pillai N.R. AlDhaheri N.S. Ghosh R. Lim J. Streff H. Nayak A. Graham B.H. Hanchard N.A. Elsea S.H. Scaglia F. Biallelic variants in COX4I1 associated with a novel phenotype resembling Leigh syndrome with developmental regression, intellectual disability, and seizures Am. J. Med. Genet. 2019 179 2138 2143 10.1002/ajmg.a.61288 31290619
360. Shteyer E. Saada A. Shaag A. Al-Hijawi F.A. Kidess R. Revel-Vilk S. Elpeleg O. Exocrine pancreatic insufficiency, dyserythropoeitic anemia, and calvarial hyperostosis are caused by a mutation in the COX4I2 gene Am. J. Hum. Genet. 2009 84 412 417 10.1016/j.ajhg.2009.02.006 19268275
361. Baertling F. Al-Murshedi F. Sánchez-Caballero L. Al-Senaidi K. Joshi N.P. Venselaar H. van den Brand M.A. Nijtmans L.G. Rodenburg R.J. Mutation in mitochondrial complex IV subunit COX5A causes pulmonary arterial hypertension, lactic acidemia, and failure to thrive Hum. Mutat. 2017 38 692 703 10.1002/humu.23210 28247525
362. Tamiya G. Makino S. Hayashi M. Abe A. Numakura C. Ueki M. Tanaka A. Ito C. Toshimori K. Ogawa N. A mutation of COX6A1 causes a recessive axonal or mixed form of charcot-marie-tooth disease Am. J. Hum. Genet. 2014 95 294 300 10.1016/j.ajhg.2014.07.013 25152455
363. Inoue M. Uchino S. Iida A. Noguchi S. Hayashi S. Takahashi T. Fujii K. Komaki H. Takeshita E. Nonaka I. COX6A2 variants cause a muscle-specific cytochrome c oxidase deficiency Ann. Neurol. 2019 86 193 202 10.1002/ana.25517 31155743
364. Vondrackova A. Vesela K. Hansikova H. Docekalova D.Z. Rozsypalova E. Zeman J. Tesarova M. High-resolution melting analysis of 15 genes in 60 patients with cytochrome-c oxidase deficiency J. Hum. Genet. 2012 57 442 448 10.1038/jhg.2012.49 22592081
365. Indrieri A. van Rahden V.A. Tiranti V. Morleo M. Iaconis D. Tammaro R. D’Amato I. Conte I. Maystadt I. Demuth S. Mutations in COX7B cause microphthalmia with linear skin lesions, an unconventional mitochondrial disease Am. J. Hum. Genet. 2012 91 942 949 10.1016/j.ajhg.2012.09.016 23122588
366. Hallmann K. Kudin A.P. Zsurka G. Kornblum C. Reimann J. Stüve B. Waltz S. Hattingen E. Thiele H. Nürnberg P. Loss of the smallest subunit of cytochrome c oxidase, COX8A, causes Leigh-like syndrome and epilepsy Brain 2016 139 338 345 10.1093/brain/awv357 26685157
367. Echaniz-Laguna A. Ghezzi D. Chassagne M. Mayencon M. Padet S. Melchionda L. Rouvet I. Lannes B. Bozon D. Latour P. SURF1 deficiency causes demyelinating charcot-marie-tooth disease Neurology 2013 81 1523 1530 10.1212/WNL.0b013e3182a4a518 24027061
368. Valnot I. Von Kleist-Retzow J.-C. Barrientos A. Gorbatyuk M. Taanman J.-W. Mehaye B. Rustin P. Tzagoloff A. Munnich A. Rotig A. A mutation in the human heme A: Farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency Hum. Mol. Genet. 2000 9 1245 1249 10.1093/hmg/9.8.1245 10767350
369. Antonicka H. Pankratz N. Nichols W.C. Uniacke S.K. Halter C. Murrell J. Rudolph A. Shults C.W. Conneally P.M. Foroud T. Mutations in COX10 result in a defect in mitochondrial heme A biosynthesis and account for multiple, early-onset clinical phenotypes associated with isolated COX deficiency Hum. Mol. Genet. 2003 12 2693 2702 10.1093/hmg/ddg284 12928484
370. Coenen M.J.H. van den Heuvel L.P. Ugalde C. ten Brinke M. Nijtmans L.G.J. Trijbels F.J.M. Beblo S. Maier E.M. Muntau A.C. Smeitink J.A.M. Cytochromec oxidase biogenesis in a patient with a mutation in COX10 gene Ann. Neurol. 2004 56 560 564 10.1002/ana.20229 15455402
371. Antonicka H. Mattman A. Carlson C.G. Glerum D.M. Hoffbuhr K.C. Leary S.C. Kennaway N.G. Shoubridge E.A. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy Am. J. Hum. Genet. 2003 72 101 114 10.1086/345489 12474143
372. Alfadhel M. Lillquist Y.P. Waters P.J. Sinclair G. Struys E. McFadden D. Hendson G. Hyams L. Shoffner J. Vallance H.D. Infantile cardioencephalopathy due to a COX15 gene defect: Report and review Am. J. Med. Genet. 2011 155 840 844 10.1002/ajmg.a.33881
373. Bugiani M. Tiranti V. Farina L. Uziel G. Zeviani M. Novel mutations in COX15 in a long surviving Leigh syndrome patient with cytochrome c oxidase deficiency J. Med. Genet. 2005 42 e28 10.1136/jmg.2004.029926 15863660
374. Fernández-Vizarra E. Tiranti V. Zeviani M. Assembly of the oxidative phosphorylation system in humans: What we have learned by studying its defects Biochim. Biophys. Acta (BBA)-Bioenerg. 2009 1793 200 211 10.1016/j.bbamcr.2008.05.028
375. Leary S.C. Antonicka H. Sasarman F. Weraarpachai W. Cobine P.A. Pan M. Brown G.K. Brown R. Majewski J. Ha K.C.H. Novel mutations in SCO1 as a cause of fatal infantile encephalopathy and lactic acidosis Hum. Mutat. 2013 34 1366 1370 10.1002/humu.22385 23878101
376. Brix N. Jensen J.M. Pedersen I.S. Ernst A. Frost S. Bogaard P. Petersen M.B. Bender L. Mitochondrial disease caused by a novel homozygous mutation (Gly106del) in the SCO1 gene Neonatology 2019 116 290 294 10.1159/000499488 31352446
377. Papadopoulou L.C. Sue C.M. Davidson M.M. Tanji K. Nishino I. Sadlock J.E. Krishna S. Walker W. Selby J. Glerum D.M. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene Nat. Genet. 1999 23 333 337 10.1038/15513 10545952
378. Jaksch M. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency Hum. Mol. Genet. 2000 9 795 801 10.1093/hmg/9.5.795 10749987
379. Sue C.M. Karadimas C. Checcarelli N. Tanji K. Papadopoulou L.C. Pallotti F. Guo F.L. Shanske S. Hirano M. De Vivo D.C. Differential features of patients with mutations in two COX assembly genes, SURF-1 and SCO2 Ann. Neurol. 2000 47 589 595 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.0.CO;2-D 10805329
380. Jaksch M. Horvath R. Horn N. Auer D.P. Macmillan C. Peters J. Gerbitz K.-D. Kraegeloh-Mann I. Muntau A. Karcagi V. Homozygosity (E140K) in SCO2 causes delayed infantile onset of cardiomyopathy and neuropathy Neurology 2001 57 1440 1446 10.1212/WNL.57.8.1440 11673586
381. Pronicki M. Kowalski P. Piekutowska-Abramczuk D. Taybert J. Karkucinska-Wieckowska A. Szymanska-Debinska T. Karczmarewicz E. Pajdowska M. Migdal M. Milewska-Bobula B. A homozygous mutation in the SCO2 gene causes a spinal muscular atrophy like presentation with stridor and respiratory insufficiency Eur. J. Paediatr. Neurol. 2010 14 253 260 10.1016/j.ejpn.2009.09.008 19879173
382. Pronicka E. Piekutowska-Abramczuk D. Szymańska-Dębińska T. Bielecka L. Kowalski P. Łuczak S. Karkucińska-Więckowska A. Migdał M. Kubalska J. Zimowski J. The natural history of SCO2 deficiency in 36 Polish children confirmed the genotype-phenotype correlation Mitochondrion 2013 13 810 816 10.1016/j.mito.2013.05.007 23719228
383. Rebelo A.P. Saade D. Pereira C.V. Farooq A. Huff T.C. Abreu L. Moraes C.T. Mnatsakanova D. Mathews K. Yang H. SCO2 mutations cause early-onset axonal charcot-marie-tooth disease associated with cellular copper deficiency Brain 2018 141 662 672 10.1093/brain/awx369 29351582
384. Barcia G. Assouline Z. Pennisi A. Gitiaux C. Schiff M. Boddaert N. Munnich A. Bonnefont J.-P. Rötig A. Cytochrome c oxidase deficiency caused by biallelic SCO2 mutations in two sibs with cerebellar ataxia and progressive peripheral axonal neuropathy Mol. Genet. Metab. Rep. 2019 21 100528 10.1016/j.ymgmr.2019.100528 31844624
385. Ghosh A. Trivedi P.P. Timbalia S.A. Griffin A.T. Rahn J.J. Chan S.S.L. Gohil V.M. Copper supplementation restores cytochrome c oxidase assembly defect in a mitochondrial disease model of coa6 deficiency Hum. Mol. Genet. 2014 23 3596 3606 10.1093/hmg/ddu069 24549041
386. Baertling F. Brand M.A.V.D. Hertecant J.L. Al-Shamsi A. Heuvel L.P.V.D. Distelmaier F. Mayatepek E. Smeitink J.A. Nijtmans L.G. Rodenburg R. Mutations in COA6 cause cytochrome c oxidase deficiency and neonatal hypertrophic cardiomyopathy Hum. Mutat. 2015 36 34 38 10.1002/humu.22715 25339201
387. Salvador-Severo K. Gómez-Caudillo L. Quezada H. de García-Trejo J.J. Cárdenas-Conejo A. Vázquez-Memije M.E. Minauro-Sanmiguel F. Mitochondrial proteomic profile of complex IV deficiency fibroblasts: Rearrangement of oxidative phosphorylation complex/supercomplex and other metabolic pathways Bol. Méd. Del Hosp. Infant. México 2017 74 175 180 10.1016/j.bmhimx.2017.05.001
388. Weraarpachai W. Antonicka H. Sasarman F. Seeger J. Schrank B. Kolesar J.E. Lochmüller H. Chevrette M. Kaufman B.A. Horvath R. Mutation in TACO1, encoding a translational activator of COX I, results in cytochrome c oxidase deficiency and late-onset leigh syndrome Nat. Genet. 2009 41 833 837 10.1038/ng.390 19503089
389. Oktay Y. Güngör S. Zeltner L. Wiethoff S. Schöls L. Sonmezler E. Yilmaz E. Munro B. Bender B. Kernstock C. Confirmation of TACO1 as a Leigh syndrome disease gene in two additional families J. Neuromuscul. Dis. 2020 7 301 308 10.3233/JND-200510 32444556
390. Xu F. Morin C. Mitchell G. Ackerley C. Robinson B.H. The role of the LRPPRC (Leucine-Rich pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: Mutation causes lowered levels of COX (cytochrome c oxidase) I and COX III MRNA Biochem. J. 2004 382 331 336 10.1042/BJ20040469 15139850
391. Antonicka H. Shoubridge E.A. Mitochondrial RNA granules are centers for posttranscriptional RNA processing and ribosome biogenesis Cell Rep. 2015 10 920 932 10.1016/j.celrep.2015.01.030 25683715
392. Ghezzi D. Saada A. D’Adamo P. Fernandez-Vizarra E. Gasparini P. Tiranti V. Elpeleg O. Zeviani M. FASTKD2 nonsense mutation in an infantile mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency Am. J. Hum. Genet. 2008 83 415 423 10.1016/j.ajhg.2008.08.009 18771761
393. Wei X. Du M. Li D. Wen S. Xie J. Li Y. Chen A. Zhang K. Xu P. Jia M. Mutations in FASTKD2 are associated with mitochondrial disease with multi-OXPHOS deficiency Hum. Mutat. 2020 41 961 972 10.1002/humu.23985 31944455
394. Nobrega M.P. Nobrega F.G. Tzagoloff A. COX10 codes for a protein homologous to the ORF1 product of paracoccus denitrificans and is required for the synthesis of yeast cytochrome oxidase J. Biol. Chem. 1990 265 14220 14226 10.1016/S0021-9258(18)77289-X 2167310
395. Valnot I. Osmond S. Gigarel N. Mehaye B. Amiel J. Cormier-Daire V. Munnich A. Bonnefont J.-P. Rustin P. Rötig A. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy Am. J. Hum. Genet. 2000 67 1104 1109 10.1016/S0002-9297(07)62940-1 11013136
396. Glerum D.M. Muroff I. Jin C. Tzagoloff A. COX15 codes for a mitochondrial protein essential for the assembly of yeast cytochrome oxidase J. Biol. Chem. 1997 272 19088 19094 10.1074/jbc.272.30.19088 9228094
397. Oquendo C.E. Antonicka H. Shoubridge E. Reardon W. Brown G.K. Functional and genetic studies demonstrate that mutation in the COX15 gene can cause Leigh syndrome J. Med. Genet. 2004 41 540 544 10.1136/jmg.2003.017426 15235026
398. Smith D. Gray J. Mitchell L. Antholine W.E. Hosler J.P. Assembly of cytochrome-c oxidase in the absence of assembly protein Surf1p leads to loss of the active site heme J. Biol. Chem. 2005 280 17652 17656 10.1074/jbc.C500061200 15764605
399. Huigsloot M. Nijtmans L.G. Szklarczyk R. Baars M.J.H. van den Brand M.A.M. HendriksFranssen M.G.M. van den Heuvel L.P. Smeitink J.A.M. Huynen M.A. Rodenburg R.J.T. A mutation in C2orf64 causes impaired cytochrome c oxidase assembly and mitochondrial cardiomyopathy Am. J. Hum. Genet. 2011 88 488 493 10.1016/j.ajhg.2011.03.002 21457908
400. Stroud D.A. Maher M.J. Lindau C. Vögtle F.-N. Frazier A.E. Surgenor E. Mountford H. Singh A.P. Bonas M. Oeljeklaus S. COA6 is a mitochondrial complex IV assembly factor critical for biogenesis of MtDNA-encoded COX2 Hum. Mol. Genet. 2015 24 5404 5415 10.1093/hmg/ddv265 26160915
401. Leary S.C. Kaufman B.A. Pellecchia G. Guercin G.-H. Mattman A. Jaksch M. Shoubridge E.A. Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase Hum. Mol. Genet. 2004 13 1839 1848 10.1093/hmg/ddh197 15229189
402. Stiburek L. Vesela K. Hansikova H. Hulkova H. Zeman J. Loss of function of Sco1 and its interaction with cytochrome c oxidase Am. J. Physiol. Cell Physiol. 2009 296 C1218 C1226 10.1152/ajpcell.00564.2008 19295170
403. Hiser L. Di Valentin M. Hamer A.G. Hosler J.P. Cox11p is required for stable formation of the CuBand magnesium centers of cytochrome c oxidase J. Biol. Chem. 2000 275 619 623 10.1074/jbc.275.1.619 10617659
404. Cerqua C. Morbidoni V. Desbats M.A. Doimo M. Frasson C. Sacconi S. Baldoin M.C. Sartori G. Basso G. Salviati L. COX16 is required for assembly of cytochrome c oxidase in human cells and is involved in copper delivery to COX2 Biochim. Biophys. Acta (BBA)-Bioenerg. 2018 1859 244 252 10.1016/j.bbabio.2018.01.004
405. Carlson C.G. Barrientos A. Tzagoloff A. Glerum D.M. Cox16 encodes a novel protein required for the assembly of cytochrome oxidase in saccharomyces cerevisiae J. Biol. Chem. 2003 278 3770 3775 10.1074/jbc.M209893200 12446688
406. Glerum D.M. Shtanko A. Tzagoloff A. Characterization of, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase J. Biol. Chem. 1996 271 14504 14509 10.1074/jbc.271.24.14504 8662933
407. Bode M. Woellhaf M.W. Bohnert M. van der Laan M. Sommer F. Jung M. Zimmermann R. Schroda M. Herrmann J.M. Redox-regulated dynamic interplay between Cox19 and the copper-binding protein Cox11 in the intermembrane space of mitochondria facilitates biogenesis of cytochrome c oxidase Mol. Biol Cell 2015 26 2385 2401 10.1091/mbc.E14-11-1526 25926683
408. Nobrega M.P. Bandeira S.C.B. Beers J. Tzagoloff A. Characterization of COX19, a widely distributed gene required for expression of mitochondrial cytochrome oxidase J. Biol. Chem. 2002 277 40206 40211 10.1074/jbc.M207348200 12171940
409. Naess K. Bruhn H. Stranneheim H. Freyer C. Wibom R. Mourier A. Engvall M. Nennesmo I. Lesko N. Wredenberg A. Clinical presentation, genetic etiology, and coenzyme Q10 levels in 55 children with combined enzyme deficiencies of the mitochondrial respiratory chain J. Pediatr. 2021 228 240 251.e2 10.1016/j.jpeds.2020.08.025 32827528
410. Szklarczyk R. Wanschers B.F.J. Nijtmans L.G. Rodenburg R.J. Zschocke J. Dikow N. van den Brand M.A.M. Hendriks-Franssen M.G.M. Gilissen C. Veltman J.A. A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia Hum. Mol. Genet. 2013 22 656 667 10.1093/hmg/dds473 23125284
411. Doss S. Lohmann K. Seibler P. Arns B. Klopstock T. Zühlke C. Freimann K. Winkler S. Lohnau T. Drungowski M. Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation J. Neurol. 2014 261 207 212 10.1007/s00415-013-7177-7 24202787
412. Clemente P. Peralta S. Cruz-Bermudez A. Echevarría L. Fontanesi F. Barrientos A. Fernandez-Moreno M.A. Garesse R. HCOA3 stabilizes cytochrome c oxidase 1 (COX1) and promotes cytochrome c oxidase assembly in human mitochondria* J. Biol. Chem. 2013 288 8321 8331 10.1074/jbc.M112.422220 23362268
413. Mick D.U. Vukotic M. Piechura H. Meyer H.E. Warscheid B. Deckers M. Rehling P. Coa3 and Cox14 are essential for negative feedback regulation of COX1 translation in mitochondria J. Cell Biol. 2010 191 141 154 10.1083/jcb.201007026 20876281
414. Mick D.U. Dennerlein S. Wiese H. Reinhold R. Pacheu-Grau D. Lorenzi I. Sasarman F. Weraarpachai W. Shoubridge E.A. Warscheid B. MITRAC links mitochondrial protein translocation to respiratory-chain assembly and translational regulation Cell 2012 151 1528 1541 10.1016/j.cell.2012.11.053 23260140
415. Ostergaard E. Weraarpachai W. Ravn K. Born A.P. Jønson L. Duno M. Wibrand F. Shoubridge E.A. Vissing J. Mutations in COA3 cause isolated complex IV deficiency associated with neuropathy, exercise intolerance, obesity, and short stature J. Med. Genet. 2015 52 203 207 10.1136/jmedgenet-2014-102914 25604084
416. Higuchi Y. Okunushi R. Hara T. Hashiguchi A. Yuan J. Yoshimura A. Murayama K. Ohtake A. Ando M. Hiramatsu Y. Mutations in COA7 cause spinocerebellar ataxia with axonal neuropathy Brain 2018 141 1622 1636 10.1093/brain/awy104 29718187
417. Weraarpachai W. Sasarman F. Nishimura T. Antonicka H. Auré K. Rötig A. Lombès A. Shoubridge E.A. Mutations in C12orf62, a factor that couples COX I synthesis with cytochrome c oxidase assembly, cause fatal neonatal lactic acidosis Am. J. Hum. Genet. 2012 90 142 151 10.1016/j.ajhg.2011.11.027 22243966
418. Bourens M. Barrientos A. A CMC 1 knockout reveals translation-independent control of human mitochondrial complex IV biogenesis EMBO Rep. 2017 18 477 494 10.15252/embr.201643103 28082314
419. Hell K. Tzagoloff A. Neupert W. Stuart R.A. Identification of Cox20p, a novel protein involved in the maturation and assembly of cytochrome oxidase subunit 2 J. Biol. Chem. 2000 275 4571 4578 10.1074/jbc.275.7.4571 10671482
420. Church C. Chapon C. Poyton R.O. Cloning and characterization of PET100, a gene required for the assembly of yeast cytochrome c oxidase J. Biol. Chem. 1996 271 18499 18507 10.1074/jbc.271.31.18499 8702496
421. Lim S.C. Smith K.R. Stroud D.A. Compton A.G. Tucker E.J. Dasvarma A. Gandolfo L.C. Marum J.E. McKenzie M. Peters H.L. A founder mutation in PET100 causes isolated complex IV deficiency in Lebanese individuals with leigh syndrome Am. J. Hum. Genet. 2014 94 209 222 10.1016/j.ajhg.2013.12.015 24462369
422. Oláhová M. Haack T.B. Alston C.L. Houghton J.A. He L. Morris A.A. Brown G.K. McFarland R. Chrzanowska-Lightowlers Z.M. Lightowlers R.N. A truncating PET100 variant causing fatal infantile lactic acidosis and isolated cytochrome c oxidase deficiency Eur. J. Hum. Genet. 2015 23 935 939 10.1038/ejhg.2014.214 25293719
423. Taylor N.G. Swenson S. Harris N.J. Germany E.M. Fox J.L. Khalimonchuk O. The assembly factor Pet117 couples heme a synthase activity to cytochrome oxidase assembly J. Biol. Chem. 2017 292 1815 1825 10.1074/jbc.M116.766980 27998984
424. McEwen J.E. Hong K.H. Park S. Preciado G.T. Sequence and chromosomal localization of two PET genes required for cytochrome c oxidase assembly in saccharomyces cerevisiae Curr. Genet. 1993 23 9 14 10.1007/BF00336742 8381337
425. Renkema G.H. Visser G. Baertling F. Wintjes L.T. Wolters V.M. van Montfrans J. de Kort G.A.P. Nikkels P.G.J. van Hasselt P.M. van der Crabben S.N. Mutated PET117 causes complex IV deficiency and is associated with neurodevelopmental regression and medulla oblongata lesions Hum. Genet. 2017 136 759 769 10.1007/s00439-017-1794-7 28386624
426. Signes A. Cerutti R. Dickson A.S. Benincá C. Hinchy E.C. Ghezzi D. Carrozzo R. Bertini E. Murphy M.P. Nathan J.A. APOPT 1/ COA 8 assists COX assembly and is oppositely regulated by UPS and ROS EMBO Mol. Med. 2019 11 e9582 10.15252/emmm.201809582 30552096
427. Melchionda L. Damseh N.S. Abu Libdeh B.Y. Nasca A. Elpeleg O. Zanolini A. Ghezzi D. A novel mutation in TTC19 associated with isolated Complex III deficiency, cerebellar hypoplasia, and bilateral basal ganglia lesions Front. Genet. 2014 5 397 10.3389/fgene.2014.00397 25452764
428. Hedberg-Oldfors C. Darin N. Thomsen C. Lindberg C. Oldfors A. COX deficiency and leukoencephalopathy due to a novel homozygous APOPT1/COA8 mutation Neurol. Genet. 2020 6 e464 10.1212/NXG.0000000000000464 32637636
429. Souza R.L. Green-Willms N.S. Fox T.D. Tzagoloff A. Nobrega F.G. Cloning and characterization of COX18, ASaccharomyces cerevisiae PET gene required for the assembly of cytochrome oxidase J. Biol. Chem. 2000 275 14898 14902 10.1074/jbc.275.20.14898 10809734
430. Bourens M. Barrientos A. Human mitochondrial cytochrome c oxidase assembly factor COX18 acts transiently as a membrane insertase within the subunit 2 maturation module J. Biol. Chem. 2017 292 7774 7783 10.1074/jbc.M117.778514 28330871
431. Sacconi S. Trevisson E. Pistollato F. Baldoin M.C. Rezzonico R. Bourget I. Desnuelle C. Tenconi R. Basso G. DiMauro S. HCOX18 and HCOX19: Two human genes involved in cytochrome c oxidase assembly Biochem. Biophys. Res. Commun. 2005 337 832 839 10.1016/j.bbrc.2005.09.127 16212937
432. Legati A. Reyes A. Nasca A. Invernizzi F. Lamantea E. Tiranti V. Garavaglia B. Lamperti C. Ardissone A. Moroni I. New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies Biochim. Biophys. Acta (BBA)-Bioenerg. 2016 1857 1326 1335 10.1016/j.bbabio.2016.02.022 26968897
433. Jonckheere A.I. Smeitink J.A.M. Rodenburg R.J.T. Mitochondrial ATP synthase: Architecture, function and pathology J. Inherit. Metab. Dis. 2012 35 211 225 10.1007/s10545-011-9382-9 21874297
434. Abrahams J.P. Leslie A.G.W. Lutter R. Walker J.E. Structure at 2.8 Â resolution of F1-ATPase from bovine heart mitochondria Nature 1994 370 621 628 10.1038/370621a0 8065448
435. He J. Ford H.C. Carroll J. Douglas C. Gonzales E. Ding S. Fearnley I.M. Walker J.E. Assembly of the membrane domain of ATP synthase in human mitochondria Proc. Natl. Acad. Sci. USA 2018 115 2988 2993 10.1073/pnas.1722086115 29440398
436. Spikes T.E. Montgomery M.G. Walker J.E. Structure of the dimeric ATP synthase from bovine mitochondria Proc. Natl. Acad. Sci. USA 2020 117 23519 23526 10.1073/pnas.2013998117 32900941
437. Pinke G. Zhou L. Sazanov L.A. Cryo-EM structure of the entire mammalian F-type ATP synthase Nat. Struct. Mol. Biol. 2020 27 1077 1085 10.1038/s41594-020-0503-8 32929284
438. Nijtmans L.G.J. Klement P. Houštěk J. van den Bogert C. Assembly of mitochondrial ATP synthase in cultured human cells: Implications for mitochondrial diseases Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 1995 1272 190 198 10.1016/0925-4439(95)00087-9
439. Wittig I. Meyer B. Heide H. Steger M. Bleier L. Wumaier Z. Karas M. Schägger H. Assembly and oligomerization of human ATP synthase lacking mitochondrial subunits a and A6L Biochim. Biophys. Acta (BBA)-Bioenerg. 2010 1797 1004 1011 10.1016/j.bbabio.2010.02.021
440. Wang Z.G. Ackerman S.H. The assembly factor Atp11p binds to the beta-subunit of the mitochondrial F(1)-ATPase J. Biol. Chem. 2000 275 5767 5772 10.1074/jbc.275.8.5767 10681564
441. Wang Z.-G. Sheluho D. Gatti D.L. Ackerman S.H. The alpha -subunit of the mitochondrial F1 ATPase interacts directly with the assembly factor Atp12p EMBO J. 2000 19 1486 1493 10.1093/emboj/19.7.1486 10747017
442. Shoffner J.M. Fernhoff P.M. Krawiecki N.S. Caplan D.B. Holt P.J. Koontz D.A. Takei Y. Newman N.J. Ortiz R.G. Polak M. Subacute necrotizing encephalopathy: Oxidative phosphorylation defects and the ATPase 6 point mutation Neurology 1992 42 2168 10.1212/WNL.42.11.2168 1436530
443. White S.L. Shanske S. Biros I. Warwick L. Dahl H.M. Thorburn D.R. Di Mauro S. Two cases of prenatal analysis for the pathogenic T to G substitution at nucleotide 8993 in mitochondrial DNA Prenat. Diagn. 1999 19 1165 1168 10.1002/(SICI)1097-0223(199912)19:12<1165::AID-PD719>3.0.CO;2-D 10590437
444. Burrage L.C. Tang S. Wang J. Donti T.R. Walkiewicz M. Luchak J.M. Chen L.-C. Schmitt E.S. Niu Z. Erana R. Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G>A) in the mitochondrial encoded ATP6 gene Mol. Genet. Metab. 2014 113 207 212 10.1016/j.ymgme.2014.06.004 25037980
445. Rantamäki M.T. Soini H.K. Finnilä S.M. Majamaa K. Udd B. Adult-onset ataxia and polyneuropathy caused by mitochondrial 8993T-C mutation Ann. Neurol. 2005 58 337 340 10.1002/ana.20555 16049925
446. Craig K. Elliott H.R. Keers S.M. Lambert C. Pyle A. Graves T.D. Woodward C. Sweeney M.G. Davis M.B. Hanna M.G. Episodic ataxia and hemiplegia caused by the 8993T->C mitochondrial DNA mutation J. Med. Genet. 2007 44 797 799 10.1136/jmg.2007.052902 18055910
447. Pfeffer G. Blakely E.L. Alston C.L. Hassani A. Boggild M. Horvath R. Samuels D.C. Taylor R.W. Chinnery P.F. Adult-onset spinocerebellar ataxia syndromes due to MTATP6 mutations J. Neurol. Neurosurg. Psychiatry 2012 83 883 886 10.1136/jnnp-2012-302568 22577227
448. De Meirleir L. Seneca S. Lissens W. Schoentjes E. Desprechins B. Bilateral striatal necrosis with a novel point mutation in the mitochondrial ATPase 6 gene Pediatr. Neurol. 1995 13 242 246 10.1016/0887-8994(95)00184-H 8554662
449. Thyagarajan D. Shanske S. Vazquez -Memije M. Devivo D. Dimauro S. A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis Ann. Neurol. 1995 38 468 472 10.1002/ana.410380321 7668837
450. Brum M. Semedo C. Guerreiro R. Pinto Marques J. Motor neuron syndrome as a new phenotypic manifestation of mutation 9185T>C in gene MTATP6 Case Rep. Neurol. Med. 2014 2014 701761 10.1155/2014/701761 25548692
451. Takahashi S. Makita Y. Oki J. Miyamoto A. Yanagawa J. Naito E. Goto Y. Okuno A. De novo MtDNA Nt 8993 (T—G) mutation resulting in leigh syndrome Am. J. Hum. Genet. 1998 62 717 719 10.1086/301751 9556461
452. Vilarinho L. Barbot C. Carrozzo R. Calado E. Tessa A. Dionisi-Vici C. Guimarães A. Santorelli F.M. Clinical and molecular findings in four new patients harbouring the MtDNA 8993T’C mutation J. Inherit. Metab. Dis. 2001 24 883 884 10.1023/A:1013908728445 11916326
453. Carrozzo R. Tessa A. Vazquez-Memije M.E. Piemonte F. Patrono C. Malandrini A. Dionisi-Vici C. Vilarinho L. Villanova M. Schagger H. The T9176G MtDNA mutation severely affects ATP production and results in Leigh syndrome Neurology 2001 56 687 690 10.1212/WNL.56.5.687 11245730
454. Lopez-Gallardo E. Solano A. Herrero-Martin M.D. Martinez-Romero I. Castano-Perez M.D. Andreu A.L. Herrera A. Lopez-Perez M.J. Ruiz-Pesini E. Montoya J. NARP syndrome in a patient harbouring an insertion in the MT-ATP6 gene that results in a truncated protein J. Med. Genet. 2008 46 64 67 10.1136/jmg.2008.060616
455. D’Aurelio M. Vives-Bauza C. Davidson M.M. Manfredi G. Mitochondrial DNA background modifies the bioenergetics of NARP/MILS ATP6 mutant cells Hum. Mol. Genet. 2010 19 374 386 10.1093/hmg/ddp503 19875463
456. de Coo I.F. Smeets H.J. Gabreëls F.J. Arts N. van Oost B.A. Isolated case of mental retardation and ataxia due to a de novo mitochondrial T8993G mutation Am. J. Hum. Genet. 1996 58 636 638 8644724
457. Ware S.M. El-Hassan N. Kahler S.G. Zhang Q. Ma Y.-W. Miller E. Wong B. Spicer R.L. Craigen W.J. Kozel B.A. Infantile cardiomyopathy caused by a mutation in the overlapping region of mitochondrial ATPase 6 and 8 genes J. Med. Genet. 2009 46 308 314 10.1136/jmg.2008.063149 19188198
458. Galimberti C.A. Diegoli M. Sartori I. Uggetti C. Brega A. Tartara A. Arbustini E. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation Neurology 2006 67 1715 1717 10.1212/01.wnl.0000242882.58086.9a 17101920
459. Jonckheere A.I. Hogeveen M. Nijtmans L. van den Brand M. Janssen A. Diepstra H. van den Brandt F. van den Heuvel B. Hol F. Hofste T. A novel mitochondrial ATP8 gene mutation in a patient with apical hypertrophic cardiomyopathy and neuropathy J Med Genet. 2008 45 129 133 10.1136/jmg.2007.052084 17954552
460. Jonckheere A.I. Renkema G.H. Bras M. van den Heuvel L.P. Hoischen A. Gilissen C. Nabuurs S.B. Huynen M.A. de Vries M.C. Smeitink J.A.M. A complex V ATP5A1 defect causes fatal neonatal mitochondrial encephalopathy Brain 2013 136 1544 1554 10.1093/brain/awt086 23599390
461. Lieber D.S. Calvo S.E. Shanahan K. Slate N.G. Liu S. Hershman S.G. Gold N.B. Chapman B.A. Thorburn D.R. Berry G.T. Targeted exome sequencing of suspected mitochondrial disorders Neurology 2013 80 1762 1770 10.1212/WNL.0b013e3182918c40 23596069
462. Oláhová M. Yoon W.H. Thompson K. Jangam S. Fernandez L. Davidson J.M. Kyle J.E. Grove M.E. Fisk D.G. Kohler J.N. Biallelic mutations in ATP5F1D, which encodes a subunit of ATP synthase, cause a metabolic disorder Am. J. Hum. Genet. 2018 102 494 504 10.1016/j.ajhg.2018.01.020 29478781
463. Mayr J.A. Havlickova V. Zimmermann F. Magler I. Kaplanova V. Jesina P. Pecinova A. Nuskova H. Koch J. Sperl W. Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 subunit Hum. Mol. Genet. 2010 19 3430 3439 10.1093/hmg/ddq254 20566710
464. Schauberger E.M. Ewart S.L. Arshad S.H. Huebner M. Karmaus W. Holloway J.W. Friderici K.H. Ziegler J.T. Zhang H. Rose-Zerilli M.J. Identification of ATPAF1 as a novel candidate gene for asthma in children J. Allergy Clin. Immunol. 2011 128 753 760 10.1016/j.jaci.2011.04.058 21696813
465. De Meirleir L. Respiratory Chain Complex V Deficiency due to a mutation in the assembly gene ATP12 J. Med. Genet. 2004 41 120 124 10.1136/jmg.2003.012047 14757859
466. de Vries D.D. van Engelen B.G.M. Gabreëls F.J.M. Ruitenbeek W. van Oost B.A. A second missense mutation in the mitochondrial ATPase 6 gene in Leigh’s syndrome: MtDNA mutation in Leigh’s syndrome Ann. Neurol. 1993 34 410 412 10.1002/ana.410340319 8395787
467. White S.L. Shanske S. McGill J.J. Mountain H. Geraghty M.T. DiMauro S. Dahl H.-H.M. Thorburn D.R. Mitochondrial DNA mutations at nucleotide 8993 show a lack of tissue- or age-related variation J. Inherit. Metab. Dis. 1999 22 899 914 10.1023/A:1005639407166 10604142
468. houštěk j. pícková a. vojtíšková a. mráček t. pecina p. ješina p. mitochondrial diseases and genetic defects of ATP synthase Biochim. Biophys. Acta (BBA)-Bioenerg. 2006 1757 1400 1405 10.1016/j.bbabio.2006.04.006
469. Schägger H. Respiratory chain supercomplexes of mitochondria and bacteria Biochim. Biophys. Acta (BBA)-Bioenerg. 2002 1555 154 159 10.1016/S0005-2728(02)00271-2
470. Wittig I. Schägger H. Structural organization of mitochondrial ATP synthase Biochim. Biophys. Acta (BBA)-Bioenerg. 2008 1777 592 598 10.1016/j.bbabio.2008.04.027
471. Mourier A. Matic S. Ruzzenente B. Larsson N.-G. Milenkovic D. The respiratory chain supercomplex organization is independent of COX7a2l isoforms Cell Metab. 2014 20 1069 1075 10.1016/j.cmet.2014.11.005 25470551
472. Acín-Pérez R. Fernández-Silva P. Peleato M.L. Pérez-Martos A. Enriquez J.A. Respiratory active mitochondrial supercomplexes Mol. Cell 2008 32 529 539 10.1016/j.molcel.2008.10.021 19026783
473. Gu J. Wu M. Guo R. Yan K. Lei J. Gao N. Yang M. The architecture of the mammalian respirasome Nature 2016 537 639 643 10.1038/nature19359 27654917
474. Wu M. Gu J. Guo R. Huang Y. Yang M. Structure of mammalian respiratory supercomplex I 1 III 2 IV 1 Cell 2016 167 1598 1609 10.1016/j.cell.2016.11.012 27912063
475. Letts J.A. Fiedorczuk K. Sazanov L.A. The architecture of respiratory supercomplexes Nature 2016 537 644 648 10.1038/nature19774 27654913
476. Sousa J.S. Mills D.J. Vonck J. Kühlbrandt W. Functional asymmetry and electron flow in the bovine respirasome eLife 2016 5 e21290 10.7554/eLife.21290 27830641
477. Lapuente-Brun E. Moreno-Loshuertos R. Acín-Pérez R. Latorre-Pellicer A. Colás C. Balsa E. Perales-Clemente E. Quirós P.M. Calvo E. Rodríguez-Hernández M.A. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain Science 2013 340 1567 1570 10.1126/science.1230381 23812712
478. Genova M.L. Lenaz G. Functional role of mitochondrial respiratory supercomplexes Biochim. Biophys. Acta (BBA)-Bioenerg. 2014 1837 427 443 10.1016/j.bbabio.2013.11.002
479. Lenaz G. Tioli G. Falasca A.I. Genova M.L. Complex I function in mitochondrial supercomplexes Biochim. Biophys. Acta (BBA)-Bioenerg. 2016 1857 991 1000 10.1016/j.bbabio.2016.01.013
480. Calvo E. Cogliati S. Hernansanz-Agustín P. Loureiro-López M. Guarás A. Casuso R.A. García-Marqués F. Acín-Pérez R. Martí-Mateos Y. Silla-Castro J. Functional role of respiratory supercomplexes in mice: SCAF1 relevance and segmentation of the Q pool Sci. Adv. 2020 6 eaba7509 10.1126/sciadv.aba7509 32637615
481. Capitanio G. Papa F. Papa S. The allosteric protein interactions in the proton-motive function of mammalian redox enzymes of the respiratory chain Biochimie 2021 189 1 12 10.1016/j.biochi.2021.05.018 34097987
482. Loeffen J.L.C.M. Smeitink J.A.M. Trijbels J.M.F. Janssen A.J.M. Triepels R.H. Sengers R.C.A. van den Heuvel L.P. Isolated complex I deficiency in children: Clinical, biochemical and genetic aspects Hum. Mutat. 2000 15 123 134 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.0.CO;2-P 10649489
483. Protasoni M. Pérez-Pérez R. Lobo-Jarne T. Harbour M.E. Ding S. Peñas A. Diaz F. Moraes C.T. Fearnley I.M. Zeviani M. Respiratory supercomplexes act as a platform for complex III -mediated maturation of human mitochondrial complexes I and IV EMBO J. 2020 39 e102817 10.15252/embj.2019102817 31912925
484. Pernas L. Scorrano L. Mito-morphosis: Mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function Annu. Rev. Physiol. 2016 78 505 531 10.1146/annurev-physiol-021115-105011 26667075
485. Cogliati S. Enriquez J.A. Scorrano L. Mitochondrial cristae: Where beauty meets functionality Trends Biochem. Sci. 2016 41 261 273 10.1016/j.tibs.2016.01.001 26857402
486. Silva Ramos E. Larsson N.-G. Mourier A. Bioenergetic roles of mitochondrial fusion Biochim. Biophys. Acta (BBA)-Bioenerg. 2016 1857 1277 1283 10.1016/j.bbabio.2016.04.002
487. Letts J.A. Sazanov L.A. Clarifying the supercomplex: The higher-order organization of the mitochondrial electron transport chain Nat. Struct. Mol. Biol. 2017 24 800 808 10.1038/nsmb.3460 28981073

